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In response to MCMV infection, NK cells undergo three distinct phases of proliferation: the non-
specific phase mediated by pro-proliferative cytokines; the specific phase mediated by 
recognition of an MCMV-encoded protein by an NK cell activating receptor, Ly49H; and the 
resolution phase, whose mechanism is unknown.  MCMV infection of RAG mice, which lack all 
adaptive immune cells, results in prolonged proliferation of NK cells despite similar viral titers 
compared to wildtype mice.  Interestingly, there are different kinetics for Ly49H+ and Ly49H- 
NK cells.  We have identified several additional markers that may distinguish NK cells that have 
been specifically activated through their receptor from those non-specifically activated by 
cytokines.  Using mice that lack only one or two adaptive lymphocyte populations, we 
determined that αβ and γδ T cells have a redundant ability to resolve NK cell proliferation. An 
adoptive transfer system was developed to further probe the characteristics of T cells required for 
this process.  Finally, we have observed a significant decrease in NK cell numbers coincident 
with the resolution of various NK cell effector functions (IFNγ production and proliferation), 
which suggests a role for apoptosis in the resolution of NK cell activation.  The resolution of 
 xii 
IFNγ production is associated with increased formation of active caspase 8, which appears to be 
dependent on signaling through TRAIL-R. 
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Chapter 1: Introduction 
Natural Killer Cells 
Natural killer cells (NK cells) are innate immune lymphocytes that are able to kill cells without 
prior sensitization.  In mice they are identified as CD3- and NKp46+ and/or NK1.1+ (in NK1.1-
expressing strains, such as C57BL/6 (B6)).  In both humans and mice, NK cells have been shown 
to have important roles in the immune response to cancer and viral infections, especially to 
infections by herpes viruses, such as murine cytomegalovirus (MCMV).  NK cell activity can be 
modulated by a variety of cytokines, including interleukin 15 (IL-15), and/or by signals from 
germ-line encoded activation and inhibitory receptors.  NK cell activation results in 
cytokine/chemokine production, cytotoxicity, and proliferation.   
 
NK cells express variable numbers of inhibitory and activating receptors.  In humans the 
majority of these receptors are killer cell immunoglobulin-like receptors (KIRs) (reviewed in 
(1)), and in mice, most are C-type lectin-like proteins of the Ly49 family (reviewed in (2)).  In 
addition, NK cells from both humans and mice can express CD94 coupled to members of the 
NKG2 family.   
 
Activation receptors are associated with adaptor molecules, such as DAP12, that contain 
immunoreceptor tyrosine-based activation motifs (ITAMs), which are required for signaling.  
Some of these receptors, such as NKG2D, recognize MHC class I-like ligands that are induced 
by stress, such as DNA damage or infection (3).  Alternatively, other activating receptors 
recognize proteins derived from pathogens.  One of the best characterized of these is the murine 
Ly49H receptor, which recognizes m157, a protein encoded by MCMV (4, 5).   
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NK cell responses are restrained by inhibitory receptors, which recognize major 
histocompatibility complex (MHC) class I molecules.  Normally, NK cell activation is inhibited 
by the binding of inhibitory receptors to the ubiquitously expressed MHC class I.  These 
receptors mediate the “missing self” phenomenon, whereby NK cells become activated by cells 
that do not express self class I MHC (6, 7).  Physiologically, this occurs during some viral 
infections and malignancies.  Infected or transformed cells may downregulate class I MHC to 
prevent recognition by CD8+ cytotoxic T cells; however, this sensitizes these cells to attack by 
NK cells.   
 
Additionally, NK cell inhibitory receptors are required for NK cells to be functionally 
responsive, a process called NK cell licensing (reviewed in (8)).  Despite missing-self 
recognition, NK cells from mice that lack MHC class I are paradoxically less responsive than 
NK cells from MHC class I-sufficient mice (9).  Moreover, NK cells that do not express 
inhibitory receptors that recognize self-MHC are also hyporesponsive (10-12).  These 
phenomena are consistent with NK cell licensing, which is a process by which inhibitory NK cell 
receptor recognition of self-MHC class I renders NK cells fully responsive to subsequent 
stimulation through activation receptors (12-14).  Thus, NK cells that lack expression of a self-
MHC specific inhibitory receptor are unlicensed and autoreactivity is prevented as a result of 
their hyporesponsiveness. 
 
Cytomegalovirus 
Cytomegalovirus (CMV) is a β-herpesvirus in the Herpesviridae family.  These viruses are large 
double stranded DNA viruses, which encode a variety of immunomodulatory genes.  A study of 
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the seroprevalence of human CMV (HCMV) in the United States showed that approximately 
60% of people older than 6 years old were seropositive for HCMV and that this number 
increased to greater than 90% of those over the age of 80 (15).  Infection with HCMV is 
generally asymptomatic, but it can cause a mono-like illness.  However, HCMV infections have 
been reported to be especially severe in some immunocompromised patients, including those 
with NK cell deficiencies (16).  Following acute infection, HCMV can establish life-long latency 
in the host.  CMVs display exquisite species tropism, so in order to study HCMV in a mouse 
model, MCMV is used. 
 
NK cells have been shown to be vitally important to mouse survival after MCMV infection (17).  
Moreover, there are several lines of evidence that Ly49H is required for mediating resistance to 
MCMV in mice.  First, mouse strains that do not express Ly49H, such as BALB/C, are 
susceptible to MCMV infection, while those that do, such as B6, are resistant (18-20).  Also, 
congenic B6 mouse strains that lack expression of Ly49H are susceptible MCMV (18, 21), and 
transgenic expression of Ly49H in susceptible mouse strains results in resistance to MCMV (22).  
Additionally, when infected with an m157-deficient virus, resistant strains of mice become 
susceptible to MCMV infection (23, 24).  Mechanistically, Ly49H binding to its ligand, m157, 
results in NK cell activation and the killing of infected cells (4, 5).  Together, these findings 
demonstrate a non-redundant role for Ly49H in conferring resistance to MCMV infection. 
 
Furthermore, other NK cell activation receptors have been shown to mediate resistance to a 
variety of infections (25-28).  For example, Pyzik et al showed that NK cells that express a 
variety of different activating receptors (e.g. Ly49P in MA/My mice and Ly49L in BALB mice) 
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can recognize MCMV infected cells (specifically the m04 protein) and that this was dependent 
on specific MHC class I haplotypes (26).  In addition, CD94/NKG2E appears to be required for 
resistance to ectromelia virus (28).  Interestingly, we see a similar phenomenon in humans (29-
32).  For instance, there is extensive expansion of NKG2C+ NK cells following HCMV 
infection, which suggests a role for this receptor in NK cell activation during HCMV infection 
(30, 32).  Similarly, there was significant expansion of NKG2C+ NK cells following a hantavirus 
outbreak that occurred in Sweden (31). 
 
NK Cell Responses to MCMV 
During the course of infection, NK cell activation and effector functions are tightly regulated.  
NK cell activation following MCMV infection occurs in 2 distinct phases.  During the first or 
nonselective phase there is activation of both Ly49H+ and Ly49H- NK cells, which is mediated 
by pro-inflammatory cytokines.  During this time, stimulation by interleukins 12, 15 and 18 (IL-
12, IL-15 and IL-18) results in NK cells production of IFNγ and NK cell proliferation (33, 34).  
Splenic NK cell production of interferon gamma (IFNγ) peaks at 1.5 days post infection (p.i.) 
and then rapidly returns to baseline (35, 36).  Subsequently, during the specific phase of 
activation there is preferential proliferation of Ly49H+ NK cells, which results in the expansion 
of the Ly49H+ NK cell population (35, 37, 38), which may be important for the generation of 
memory NK cells.  This preferential proliferation is driven by the specific recognition of m157 
by Ly49H.  Finally, there is the resolution of NK cell proliferation and contraction of NK cell 
numbers.  The mechanism of this process is unknown. 
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Interactions between NK cells and adaptive lymphocytes 
Initial reports of regulatory T cell (Treg) deficient mice (both constitutive and inducible) showed 
increased NK cell numbers and reactivity, including proliferation (39, 40).  Subsequently, several 
studies have shown that Tregs are important for controlling NK cell behavior.  In several of these 
studies, Tregs control NK cell activation by limiting the availability of IL-2 produced by CD4+ T 
cells (41, 42).  In addition, studies of Treg/NK cell interactions in tumors show that Treg-
produced TGFβ can suppress NK cell activation (39, 43). 
 
In addition to T cells influencing NK cell responses, NK cells have been shown to influence the 
adaptive immune response to a variety of infections.  In both humans and mice, NK cells can kill 
activated CD8+ and CD4+ T cells (44-46).  For example, it has been shown in patients with 
chronic HBV infections that NK cells can kill activated, HBV-specific CD8+ T cells.  In contrast, 
NK cells can also promote T cell responses (44).  For example, IFNγ production by NK cells 
promotes antigen presentation to T cells as well as T helper type I polarization.  Additionally, 
NK cells have been shown to regulate the migration of T cells and dendritic cells to the lymph 
node during influenza A infection, which is required for the normal T cell response to influenza 
(47).  Similarly, NK cell interactions with DCs are required for the survival of CD8α+ DCs 
following MCMV infection (48), and NK/DC interactions have been shown to result in DC 
maturation both in vitro and in vivo (49-51).  Thus, there is a complex, bi-directional interaction 
between NK cells and the adaptive immune response. 
 
NK cells and apoptosis                  
Apoptosis, or programmed cell death, is an important mechanism for the contraction of a variety 
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of immune cell populations following activation and expansion.  Apoptosis can be mediated by 
the intrinsic (i.e. mitochondrial) or extrinsic (i.e. death-receptor) pathways (Fig. 1.1).  The death 
receptor pathway is initiated by the ligation of a death receptor by its ligand.  This results in the 
recruitment and cleavage of pro-caspase-8 into its activated form.  Active caspase-8 can then 
cleave pro-caspase-3 and-7 into their active forms.  Active caspase-3 and-7 can then produce the 
morphological changes associated with apoptosis, including membrane blebbing and DNA 
fragmentation.   
 
In contrast, the extrinsic pathway is controlled by the balance of pro- and anti-apoptotic members 
of the bcl-2 protein family.  Upon an initiating stimulus, such as cytokine withdrawal, there is 
activation of pro-apoptotic members of the bcl-2 family of proteins.  These proteins promote the 
homodimerization of a second group of pro-apoptotic bcl-2 family members (bax and bak), 
which results in the permeabilizaiton of the outer mitochondrial membrane and the release of 
cytochrome c into the cytoplasm.  Cytochrome c can then form a complex with APAF-1 to form 
the apoptosome, which can then cleave pro-caspase-9 into its active form.  Active caspase-9 can 
then cleave pro-caspase-3 and -7 into their active forms. 
 
In NK cells, apoptosis has been shown to have a role in controlling NK cell activation.  For 
example, IL-15 supports NK cells survival by maintaining expression of bcl-2, an anti-apoptotic 
member of the bcl-2 family (52).  In addition, IL-15 suppresses Bim, a pro-apoptotic member of 
the bcl-2 family, via the signaling of PI(3)K and Akt (53).  During the resolution/contraction 
phase of NK cell activation following MCMV infection, it has been shown that there is 
decreased bcl-2 expression and an increase in the frequency of apoptotic NK cells (54, 55).  
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Moreover, it has been shown that infection of Bim-deficient mice with MCMV resulted in 
prolonged expansion of NK cells (53, 56). 
 
NK Cells in human health and disease 
In humans, NK cells are identified as CD3-CD16+CD56+, and they comprise 5-15% of peripheral 
blood mononuclear cells.  Additionally, they can also reside in secondary lymphoid organs (such 
as the spleen and lymph nodes) as well as other solid organs (such as the liver) (57).  In addition, 
NK cells are the most abundant lymphocyte found in the endometrium of the uterus, where they 
seem to impact embryo implantation, vascular function and placentation (58, 59).    
 
NK cells are critical for protecting people from viral infections.  In rare cases of NK cell 
deficiency, patients suffer from severe viral infections (16, 60, 61).  In addition, patients with 
recurrent herpesvirus infections have been found to have NK cells with functional defects (62).  
Moreover, KIR/HLA haplotypes that support NK cell activation (expression of activating 
receptor and HLA ligand) are associated with protection against infections (63). 
 
While NK cells are vital for fighting infections as well as malignancies, if their activation is 
unrestrained then they can also cause damage to the host including immunopathology, 
autoimmunity, and malignancy.  Dysregulation of NK cell proliferation and/or apoptosis can 
result in chronic NK cell lymphocytosis (CNKL) or aggressive NK cells large granular cell 
leukemia (NK-LGL) (reviewed in (64)).  CNKL is diagnosed at a median age of 60.5 and is 
equally common in men and women (65).  Approximately 60% of patients are asymptomatic at 
diagnosis, and 40% present with symptoms including cytopenias, vasculitides, neuropathy and 
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splenomegaly.  CNKL generally has an indolent course, and patients with CNKL have a good 
prognosis. 
 
In contrast to CNKL, patients diagnosed with NK-LGL have a generally poor prognosis.  NK-
LGL is diagnosed at a median age of 39, and is 7 times more common in men than women (65).  
Patients generally present with fever, night sweats, weight loss, hepatosplenomegaly, cytopenias, 
and lymphadenopathy.  Even with aggressive treatment, patients with NK-LGL typically die 
within 1-2 months (66).  A better understanding of the mechanisms that control NK cell 
proliferation and apoptosis might facilitate the development of better treatments for this disease. 
 
In addition, inappropriate NK cell activation has been implicated in the pathogenesis of a variety 
of autoimmune diseases (reviewed in (67)).  While there are several studies that have shown 
decreased NK cell numbers in the peripheral blood of patients with autoimmune diseases (68-
70), there are several reports of increased NK cell numbers in affected tissues (71-74).  For 
example, NK cells constituted a significant proportion of the lymphocytes in the synovium of 
patients with rheumatoid arthritis (74).  Additionally, CNKL is associated with a variety of 
autoimmune manifestations including vasculitis, arthritis and neuropathy (75-77).  Finally, there 
are several genetic association studies that support a role for NK cells in the pathogenesis of 
autoimmune disease.  The same KIR/HLA genotype combinations that protect patients from 
infectious diseases have also been shown to predispose people to autoimmune diseases, 
including multiple sclerosis and systemic lupus erythematous (78, 79). 
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Figures 
 
 
Figure 1.1:  The extrinsic and intrinsic pathways of apoptosis. 
Apoptosis can be induced by either the extrinsic or the intrinsic pathways. Both pathways 
culminate in the production of active caspase-3 and -7, which go on to generate the 
morphological features characteristic of apoptosis (e.g. membrane blebbling, DNA 
fragmentation). The extrinsic pathway is initiated by the binding of a death receptor (e.g. 
TRAIL-R) to its ligand (e.g. TRAIL). This results in the cleavage of inactive pro-caspase-8 to its 
active form, which can then convert pro-caspase-3 and -7 into their active forms. The intrinsic 
pathway can be initiated by a variety of signals (e.g. withdrawal of growth factors and DNA 
damage). These stimuli result in the activation of pro-apoptotic members of the Bcl-2 protein 
family (e.g. Bim and Noxa). These proteins promote the homodimerization of a second group of 
pro-apoptotic Bcl-2 family members (Bax and Bak), which results in the permeabilization of the 
outer mitochondrial membrane and the release of cytochrome c into the cytoplasm. Cytochrome 
c can then associate with APAF-1 to form the apoptosome, which can cleave pro-caspase-9 into 
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active caspase-9. Active caspase-9 can cleave pro-caspase-3 and-7 into their active forms. 
Additionally, the extrinsic cascade can be amplified by the intrinsic pathway via the conversion 
of Bid, a pro-apoptotic member of the Bcl-2 family, to its truncated form (tBid) by caspase-8. 
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Abstract 
NK cell activation is controlled by the integration of signals from cytokine receptors and germ-
line encoded activation and inhibitory receptors.  NK cells undergo two distinct phases of 
activation during MCMV infection: a nonselective phase mediated by pro-inflammatory 
cytokines and a specific phase driven by signaling through Ly49H, an NK cell activation 
receptor that recognizes infected cells.  We sought to delineate cell surface markers that could 
distinguish NK cells that had been activated nonselectively from those that had been specifically 
activated through NK cell receptors.  We demonstrated that Sca-1 is highly upregulated during 
viral infections (to an even greater extent than CD69) and serves as a novel marker of early, 
nonselective NK cell activation.  Indeed, a greater proportion of Sca-1+ NK cells produced IFN-γ 
compared to Sca-1- NK cells during MCMV infection.  In contrast to the universal upregulation 
of Sca-1 (as well as KLRG1) on NK cells early during MCMV infection, differential expression 
of Sca-1, as well as CD27 and KLRG1, was observed on Ly49H+ and Ly49H- NK cells late 
during MCMV infection.  Persistently elevated levels of KLRG1 in the context of down 
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regulation of Sca-1 and CD27 were observed on NK cells that expressed Ly49H.  Furthermore, 
the differential expression patterns of these cell surface markers were dependent on Ly49H 
recognition of its ligand and did not occur solely as a result of cellular proliferation.  These 
findings demonstrate that a combination of Sca-1, CD27, and KLRG1 can distinguish NK cells 
nonselectively activated by cytokines from those specifically stimulated through activation 
receptors.   
 
Introduction 
 NK cells are innate immune lymphocytes, which were initially characterized by their 
ability to kill transformed and infected cells without prior sensitization.  Studies of rare humans 
with isolated NK cell deficiencies (1) as well as mice depleted of NK cells (2) have demonstrated 
that NK cells are a critical component of host defense against viruses, particularly herpesviruses.  
Murine cytomegalovirus (MCMV), a beta herpesvirus, has been an invaluable tool for 
delineating the role of NK cell activation receptors in early host defense. 
 
NK cell responses are controlled by cytokines and signals from activation and inhibitory 
receptors.  Previous studies have shown that mouse strains that express the Ly49H activation 
receptor, such as C57BL/6 (B6), are resistant to MCMV infection, while those that do not, such 
as BALB/c, are susceptible to infection (3-5).  Furthermore, transgenic expression of Ly49H in 
susceptible mouse strains results in resistance to MCMV (6), and congenic B6 mouse strains that 
lack the Ly49H locus are susceptible to MCMV (3, 7).  Ly49H recognizes the MCMV-encoded 
protein m157, resulting in NK cell activation and the killing of infected cells (8, 9).  Moreover, 
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when infected with an m157-deficient virus, B6 mice become susceptible to MCMV infection 
(10, 11), demonstrating the non-redundant role of Ly49H in mediating resistance to MCMV.  
NK cells undergo two distinct phases of activation during viral infections, such as MCMV.  
Early during MCMV infection, there is nonselective activation of both Ly49H+ and Ly49H- 
subsets of NK cells, which results in NK cell proliferation and IFN-γ production.  This phase is 
driven by pro-inflammatory cytokines, such as IL-15 and IL-12 (12, 13).  Subsequently, there is 
specific activation of Ly49H+ NK cells, which is dependent on Ly49H recognition of m157 and 
results in preferential expansion of the Ly49H+ subset of NK cells (14-16).  Other activation 
receptor/ligand pairs have been identified in a variety of different infection systems and/or 
mouse strains (17-20).  Moreover, preferential expansion of specific NK cell subsets has also 
been observed following a number of human infections (21-23), implicating a role for specific 
NK cell activation in human health and disease. 
 
To our knowledge, there have been no reports of distinct cell surface proteins (“markers”) 
associated with the specific activation of NK cells.  In contrast, several markers of early, 
nonspecific NK cell activation have been described, including the C-type lectin-like cell 
receptors CD69 (also called very early antigen) and the killer cell lectin-like receptor G1 
(KLRG1) (24, 25). While CD69 is not expressed on resting NK cells (26), approximately 30-
40% of resting NK cells express KLRG1 (24, 27, 28).  Despite this difference, both CD69 and 
KLRG1 are highly upregulated on NK cells following activation by a variety of stimuli, 
including viral infections (26, 28-30).  However, CD69 is only transiently upregulated on NK 
cells following MCMV infection while there is prolonged upregulation of KLRG1 expression for 
more than a week (28, 31).  Previous studies have shown that KLRG1+ NK cells are less 
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activated (28) and more prone to apoptosis following MCMV infection (31) than KLRG1- NK 
cells.  However, none of these studies have examined the relationship between KLRG1 and 
Ly49H expression during the specific phase of NK cell activation during MCMV infection. 
 
Although stem cell antigen 1 (Sca-1, also called Ly-6A/E) has been best characterized as a 
marker of hematopoietic stem cells (reviewed in (32)), it was initially identified on activated 
lymphocytes (33).  Interestingly, there is conflicting evidence as to whether Sca-1 has an 
activating or inhibitory effect on lymphocytes. Initial studies demonstrated that antibody cross-
linking of Sca-1 resulted in T and B cell activation in vitro (34-37).  However, subsequent 
experiments demonstrated that effector T cells from Sca-1 deficient mice had increased 
proliferative responses (38) and that double negative regulatory T cells from Sca-1 deficient 
mice are unable to suppress skin allograft rejection (39).  However, the expression and function 
of Sca-1 on NK cells is unknown.   
 
We hypothesized that the nonselective and specific phases of NK cell activation would result in 
characteristic expression patterns of cell surface proteins (or markers).  Markers of early, 
nonselective activation would be highly expressed early following infection on most NK cells, 
but have negligible expression on naïve NK cells (similar to that of CD69).  Conversely, markers 
of specific activation would be differentially modulated on cells expressing the appropriate 
activation receptor.  For example, one would expect differential expression of the markers on 
Ly49H+ and Ly49H- subsets of NK cells during MCMV infection of B6 mice.  The identification 
of such a panel of cell surface proteins will facilitate the study and identification of activation 
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receptor/ligand pairs in other systems.  In this study, we have identified and characterized cell 
surface markers of both nonselective and specific NK cell activation. 
Materials and Methods 
Mice 
C57BL/6 mice were obtained from National Cancer Institute (Charles River, MA).  129.IFNαβR-
deficient mice (IFNαβR-/-, (40)) were backcrossed onto a C57BL/6 background for 10 
generations as previously described (16).  C57BL/6.Sca-1EGFP/EGFP mice (Sca-1-/-, (41)), which 
have an enhanced GFP cassette knocked into the Sca-1 locus, were a generous gift from Timothy 
Graubert (Washington University, St. Louis, MO).  C57BL/6.DAP12 loss-of-function knock-in 
(DAP12KI; (42)) mice were a kind gift from Eric Vivier (CNRS-INSERM-Universite de la 
Mediterranee, France).  Mice were maintained under specific pathogen-free conditions and used 
between 8 and 14 weeks of age.  All experiments were conducted in accordance with 
institutional guidelines for animal care and use. 
 
Antibodies 
Biotinylated anti-Ly49H Ab (3D10) was a kind gift from Wayne Yokoyama (Washington 
University).  The following antibodies and PE-streptavidin were purchased from eBioscience 
(San Diego, CA), unless indicated otherwise: biotinylated anti-KLRG1 (2F1); FITC-conjugated 
anti-KLRG1 (2F1), -Ly49H (3D10), and -NKp46 (29A1.4, R&D Systems); PE-conjugated anti-
CD27 (LG.7F9), -CD69 (H1.2F3), -IFN-γ (XMG1.2), and -KLRG1 (2F1); PerCP/Cy5.5-
conjugated anti-CD3 (145-2C11) and -NK1.1 (PK136); PE/Cy7-conjugated anti-CD27 (LG.7F9) 
and -Sca-1 (D7); eFluor® 450-conjugated anti-NKp46 (29A1.4); allophycocyanin-conjugated 
anti-Ly49H (3D10); allophycocyanin/eFluor® 780-conjugated anti-CD3 (17A2); 
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allophycocyanin/Cy7-conjugated anti-CD3e (145-2C11, BD Pharmingen, San Diego, CA); 
V500-conjugated anti-Sca-1 (D7, BD Biosciences, San Jose, CA) and V450-conjugated anti-
CD69 (H1.2F3, BD Biosciences).  
 
Viruses and injection of mice 
Salivary gland stock of Smith strain MCMV (American Type Culture Collection [ATCC]; 
Manassas, VA) was prepared using young BALB/c mice that were i.p. injected with 1 x 106 PFU 
of tissue-culture propagated MCMV.  The titer of the stock was determined using a standard 
plaque assay (3) in permissive NIH3T12 fibroblasts (ATCC).  MCMV-AT1.5 (G881A mutation 
creating a premature stop codon) is an m157-deficient isolate of MCMV (MCMV-Δm157), 
which has been previously described (11).  Unless otherwise indicated, mice were injected i.p. 
with 5 x 104 PFU/mouse of salivary gland stock MCMV.  
 
Vaccinia virus (VV, ATCC) was propagated as previously described (43).  All VV infections 
were done by i.p. injection with 5 x 106 PFU/mouse.  HSV strain 17 was a kind gift from David 
Leib (Dartmouth Medical School, Lebanon, NH).  HSV was propagated and titered as previously 
described (43).  All HSV infections were done by i.p. injection of 1.5 x 106 PFU/mouse.   
 
Splenocyte preparation, intracellular staining and flow cytometry 
Single-cell suspensions of splenocytes were prepared using standard techniques (14).  To block 
non-specific binding of antibodies to Fc receptors, splenocytes were incubated in 2.4G2 (anti-Fcγ 
II/III receptor) supernatants (hybridoma from ATCC) prior to staining with labeled Abs.  Data 
acquisition was performed with a FACSCalibur flow cytometer (BD Pharmingen) using 
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CellQuest software (BD Biosciences) or with a FACScan (BD Pharmingen) with DxP multi-
color upgrade (Cytek Development, Fremont, CA) and FlowJo CE software (Tree Star, Ashland 
Organ).  Data analysis was performed using FlowJo (Tree Star).  Intracellular IFN-γ staining was 
done as previously described (14).  NK cells were identified as CD3-, NK1.1+, or as CD3-, 
NK1.1+, NKp46+.  All histograms have been scaled for the purpose of comparison. 
 
Quantification of MCMV viral loads using real-time PCR 
MCMV viral loads were determined by quantifying the copies of the IE1 gene using qRT-PCR 
(TaqMan) as previously described (44), with the following modifications.  DNA was isolated 
using the QIAmp DNA Blood MiniKit (Qiagen, Valencia, CA) from homogenized spleens 
diluted 1:10 in PBS.  Five microliters of 100 and 1000 fold dilutions of each sample were run in 
triplicate.  Samples were run in 96-well plates on an ABI 7500 Fast Real-Time PCR System 
(Applied Biosystems, Inc., Foster City, CA).   
 
In vitro IL-15 proliferation assay 
Single-cell suspensions of splenocytes were enriched for NK cells by negative selection with 
magnetic bead (Miltenyi Biotec, Auburn, CA).  Splenocytes were labeled with 0.5 µM CFSE 
(Molecular Probes, Eugene, OR) as previously described (45).  CFSE-labeled splenocytes were 
cultured in 96-well plates for 72 h with various concentrations of murine IL-15 (PeproTech, 
Rocky Hill, NJ).   
 
Statistical analysis 
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Data analysis was done with Microsoft Excel and GraphPad Prism (GraphPad Software, La 
Jolla, CA).  Unless otherwise noted, unpaired, two-tailed t tests were used to determine 
statistically significant differences.  Error bars in figures represent standard deviations from 
mean value. 
 
Results 
Sca-1 is a novel marker of early, nonselective NK cell activation. 
We used flow cytometry to analyze the expression of various proteins on NK cells from naïve 
mice and from mice 2 days post infection (p.i.) with MCMV.  In these experiments, we observed 
that there was negligible expression of Sca-1 on NK cells from uninfected mice (6.7 ± 2.7%) 
while it was highly expressed on almost all NK cells 2 days p.i. with MCMV (99.1 ± 0.6%) (Fig. 
2.1A and B).  Sca-1 is also upregulated following other viral infections, including vaccinia virus 
(VV) and herpes simplex virus type 1 (HSV) infections (Fig. 2.1A and B). 
 
Subsequently, we compared the expression of Sca-1 with the expression of previously identified 
activation markers, CD69 (26, 29, 30) and KLRG1 (28) (Fig. 2.1C and D).  Like Sca-1, the 
frequency of KLRG1+ and CD69+ NK cells increased between naïve and infected mice (Table 
2.I).  Moreover, there was an increase in the abundance of each marker per cell as measured by 
an increase in the mean fluorescence intensity (MFI) (Fig. 2.1E).  Sca-1 abundance increased by 
an average of 125 ± 10 fold, KLRG1 by 4.9 ± 0.5 fold, and CD69 by 31.7 ± 11 fold.  Similarly, 
there is increased expression of Sca-1, KLRG1 and CD69 on hepatic NK cells 2 days p.i. 
MCMV (Fig. S2.1A and B).  Together these results demonstrate that Sca-1 is more strongly 
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induced on NK cells following MCMV infection than other previously described markers of 
early NK cell activation, KLRG1 and CD69. 
 
Prior studies have shown that type I interferons (IFNs) can induce the expression of both Sca-1 
(46) and CD69 (29).  To determine whether type I IFNs are required for the induction of Sca-1 
and CD69 during the early, nonspecific response to MCMV infection, we analyzed Sca-1 and 
CD69 expression on NK cells from wt B6 or IFNαβR-/- mice 2 days p.i MCMV (Fig. 2.1F).  
While the increased frequency of Sca-1+ NK cells from IFNαβR-/- mice 2 days p.i. MCMV was 
only slightly reduced compared to that seen in wt B6 mice (71.0 ± 17.1% and 91.6 ± 9.0%, 
respectively), the frequency of CD69+ NK cells was markedly less in IFNαβR-/- mice (35.9 ± 
15.6%) compared to that seen in wt B6 mice (91.8 ± 10.6%).  These results suggest that type I 
IFNs are not necessary for the induction of either marker during MCMV infection.  However, 
based on the significant decrease in the frequency of CD69+ NK cells from IFNαβR-/- mice 
compared to wt B6 mice, type I IFNs contribute substantially to the induction of CD69 
expression during MCMV infection.  In contrast, it appears that other factors can compensate for 
the absence of type I IFN signaling in inducing Sca-1 expression during MCMV infection, 
consistent with previous reports that IFN-γ, IL-6, and -9 can also induce expression of Sca-1 (47-
49).   
 
Functional consequences of Sca-1 upregulation 
We investigated whether the upregulation of these activation markers had any functional 
implications.  We looked at marker expression with respect to IFN-γ production 1.5 days p.i. 
MCMV, the time point of maximal production of IFN-γ following MCMV infection (14), in both 
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the spleen (Fig. 2.2A and B) and the liver (Figs. S2.1C, D, and E).  There was a statistically 
significant increase in the proportion of splenic Sca-1+ and CD69+ NK cells that made IFN-γ 
(51.3 ± 9.0% and 56.5 ± 8.0%, respectively) compared to Sca-1- and CD69- NK cells (39.2 ± 
11.2% and 20.1 ± 5.4%, respectively).  Contrary to a previous report by Robbins and colleagues 
(28), we did not observe a difference between the proportion of KLRG1+ and KLRG1- NK cells 
producing IFN-γ (45.3 ± 13% and 43.5 ± 11%, respectively, p = 0.22).  Similar patterns were 
seen for hepatic NK cells (Fig. S2.1C and D), although the overall magnitude was lower than 
that seen in spleen (Fig. S2.1E).  From these results, we concluded that Sca-1 and CD69 
upregulation specifically identify activated NK cells early during MCMV infection. 
 
To investigate the function of Sca-1 on NK cells, we examined NK cell responses in Sca-1-/- 
mice (41).  We did not observe any difference in splenic viral titers or the frequency of 
proliferating NK cells during MCMV infection (data not shown).  Furthermore, no differences 
were seen in NK cell mediated killing by cytokine stimulated LAK cells generated from Sca-1-/- 
or wt splenic NK cells (data not shown).  However, 1.5 days p.i. with MCMV, there was a 
significant increase in the frequency of NK cells producing IFN-γ from Sca-1-/- mice (65.3 ± 
7.3%) compared to those from wt B6 mice (44.1 ± 12.6%) (Fig. 2.2C).  These differences in 
IFN-γ production occurred in the absence of any significant differences in serum concentrations 
of IL-12 from wt B6 or Sca-1-/- mice 1.5 days p.i. with MCMV (data not shown).  These results 
suggest that Sca-1 has an inhibitory function on NK cells during MCMV infection. 
  
KLRG1, CD27, and Sca-1 are markers of specific NK cell activation 
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In contrast to markers of early, nonselective activation during MCMV infection, markers of 
specific activation should be differentially expressed on Ly49H+ and Ly49H- NK cells.  
Although early during MCMV infection Sca-1 and KLRG1 are uniformly upregulated on NK 
cells regardless of Ly49H expression (Fig. 2.3C), late during MCMV infection (6-10 days p.i.) 
we observed differential expression of both Sca-1 and KLRG1 on Ly49H+ and Ly49H- NK cells 
(Fig. 2.3A-C).  In addition, Ly49H+ and Ly49H- NK cells differentially express CD27, a co-
stimulatory molecule of the TNF receptor superfamily that has been described as a marker of NK 
cell maturation (reviewed in (50)).  KLRG1 expression is maintained on Ly49H+ NK cells (98.8 
± 0.4% at 8 days p.i.), while it is gradually lost on Ly49H- NK cells (66.6 ± 5.7% at 8 days p.i.).  
Conversely, the expression of CD27 and Sca-1 decrease more rapidly on Ly49H+ NK cells (8.8 ± 
6.3% and 17.8 ± 9.7%, respectively, at 8 days p.i.) than on Ly49H- NK cells (33.2 ± 8.3% and 
42.8 ± 11.6%, respectively, at 8 days p.i.).  The differential expression of KLRG1, CD27, and 
Sca-1 during MCMV infection suggests that these cell surface molecules function as markers of 
specific NK cell activation. 
 
The evaluation of the coexpression patterns of KLRG1, CD27, and Sca-1 supported this 
conclusion.  The coexpression of these markers was compared on NK cells that had been 
specifically activated (Ly49H+KLRG1+ NK cells) and NK cells that had not been specifically 
activated (Ly49H-KLRG1-NK cells) (Fig. 2.3D).  While there was no predominant CD27/Sca-1 
subset among the Ly49H-KLRG1- NK cells, most Ly49H+KLRG1+ NK cells became CD27-Sca-
1- over time (88.1 ± 1.8% at 8 days p.i.).  Moreover, when we gated NK cells based on the 
expression of these three markers, we observed that the KLRG1+CD27-Sca-1- population was 
enriched for Ly49H+ cells (ratio of Ly49H+ to Ly49H- NK cells of 11.8 ± 3.4 at 8 days p.i.) while 
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very few of the KLRG1-CD27+Sca-1+ NK cells were Ly49H+ (ratio of Ly49H+ to Ly49H- NK 
cells of 0.24 ± 0.1 8 days p.i.) (Fig. 2.3E).  Therefore, it may be possible to use KLRG1, CD27, 
and Sca-1 expression on NK cells during viral infections to enrich for populations with high or 
low expression of receptors responsible for specific activation.  
 
Differential expression of KLRG1, CD27, and Sca-1 is dependent on Ly49H recognition of m157 
To determine whether the distinct expression patterns of KLRG1, CD27, and Sca-1 on Ly49H+ 
and Ly49H- NK cells depend on the binding of Ly49H to m157, we analyzed the expression of 
KLRG1, CD27, and Sca-1 on NK cells from mice infected with either wt MCMV or m157-
deficient MCMV (MCMV-Δm157: (16)).  In all previous experiments, mice were infected with 5 
x 104 PFU wt MCMV; however, due to the increased virulence of MCMV-Δm157 in B6 mice 
(11, 16), we inoculated mice with 1 x 104 PFU of virus to provide sufficient stimulation but 
prevent excessive mortality.  In contrast to the differential expression of KLRG1, CD27, and 
Sca-1 that we observed when mice were infected with wt MCMV (Fig. 2.3 and 2.4A), infection 
of mice with MCMV-Δm157 resulted in similar proportions of Ly49H+ and Ly49H- NK cells 
expressing KLRG1, CD27, or Sca-1 (Fig. 2.4B).  Furthermore, studies with DAP12KI mice, 
which lack the ability to signal through Ly49H, revealed similar findings with no differential 
expression of Sca-1, KLRG1, or CD27 following infection with wt MCMV (Fig. 2.4C). 
Together, these studies demonstrated that the modulation of expression levels of KLRG1, CD27, 
and Sca-1 on Ly49H+ NK cells was dependent on the recognition of m157 by Ly49H and 
subsequent DAP12 mediated signaling. 
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Given that there was no stimulation through Ly49H in the mice infected with MCMV-Δm157, 
we expected that the expression levels of KLRG1, CD27, and Sca-1 on NK cells from mice 
infected with MCMV-Δm157 would resemble those on Ly49H- NK cells from mice infected 
with wt MCMV.  However, the observed expression levels of KLRG1 and CD27 on NK cells 
from mice infected with MCMV-Δm157 were intermediate between the levels on Ly49H+ and 
Ly49H- NK cells from mice infected with wt MCMV, while the expression levels of Sca-1 were 
substantially higher at day 6 p.i. in mice infected with MCMV-Δm157 compared to either 
Ly49H+ and Ly49H- NK cells from mice infected with wt MCMV (Fig. 2.4B). These 
observations were consistent with the higher viral loads (100-fold at days 4 and 6 p.i.) found in 
mice infected with MCMV-Δm157 compared with mice infected with wt MCMV (Fig. 2.4D).  
The differences in viral loads following infection with wt MCMV and MCMV-Δm157 were 
abrogated by days 8 and 10 p.i. (Fig. 2.4D).  We hypothesized that the prolonged elevation of 
viral loads in mice infected with MCMV-Δm157 resulted in persistent non-specific NK cell 
activation compared to infection with wt MCMV, reflected in higher than expected expression 
levels of KLRG1, CD27, and Sca-1.  We verified this hypothesis in wt B6 mice infected with 
MCMV-Δm157 treated daily with either ganciclovir (GCV) or a control solution.  The viral 
loads in mice infected with MCMV-Δm157 and treated with GCV were reduced to levels 
comparable to those seen in untreated mice infected with the wt MCMV (Figs. S2.2A and C).  
The higher than expected levels of Sca-1 observed in both Ly49H+ and Ly49H- NK cells on day 
6 p.i. with MCMV-Δm157 (Fig 2.4B; and in mice treated with control solution, Fig. S2.2B) were 
abrogated in GCV treated mice (Fig. S2.2B).  Importantly, no significant differences were 
observed in the proportions of Ly49H+ and Ly49H- NK cells that expressed KLRG1, CD27, or 
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Sca-1 when GCV treatment lowered the viral loads in mice infected with MCMV-Δm157 to 
levels comparable to those seen in mice infected with the wt MCMV (Fig. S2.2B).   
 
Differential expression of KLRG1, CD27, and Sca-1 is not the result of preferential proliferation 
During the specific activation phase of MCMV infection, Ly49H+ NK cells proliferate 
substantially more than Ly49H- NK cells (12, 14, 16, 51), raising the possibility that the 
differential regulation of KLRG1, CD27, and Sca-1 expression on Ly49H+ and Ly49H- NK cells 
could reflect a by-product of cellular proliferation rather than NK cell receptor-mediated 
activation.  Moreover, previous studies have shown that KLRG1 and CD27 are upregulated 
following adoptive transfer of NK cells into lymphopenic hosts (RAG/common gamma chain-
deficient mice) and subsequent homeostatic proliferation (52, 53).  To determine whether 
proliferation alone was sufficient to change expression of these markers, we analyzed their 
expression on CFSE-labeled NK cells cultured in vitro with various concentrations of IL-15 for 
72 h (Fig. 2.5).  Based on CFSE dilution, we identified subsets of NK cells that had divided 
(diluted CFSE) and those that had not (no CFSE dilution) (Fig. 2.5A).  While no differences 
(Fig. 2.5B and C) were seen in CD27 expression on subsets of NK cells that had divided versus 
those that had not (with 50 ng/mL IL-15, 97.4 ± 1.5% and 92.6 ± 4.2%, respectively), there was 
a decreased frequency of KLRG1+ NK cells among those that had divided compared to those that 
had not (with 50 ng/mL IL-15, 17.2 ± 4.6% and 37.3 ± 2.0%, respectively).  In contrast, there 
was a slightly greater frequency of Sca-1+ NK cells that had divided compared to those that had 
not (with 50 ng/mL IL-15, 23.8 ± 1.3% and 9.88 ± 3.7%, respectively, Figs. 2.5B and C).  These 
minor perturbations of KLRG1 and Sca-1 expression contrast with the modulation of these 
markers during MCMV infection.  Furthermore, the patterns of change are the opposite of what 
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we saw for Ly49H+ (analogous to the proliferative subset) and Ly49H- NK cells in vivo during 
MCMV infection.  Taken together, these results demonstrate that the differential expression of 
KLRG1, CD27, and Sca-1 during MCMV infection is not a mere consequence of preferential 
proliferation. 
 
Discussion 
While it is well-established that distinct mechanisms mediate the nonselective and specific 
activation of NK cells, we have for the first time demonstrated the presence of cell surface 
markers that distinguish NK cells that have been nonselectively activated by cytokines from 
those that have been specifically stimulated through activation receptors.  Whereas markers of 
nonselective activation are universally upregulated on all NK cells early during viral infection, 
markers of specifically activated NK cells become differentially expressed at later times during 
infection on NK cells that express or lack expression of an activating receptor able to recognize 
infected cells.  We have shown that Sca-1 is highly upregulated early during viral infections, and 
at later times can be used to distinguish cells that have been specifically activated through an 
activation receptor.  Additionally, KLRG1 and CD27 expression levels are differentially 
modulated on specifically activated cells.  Together, the differential expression patterns of 
KLRG1, CD27, and Sca-1 can identify a population enriched for specifically activated NK cells.   
 
We identified the upregulation of Sca-1 as a novel marker of nonselectively activated NK cells.  
Similar to CD69 and KLRG1, which have previously been shown to be upregulated following 
NK cell activation (28, 54), there is a dramatic increase in the frequency of Sca-1+ NK cells 
following MCMV infection, as well as VV and HSV infections (Fig. 2.1A and B).  However, the 
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increase in the abundance of Sca-1 per cell is substantially greater than that of either KLRG1 or 
CD69 (Fig. 2.1F).  Our observations at the protein level are corroborated by similar findings at 
the transcript level in recent data from the Immunological Genome Project (55), which reveals 
that Sca-1 is the most highly upregulated transcript on NK cells (greater than 65 fold) at 1 day 
p.i. with MCMV.  In contrast, CD69 transcript levels increase by only 6 fold.   
 
Both Sca-1 and CD69 identify functionally active NK cells, as demonstrated by the increased 
proportion of Sca-1+ and CD69+ NK cells that make IFN-γ compared to NK cells that do not 
express these markers (Fig. 2.2A and B).  Although a greater proportion of Sca-1+ NK cells 
made IFN-γ compared to Sca-1- NK cells in wt mice, NK cells from Sca-1-deficient mice 
produced more IFN-γ compared to those from wt B6 mice during MCMV infection (Fig. 2.2C).  
This observation suggests that Sca-1 may have an inhibitory function on activated cells.  These 
findings are in concordance with the increased T cell responses observed in Sca-1 deficient mice 
(38).  In addition, T cells from mice that overexpress Sca-1 have blunted responses to a variety 
of stimuli (56).  Interestingly, similar observations have been made regarding CD69.  While 
CD69 is highly expressed on activated NK cells, CD69-deficient mice manifest greater NK-cell 
dependent rejection of MHC class I-deficient tumor cells than wt mice (57).  These results 
support the conclusion that Sca-1 is an inhibitory receptor that marks nonselectively activated 
NK cells. 
 
Although there are other reports of an inhibitory function for Sca-1 (38, 56), the mechanism of 
this inhibition remains unclear.  Sca-1 is a GPI anchored protein of the Ly-6 gene family (58). 
Sca-1 may bind to CD22 on B cells (59), but it is unclear whether this is the only ligand for Sca-
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1.  Various mechanisms for Sca-1 activity have been proposed (reviewed in (60)).  Sca-1 may act 
through association with an accessory signaling protein, such as the CD3 ζ chain (61, 62), 
allowing Sca-1 ligation to transduce a signal and potentially inhibit other cellular processes by 
competing for downstream signaling molecules.  Alternatively, the function of Sca-1 might be 
dependent on its association with “lipid rafts” (63), specialized regions of the cell membrane that 
are enriched with saturated sphingolipids, cholesterol and a variety of proteins, including GPI-
anchored proteins (reviewed in (64)).  “Lipid rafts” and their associated proteins may regulate 
other protein-protein and protein-lipid interactions.  For example, it has been shown that ligation 
of Sca-1 with plate bound antibody inhibits TCR-induced proliferation of T cells by preventing 
the translocation of the IL-2Rα chain from “lipid rafts” into the soluble membrane fraction where 
IL-2Rβ and γ chains are located (65).  Future work will be required to determine the mechanism 
of action of Sca-1 on NK cell function.   
 
During the specific phase of NK cell activation during MCMV infection, Ly49H signaling 
following recognition of m157 results in selective activation of Ly49H+ NK cells.  We have 
shown that Ly49H signaling through DAP12 results in the differential expression of KLRG1, 
CD27, and Sca-1 on Ly49H+ NK cells compared with Ly49H- NK cells.  Ly49H+ NK cells 
persistently express KLRG1 but downregulate CD27 and Sca-1 expression more rapidly than 
Ly49H- NK cells (Fig. 2.3).  By 8 days p.i. MCMV, KLRG1+CD27-Sca-1- NK cells are 
predominately Ly49H+, while KLRG1-CD27+Sca-1+ NK cells are primarily Ly49H- (Fig. 2.3E).  
We demonstrated that the differential expression of these markers is dependent on Ly49H 
recognition of m157 and the subsequent signaling via DAP12 (Fig. 2.4).  Interestingly, Chen and 
colleagues have observed a similar expression pattern for Sca-1 on B cells: non-specific 
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activation of B cells with IFN-γ results in Sca-1 upregulation, while stimulation through the B 
cell receptor results in decreased expression of Sca-1 (66).  Additionally, there is increased 
expression of KLRG1 and decreased expression of CD27 on virus-specific T cells from both 
humans and mice (67, 68).  Thus, the context-dependent regulation of activation markers is not 
unique to NK cells, but rather, it seems to be a more general phenomenon also observed in other 
immune cells. 
 
Furthermore, we have demonstrated that the differential expression of KLRG1, CD27, and Sca-1 
on Ly49H+ and Ly49H- NK cells is not a direct consequence of preferential proliferation of the 
Ly49H+ NK cells (Fig. 2.5).  In contrast with our in vitro experiments, two previous reports 
showed increased KLRG1 and CD27 expression on NK cells that had undergone homeostatic 
proliferation in vivo following adoptive transfer into lymphopenic hosts (52, 53).  This 
discrepancy may reflect the influence of increased levels of other cytokines in the RAG/common 
gamma chain-deficient recipients.  Although our in vitro system does not fully mirror in vivo 
homeostatic proliferation, it does provide a simplified system to be able to look directly at the 
effects of proliferation. 
 
In summary, the identification of markers of nonselective and specific NK cell activation will 
significantly facilitate in vivo studies of NK cell activation during viral infections and has 
potential applications in other areas of NK cell research.  For example, Sun and colleagues have 
suggested that increased expression of KLRG1 and decreased expression of CD27 are 
characteristic of memory NK cells (69).  Although additional studies will be needed to determine 
how Sca-1 is related to memory NK cells, it appears that KLRG1 and CD27 expression correlate 
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with both specific NK cell activation and memory response potential.  The distinct expression 
patterns of KLRG1, CD27, and Sca-1 may also prove useful in isolating specifically activated 
NK cells during other viral infections and in identifying previously undiscovered activation 
receptors involved in responses to infections or other stimuli.   
Figures 
 
Figure 2.1: Sca-l is upregulated on NK cells 2 days p.i. MCMV to a greater extent than 
other identified activation markers.  
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A) Percentage of NK cells that express Sca-1 in naïve B6 mice (grey fill) or B6 mice 2 days p.i. 
MCMV (no fill), VV (stripes), or HSV (dots).  B) Fold change of the MFI of Sca-1 between NK 
cells from naïve B6 mice and B6 mice 2 days p.i. MCMV (no fill), VV (stripes), or HSV (dots).  
C) Representative histograms showing Sca-1, KLRG1, or CD69 expression on splenic NK cells 
from naïve B6 mice (thin line, grey fill) or from B6 mice 2 days p.i. wt MCMV (thick line, no 
fill).  D) Percentage of NK cells that express Sca-1, KLRG1, or CD69 in naïve B6 mice (grey 
fill) or B6 mice 2 days p.i. MCMV (no fill).  E) Fold change of the MFI of Sca-1, KLRG1, or 
CD69 between NK cells from naïve B6 mice and B6 mice 2 days p.i. MCMV.  F) Frequency of 
Sca-1+ or CD69+ NK cells from wt B6 (solid outline) or IFNαβR-/- (dashed outline) mice 2 days 
p.i. MCMV relative to that seen in wt B6 mice.  Composite data from 2 independent experiments 
each with 3-4 mice/genotype.  B and E) MFI values are for the entire NK cell population.  A), 
B), D), and E) show composite results from 2-3 independent experiments with a total of 3-5 
naïve mice and 7-9 infected mice.   
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Figure 2.2: Sca-1 and CD69 expression correlate with IFN-γ production.  
A) Representative histograms showing relative proportions of splenic NK cells making IFN-γ 1.5 
days p.i. MCMV based on expression of Sca-1 (left), KLRG1 (middle), or CD69 (right).  B) 
Proportion of splenic NK cells that make IFN-γ 1.5 days p.i. MCMV based on Sca-1, KLRG1, or 
CD69 expression.  Marker negative cells () and marker expressing cells ().  Composite data 
from 2 independent experiments with 3-5 mice/group.  Statistical significance was determined 
using paired, two-tailed t-tests.  C) IFN-γ production by splenic NK cells from wt B6 mice or 
Sca-1-/- mice 1.5 days p.i. MCMV.  Composite data from 2 independent experiments with 4-5 
mice/group. **p < 0.01, ***p < 0.001. 
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Figure 2.3:  Expression of KLRG1, CD27, and Sca-1 is differentially regulated on Ly49H+ 
and Ly49H- NK cells during MCMV infection.   
A) Representative dot plots showing KLRG1 (top), CD27 (middle), or Sca-1 (bottom) expression 
with respect to Ly49H expression and B) histograms showing the expression of these markers on 
Ly49H+ (solid line, no fill) or Ly49H- (dashed line, grey fill) splenic NK cells from B6 mice 8 
days p.i. MCMV.  C) Proportion of Ly49H+ (, solid line) or Ly49H- (, dashed line) splenic 
NK cells that express KLRG1, CD27, or Sca-1 from B6 mice 0, 2, 4, 6, 8, or 10 days p.i. 
MCMV.  D) Frequency of CD27/Sca-1 subsets among Ly49H-KLRG1- or Ly49H+KLRG1+ NK 
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cells from wt B6 mice 4, 6 or 8 days p.i. MCMV.  Sca-1+CD27- (black), Sca-1+CD27+ (black 
stripes), Sca-1-CD27+ (black dots), Sca-1-CD27- (no fill).  E) Representative histogram showing 
frequency of Ly49H+ NK cells among NK cell subsets based on KLRG1, CD27, and Sca-1 
coexpression patterns from wt B6 mice 8 days p.i. MCMV, which is quantified on the graph to 
the right as the ratio of Ly49H+ to Ly49H- NK cells in each subset.  All panels show cumulative 
results from 2, independent experiments with 4-5 mice/group/time point.  Statistical significance 
was determined using paired, two-tailed t-tests.  ***p < 0.001, **p < 0.01 
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Figure 2.4:  Differential expression of KLRG1, CD27, and Sca-1 on Ly49H+ and Ly49H- 
NK cells during MCMV infection depends on Ly49H recognition of m157 protein.  
A, B, and C) Proportion of Ly49H+ (filled symbol, solid line) or Ly49H- (open symbol, dashed 
line) splenic NK cells that express KLRG1 (left), CD27 (middle), or Sca-1 (right) from wt B6 
mice (A and B, diamonds) or DAP12KI mice (C, squares) 6, 8, or 10 days p.i. with 1 x 104 PFU 
wt MCMV (A and C, black) or MCMV-Δm157 (B, grey).  Figures show cumulative results from 
2-3 independent experiments with 3-5 mice/group/time point.  D) Viral loads from spleens of wt 
B6 mice 2, 4, 6, 8, or 10 days p.i. with 1 x 104 PFU wt MCMV (black) or MCMV-Δm157 (grey).  
Symbols represent viral loads for an individual mouse. **p<0.01, ***p<0.001. 
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Figure 2.5:  Proliferation alone does not result in the differential expression of KLRG1, 
CD27, or Sca-1.   
A) Representative histograms showing CFSE dilution and peak identification of NK cells that 
had (solid, thick line) or had not (dashed line) divided.  B) Representative histograms showing 
relative expression of KLRG1, CD27, and Sca-1 on splenic NK cells that had (solid line) or had 
not divided (dashed line). C) Proportion of NK cells that had (■ , solid line) or had not divided (
◇ , dashed line) that expressed KLRG1 (left), CD27 (middle), or Sca-1 (right) following 72 h of 
culture in 3, 20 or 50 ng/mL of IL-15.  Data is composite of 2-3 independent experiments with 
pooled triplicates. 
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Supplemental Figure 2.1: Marker expression on and IFN-γ production by hepatic NK cells 
following MCMV infection.   
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A) Representative histograms showing Sca-1, KLRG1, or CD69 expression on hepatic NK cells 
from naïve B6 mice (thin line, grey fill) or from B6 mice 2 days p.i. wt MCMV (thick line, no 
fill).  B) Percentage of hepatic NK cells that express Sca-1, KLRG1, or CD69 in naïve B6 mice 
(grey fill) or B6 mice 2 days p.i. MCMV (no fill).  C) Representative histograms showing 
relative proportions of hepatic NK cells making IFN-γ 1.5 days p.i. MCMV based on expression 
of Sca-1 (left), KLRG1 (middle), or CD69 (right).  D) Proportion of hepatic NK cells that make 
IFN-γ 1.5 days p.i. MCMV based on Sca-1, KLRG1, or CD69 expression.  Marker negative cells 
(☐) and marker expressing cells ().  Statistical significance was determined using paired, two-
tailed t-tests.  ***p<0.001, **p<0.01  E) Frequency of IFN-γ+ splenic ( , open) or hepatic (☐, 
grey fill) NK cells from naïve mice or from mice 1.5 or 2 days p.i. MCMV.  F) and G) Number 
of hepatic (F, grey) and splenic (G, black) NK cells that make IFN-γ 1.5 (diamonds, top row) or 
2 (circles, bottom row) days p.i. MCMV based on the expression of Sca-1, KLRG1, and CD69.  
Marker negative cells (open symbols) and marker expressing cells (filled symbols).  All panels 
show results from a 1-2 independent experiments with 3-4 mice/group.  Hepatic leukocytes were 
prepared as previously described (14). 
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Supplemental Figure 2.2: Viral load does not affect the differential expression of KLRG1, 
CD27, and Sca-1 on Ly49H+ and Ly49H- NK cells during MCMV-Δm157 infection.   
A) Viral loads from spleens of wt B6 mice 4 days p.i. with 1 x 104 PFU MCMV-Δm157.  Mice 
were injected i.p. daily with a control solution () or with 10 (), 20 (), 40 (), or 80 () 
mg/kg GCV.  B) Proportion of Ly49H+ (filled symbol, solid line) or Ly49H- (open symbol, 
dashed line) splenic NK cells that express KLRG1 (left), CD27 (middle), or Sca-1 (right) from 
wt B6 mice 6 or 8 days p.i. with 1 x 104 PFU MCMV-Δm157.  Mice were injected i.p. daily with 
either a control solution () of 80 mg/kg GCV ().  n = 4 and 8 for days 6 and 8 p.i., 
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respectively. C) Viral loads from spleens of wt B6 mice 2, 4, 6, or 8 days p.i. with 1 x 104 PFU 
MCMV-Δm157.  Mice were injected i.p. daily with either a control solution () of 80 mg/kg 
GCV ().  Symbols represent viral loads for an individual mouse. LOD is the limit of detection.  
GCV (Invivogen, San Diego, CA) was diluted according to manufacturer’s instructions.  GCV 
was diluted in PBS to its final concentration and injected in a total volume of 200 uL. 
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Table 2.I: Marker expression on NK cells from naïve mice or from mice 1.5 or 2 days p.i. 
MCMV 
 Sca-1 KLRG1 CD69 
Naïve 6.7 ± 2.7 42.8 ± 7.8 1.9 ± 0.6 
1.5 days p.i. 44.7 ± 11.9 59.5 ± 4.0 65.9 ± 17.3 Frequency of Marker+ cells (%) 
2 days p.i. 99.1 ± 0.6 83.8 ± 5.7 92.8 ± 4.4 
Frequency of Sca-1, KLRG1, and CD69 expressing splenic NK cells from naïve mice or from 
mice 1.5 or 2 days p.i. with MCMV.  Data is average from 3-4 independent experiments with a 
total of 8-13 mice/time point. 
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Abstract 
Both NK cells and T cells are important for protecting the host from a variety of viral infections, 
including infections by murine CMV (MCMV).  NK cell activation, promotes cytotoxicity, 
cytokine production, and proliferation.  NK cell proliferation following MCMV infection is a 
highly regulated process that has three distinct phases: the nonselective phase, which is mediated 
by pro-proliferative cytokines, the specific phase, which is induced by the specific recognition of 
m157 by the activating receptor Ly49H, and the resolution phase, which has an unknown 
mechanism.  Here, we show that there is abnormal resolution of NK cell proliferation in RAG-
deficient mice, which lack all adaptive immune cells. This phenotype is neither the result of 
differences in viral titers in the absence of these cells, nor is it the result of a lack of competition 
for IL-15.  However, αβ and γδ T cells have a redundant ability to resolve NK cell proliferation.  
Moreover, this process is not dependent on the presence of regulatory T cells or TGFβ, but it is 
dependent on TCR specificity.  Thus, we have identified a novel mechanism of coordination 
between the innate and adaptive immune responses to infection. 
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Introduction 
The immune system can be roughly divided into an innate arm and an adaptive arm.  The innate 
immune system is characterized by rapid, short-lived responses based on the recognition of 
pathogenic patterns.  In contrast, the adaptive immune system is highly specific and results in 
long-lasting memory, but it responds more slowly to an infection.   
 
Although NK cells exhibit some features consistent with the adaptive immune system, such as 
memory-like phenotypes (1-3), NK cells have classically been defined as innate immune 
lymphocytes.  Like other innate immune cells, NK cells rapidly respond to infection and their 
activity is controlled by the integration of signals from germ-line encoded activating and 
inhibitory receptors. 
 
In both humans and mice, NK cells are vital for the defense against a variety of herpesvirus 
infections, including CMV.  Humans that lack NK cells suffer from severe herpesvirus infections 
(4, 5), and mice that have been depleted of NK cells are highly susceptible to viral infections, 
especially herpesvirus infections (6).  Moreover, mouse resistance to mouse CMV (MCMV) 
infection has been linked to the expression of the NK cell activation receptor Ly49H (7-9), which 
recognizes the MCMV-encoded protein m157 (10, 11). 
 
While NK cells are required for resistance against MCMV infection, adaptive immunity is also 
important for fighting MCMV infection.  For example, CD4+ T cells are vital for the control of 
viral replication in the lung and salivary gland (12-14).  Additionally, the transfer of MCMV-
  59 
specific CD8+ T cells into immunocompromised mice is sufficient to protect them from disease 
(15).  Moreover, T cells have been shown to be important for limiting the reactivation of latent 
MCMV infection (16).  Finally, in the absence of T cells, MCMV is able to escape NK cell 
control by mutating m157 (17), which eventually results in the death of the mouse. 
 
While it is well appreciated that both innate and adaptive immunity are important for protection 
against MCMV infection, it remains unclear how these responses are coordinated.  Interestingly, 
the resolution of NK cell responses to MCMV coincides with the initiation of the T cell 
response.  Here, we show that there is abnormal resolution of NK cell proliferation in RAG-
deficient mice (RAG-/-), which lack all adaptive immune cells.  This is not due to differences in 
viral titers between wt and RAG-/- mice or to a lack of competition for IL-15.  However, it 
appears that αβ and γδ T cells function in a redundant manner to resolve NK cell proliferation.  
Both CD8+ and CD4+ T cells (as well as γδ T cells) are capable of terminating NK cell 
proliferation, demonstrating that this process is not dependent on regulatory T cells (Tregs).  In 
addition, this process is dependent on TCR specificity as transgenic T cells from RAG-OTI mice 
were unable to resolve NK cell proliferation.  Together, these results illustrate that the 
developing adaptive immune response actively suppresses the less specific innate immune 
response during viral infection, and for the first time demonstrates that viral specific αβ and γδ T 
cells function redundantly to suppress NK cell proliferation.     
 
Materials and Methods 
Mice                      
C57BL/6 mice were purchased from National Cancer Institute (Charles River, MA).  RAG-/- 
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mice (18), Bim-deficient mice (Bim-/-, (19)), muMT-deficient mice (µMT-/-, (20)), TCR-beta 
chain-deficient mice (TCRβ-/-, (21)), TCR-delta chain-deficient mice (TCRδ-/-, (22)), TCR-beta 
chain/TCR-delta chain double deficient mice (TCRβ/δ-/-), interleukin-10-deficient mice (IL-10-/-, 
(23)), p35-deficient mice (IL-35-/-, (24)), interleukin-4-deficient mice (IL-4-/-, (25)), interferon-
gamma-deficient mice (IFNγ-/-, (26)), mice carrying the Fas ligand-gld mutation (FasL-/-, (27)), 
and galectin-3-deficient mice (Lgals3-/-, (28)) were purchased from Jackson Laboratories (Bal 
Harbor, ME).  MuMT/TCR-beta chain double deficient mice (µMT/TCRβ-/-) were generated in 
the lab by crossing muMT-/- mice with TCRβ-/- mice.  RAG/OTI transgenic mice (29) were 
purchased from Taconic Biosciences (Germantown, NY) or were a kind gift from Skip Virgin 
(Washington University).  The following knockout mice were generously provided by the 
following: Perforin- (Prf1-/-, (30)) and granzyme-B-deficient mice (GzmB-/-, (31)) by Tim Ley 
and Todd Fehniger (Washington University); IL-21 receptor-deficient mice (IL-21R-/-, (32)) by 
Wyeth-Ayerst Pharmaceuticals; IL-10 receptor 2-deficient mice (IL-10R-/-, (33)) by Paul Allen 
(Washington University); caspase-1-deficient mice (Casp1-/-, (34)) by Scott Hultgren 
(Washington University); Klrc1-deficient mice (Klrc1-/-, unpublished) by Marco Colonna 
(Washington University); IL-17-deficient mice (IL-17-/-, (35)) by Thalachallour Mohanakumar 
(Washington University); and macrophage migration inhibitory factor-deficient mice (MIF-/-, 
(36)) by Richard Bucala (Yale University). All mice were on a C57BL/6 background.  Mice 
were maintained under specific pathogen-free conditions and used between 8 and 14 weeks of 
age.  All experiments were conducted in accordance with institutional guidelines for animal care 
and use. 
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Antibodies                                                                                                                          
Biotinylated anti-Ly49H (3D10) antibody (Ab) was a kind gift from Wayne Yokoyama 
(Washington University).  Unless stated otherwise, the following Abs and PE-streptavidin were 
purchased from eBioscience (San Diego, CA): FITC-conjugated anti-Ly49H (3D10) and -CD44 
(IM7); PE-conjugated anti-NK1.1 (PK136, BD Pharmingen, San Diego, CA) and -γδ TCR 
(eBioGL3); PerCP/Cy5.5-conjugated anti-CD3 (145-2C11); allophycocyanin-conjugated anti-
NK1.1 (PK136) and -CD4 (L3T4); PE-Cy7-conjugated anti-CD8 (53-6.7) and -TCRβ (H57-
597); allophycocyanin/eFluor® 780-conjugated anti-CD3 (17A2); allophycocyanin/Cy7-
conjugated anti-CD3e (145-2C11, BD Pharmingen); eFluor® 450-conjugated anti-CD19 
(eBio1D3), -CD11b (M1/70), and -CD44 (IM7); BV421-conjugated anti-NK1.1 (PK136, BD 
Biosciences, San Jose, CA).  
 
MCMV and treatment of mice 
Salivary gland stock of Smith strain MCMV (American Type Culture Collection [ATCC], 
Manassas, VA) was prepared as previously described (37).  A standard plaque assay in 
permissive NIH3T3 fibroblasts (ATCC) was used to determine the viral titer of the stock and 
viral titers from the organs of infected mice (7).  Mice were infected with 5 x 104 PFU/mouse of 
salivary gland stock MCMV i.p.  To test the requirement of TGFβ, mice were injected with 200 
ug anti-TGFβ Ab (clone 1D11.16.8, BioXCell, West Lebannon, NH) or isotype control (clone 
MOPC-21, BioXCell) i.p. at 5 and 7 days p.i. MCMV. 
 
Splenocyte preparation and determination of NK cell numbers     
Single-cell suspensions of splenocytes were prepared using standard techniques (38).  Prior to 
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staining with labeled Abs, splenocytes were incubated in 2.4G2 (anti-Fcγ II/III receptor) 
supernatants (hybridoma from ATCC) in order to block non-specific binding of Abs to Fc 
receptors.  Calibration beads were used to determine NK cell numbers (Spherotech, Lake Forest, 
IL). 
 
BrdU  
We used an acute pulse BrdU system to assess NK cell proliferation at specific times following 
MCMV infection.  Mice were injected i.p. with BrdU (2 mg/mouse) 3 hours before euthanasia.  
Cells were surface stained and then fixed/permeabilized with the Cytofix/Cytoperm kit (BD 
Pharmingen), treated with DNAse, and stained with FITC-conjugated anti-BrdU Abs (BD 
Pharmingen). 
 
In vitro culture of NK cells with T cells 
T cells were isolated from wt B6 mice by negative selection using the Pan T Cell Selection Kit 
(Miltenyi Biotec, Auburn, CA).  All T cells were cultured at 2 x 105 cells per well in 96-well, 
round bottomed plates in 1 ng/mL recombinant mouse IL-7 (Biolegend, San Diego, CA).  To 
stimulate T cells, T cells were cultured with 10 ug/mL plate-bound anti-CD3 (clone 145-2C11, 
BioXCell) and 2 ug/mL plate-bound anti-CD28 (clone 37.51, BioXCell).  NK cells were isolated 
by negative selection with magnetic beads (Miltenyi Biotec) from TCRβ/δ-/- mice.  NK cells 
were labeled with 2 µM CFSE (Molecular Probes, Eugene, OR) for 7 min at 37°C.  The reaction 
was quenched by incubating the cells with RPMI 1640 media with 10% fetal calf serum for 15 
min at 37°C. CFSE-labeled NK cells were cultured in 96-well plates with 20 ng/mL of IL-15 
(Peprotech, Rocky Hill, NJ).  After culture for 2 days, NK cells and 1-8 x 104 stimulated or 
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unstimulated T cells were combined and cultured for an additional 2 days in the presence of 25 
ng/mL IL-15, and 1 ng/mL IL-7.  Wells with stimulated T cells also contained plate-bound anti-
CD3 and -CD28.  Dead cells were excluded using 7-aminoactinomycin (BD Pharmingen, CA). 
 
T cell adoptive transfer 
Total T cells were enriched from mice using the Pan T cell Isolation Kit (Miltenyi Biotec), 
unless otherwise indicated.  In experiments, where only CD4+ or CD8+ T cells were transferred, 
the CD4+ T cell Isolation Kit and CD8+ T cell Isolation Kit were used, respectively (Miltenyi 
Biotec).  Cells were resuspended in PBS and injected i.v. into mice (on average, mice received 
6.5 x 106 cells).  After 6 days, mice were infected with MCMV.  For some experiments, as 
indicated in the text, T cells were isolated from spleens that had been harvested the day before 
and shipped overnight to our laboratory.  Spleens from the following knockout mice were 
graciously provided by the following: galectin-1-deficient mice (Lgals1-/-, (39)) by Barry Rouse 
(University of Tennessee); Ptprj-deficient mice (Ptprj-/-, (40)) by Art Weiss (University of 
California San Francisco); Fgl2-deficient mice (Fgl2-/-, (41)) by Steve Smiley (Trudeau 
Institute); Tigit-deficient mice (Tigit-/-, (42)) by Katherine Lewis (Zymogenetics, Seattle, WA); 
and Entpd1-deficient mice (Entpd1-/-, (43)) by Simon Robson (Harvard University).  
 
Flow Cytometry 
A FACSCalibur flow cytometer (BD Pharmingen) using CellQuest software (BD Biosciences) or 
a FACScan (BD Pharmingen) with DxP multi-color upgrade (Cytek Development, Fremont, CA) 
and FlowJo CE software (TreeStar, Ashland, OR) were used to collect flow cytometry data.  
FlowJo (TreeStar) was used to analyze data.  NK cells were identified as CD3-, NK1.1+.   
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Cell sorting and RNA Isolation 
Prior to sorting, splenocytes were enriched for T cells using either the Pan T cell Isolation Kit 
(for γδ T cells from TCRβ-/- mice, Miltenyi Biotec) or the CD8+ T cell Isolation Kit (for naïve 
CD8+ T cells, MCMV-specific C8+ T cells, and ova-specific CD8+ T cells, Miltenyi Biotec).  
Dead cells were identified by staining with 7-AAD.  Naïve CD8+ T cells were isolated from wt 
B6 mice as CD11b-CD19-NK1.1-CD3+CD8+CD4-CD44-.  Ova-specific CD8+ T cells were 
isolated from OTI transgenic mice 5 days p.i. MCMV as CD11b-CD19-NK1.1-CD3+CD8+CD4-
CD44+/-.  MCMV-specific CD8+ T cells were isolated from wt B6 mice 5 days p.i. MCMV by 
staining with m45-specific tetramers (m45tet, H-2Db/HGIRNASFI; NIH Tetramer Core Facility, 
Atlanta, GA).  Cells were identified as CD11b-CD19-NK1.1-CD3+CD8+CD4-CD44+m45tet+.  
Gamma/delta T cells were isolated from TCRβ-/- mice 5 days p.i. MCMV as CD11b-CD19-
NK1.1-CD3+CD44+γδTCR+.  The use of TCRβ-/- mice prevented any contamination by αβ T 
cells.  Each sample was isolated from an individual mouse.  We collected 54,000-290,000 cells 
for each sample using a MoFlo cell sorter (Beckman Coulter, Brea, CA).  RNA was isolated 
using the RNAqeuous-Micro kit (Invitrogen Life Technologies, Grand Island, NY) and treated 
with DNAse I. 
 
Microrarray hybridization and analysis 
RNA was amplified with the Pico SL amplification kit (NuGEN, San Carlo, CA), and labeled, 
fragmented, and hybridized, with the WT Terminal Labeling and Hybridization Kit (Affymetrix, 
Santa Clara, CA).  RNA was hybridized to the Affymetrix MoGene 1.0 ST array.  Raw data was 
normalized using the robust multichip average algorithm and quantile normalization (Partek 
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Genomic Suite, St. Louis, MO).  Genes were determined to be differentially expressed based on 
ANOVA analysis (Partek Genomic Suite).  Genes were determined to encode proteins that were 
expressed on the cell surface or secreted based on the literature, GO annotation, predicted protein 
structure, and predicted signaling sequences. 
 
Real-time PCR 
Cell sorting and RNA isolation were performed as previously described.  SuperScript III 
(Invitrogen Life Technologies) with oligo-dT primers were used to prepare cDNA.  Quantitative 
real-time PCR (qRT-PCR) was performed using Taqman Universal PCR Master Mix (Applied 
Biosystems, Foster City, CA) on an ABI 7500 Fast Real-Time PCR System (Applied 
Biosystems).  Gene expression was normalized to that of beta actin (Applied Biosystems, assay 
Mm00607939_s1).  PCR conditions were 2 min at 50°C, 10 min at 95°C, followed by 45 two-
step cycles of 30 s at 95°C and 1 min at 60°C.  The following assays were purchased from 
Applied Biosystems: Casp1, Mm00438023_m1; Gzmk, Mm00492530_m1; Lgals1, 
Mm00839408_g1; Lgals3, Mm00802901_m1; Ptprj, Mm00501277_m1; Ctla2a, 
Mm00484032_g1; Ctla2b, Mm01621586_s1; Fgl2, Mm00433327_m1; Pglyrp1, 
Mm00437150_m1; S100a4, Mm00803372_g1.   
 
Statistical analysis 
Microsoft Excel and GraphPad Prism (GraphPad Software, La Jolla, CA) were used to analyze 
data.  We used unpaired, two-tailed t tests were used to determine statistically significant 
differences.  Error bars in figures represent standard deviations from mean value. 
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Results 
NK cells undergo three distinct phases of proliferation during viral infections, such as MCMV 
(Fig. 3.1A; reviewed in (44)).  During the first, nonselective phase following MCMV infection, 
there is increased proliferation of both Ly49H+ and Ly49H- NK cells, driven by pro-proliferative 
cytokines such as IL-15 (45, 46) (Fig. 3.1A, panel I).  During the second, specific phase, there is 
preferential proliferation of Ly49H+ cells, which is the result of the specific recognition of m157 
by Ly49H (38) (Fig. 3.1A, panel II).  Following this phase there is a peak in NK cell numbers, 
representing an approximate 3-fold expansion (Fig. 3.1B).  Additionally, the specific phase of 
proliferation drives the expansion of the Ly49H+ population from approximately 55% in naïve 
mice to 85% by 6 days p.i. (Fig. 3.1C).  Finally, during the resolution phrase, there is decreased 
proliferation of NK cells back to baseline (Fig. 3.1A, panel III) and contraction of the number of 
NK cells back to homeostatic levels (Fig. 3.1B).  However, the mechanism driving the resolution 
phase is unknown. 
 
We discovered that there was prolonged proliferation of NK cells in RAG-/- mice (Fig. 3.1D), 
which lack all adaptive lymphocytes.  This abnormal resolution of proliferation was seen in both 
Ly49H+ and Ly49H- NK cell populations (Fig. 3.1E).  Despite the increased frequency of 
proliferating NK cells, there was not prolonged expansion of NK cell numbers in RAG-/- mice 
(Fig. 3.1F), which is consistent with a recent report that suggested that NK cell expansion but not 
proliferation is controlled by apoptosis (47, 48).  Moreover, we have also seen that while there is 
prolonged expansion of NK cells in Bim-/- mice (Fig. 3.2A), there is not an increase in the 
frequency of proliferating NK cells (Fig. 3.2B).  Therefore, the regulation of the proliferation and 
expansion of NK cells appears to be decoupled.   
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We hypothesized, that the prolonged proliferation of NK cells in RAG-/- mice might be in 
response to elevated viral titers in the absence of the adaptive immune system.  However, we 
could not detect a difference in splenic or hepatic viral titers between wt B6 mice, RAG-/- mice, 
or mice that lacked B cells or αβ T cells at 8 days p.i. (Fig. 3.3A and B).  Thus, the prolonged 
proliferation of NK cells in RAG-/- mice does not appear to be the result of increased viral titers 
in these animals.   
 
Next, we wanted to determine what adaptive lymphocyte populations are required to resolve NK 
cell proliferation.  To do this we infected gene-targeted mice lacking limited subsets of adaptive 
lymphocytes: TCRβ-/- mice lack all αβ T cells and NKT cells, TCRδ-/- mice lack all γδ T cells, 
and µMT-/- mice lack all B cells.  When these mice were infected and NK cell proliferation was 
assessed at several times p.i., we saw that there was no significant difference in the frequency of 
proliferating NK cells in any of the knockout mice compared to wt B6 mice (Fig. 3.3C).  Based 
on these results, we hypothesized that there may be redundancy between multiple adaptive 
lymphocyte subpopulations.  Additionally, TCRβ-/- mice lack memory T cells and NKT cells, 
which are the other major lymphocyte populations that also use IL-15 besides NK cells ((49-
52)).  Because there was normal resolution of NK cell proliferation in the TCRβ-/- mice, we 
conclude that competition for IL-15 is not what normally drives the resolution of NK cell 
proliferation. 
 
To identify what adaptive lymphocyte populations were required for the resolution of NK cell 
proliferation, we infected double knockout mice that only had a single adaptive lymphocyte 
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population: µMT/TCRβ-/- mice only have γδ T cells and TCRβ/δ-/- mice only have B cells.  There 
was normal resolution of NK cell proliferation in the µMT/TCRβ-/- mice (Fig. 3.3D), 
demonstrating that γδ T cells were sufficient for the resolution of NK cell proliferation.  
Conversely, there was prolonged proliferation in the TCRβ/δ-/- mice phenocopying that observed 
in RAG-/- mice (Fig. 3.3D).  Therefore, B cells are not sufficient for the resolution of NK cell 
proliferation, and αβ and γδ T cells appear to have a redundant ability to terminate NK cell 
proliferation.  Finally, we confirmed that there were not increased splenic or hepatic viral titers 
in the TCRβ/δ-/- mice compared to wt B6 (Fig. 3.3D and E) that might have been driving the 
increased proliferation of NK cells in the TCRβ/δ-/- mice. 
 
To confirm the ability of T cells to inhibit NK cell proliferation, we developed an in vitro co-
culture system.  In order to analyze proliferation, NK cells were labeled with CFSE (Fig. 3.4A).  
NK cells were stimulated with IL-15, and T cells with plate-bound CD3 and CD28 Abs.  After 2 
days, NK cells were combined with various numbers of T cells that either had or had not been 
stimulated by plate-bound Abs (Fig. 3.4B).  Indeed, we saw decreased CFSE dilution in NK cells 
that were cultured with stimulated T cells for 2 days (Fig. 3.4C).  This appeared to be a dose-
dependent effect, as incubation with greater numbers of T cells resulted in greater suppression of 
NK cell proliferation.  Additionally, there was greater inhibition of NK cell proliferation when 
the T cells were stimulated with plate-bound Ab during the culture with NK cells compared to 
when they were cultured without continued stimulation (Fig. 3.4C).  Furthermore, given the high 
purity of the T cell and NK cell cultures after 2 days of culture (approximately 70% and 85%, 
respectively), this data supports T cells acting directly on NK cells and not through some 
intermediary cell type. 
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In order identify specific characteristics of T cells required for the resolution of NK cell 
proliferation, we developed an adoptive transfer (AT) system (Fig. 3.5A).  Briefly, TCRβ/δ-/- 
mice were injected i.v. with T cells from a mouse of interest.  After 6 days, mice were infected 
with MCMV, and 8 days p.i. NK cell proliferation was analyzed.  When we performed a mock 
AT by injecting TCRβ/δ-/- mice with PBS, there was still an increased frequency of proliferating 
NK cells indentical to that observed in untreated TCRβ/δ-/- mice (Fig. 3.5B).  In contrast, AT of 
wt T cells resulted in a decrement in the frequency of proliferating NK cells similar to that 
observed in wt B6 mice (Fig. 3.5B), supporting our observations that T cells are able to suppress 
viral-induced NK cell proliferation.  Moreover, enriched CD8+ or CD4+ T cell populations were 
also able to mediate suppression of proliferating NK cells to similar levels as those observed in 
TCRβ/δ-/- mice which received unenriched wt T cells.  This tells us that both CD8+ and CD4+ T 
cells can resolve NK cell proliferation; however, while CD8+ T cells were able to resolve NK 
cell proliferation to levels identical to those in mice that received total T cells, mice that received 
only CD4+ T cells had an intermediate phenotype.  In contrast to several previous reports of T-
cell-mediated inhibition of NK cells (53-57), this data demonstrates that this process is not 
dependent on Tregs. 
 
To determine whether this process was dependent on TCR specificity, we adoptively transferred 
T cells from a RAG/OTI transgenic mouse, which has only CD8+ T cells that can recognize a 
peptide derived from ovalbumin and not MCMV (29).  Indeed, in these mice the transgenic T 
cells were unable to resolve NK cell proliferation and there was an increased frequency of 
proliferating NK cells identical to that observed in control mice which did not receive adoptively 
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transferred T cells (Fig. 3.5B).  We confirmed this result by directly infecting RAG/OTI mice 
with MCMV and observed prolonged NK cell proliferation similar to that observed in RAG-
deficient mice (data not shown). 
 
Having established that we could distinguish characteristics of T cells necessary to suppress 
viral-induced NK cell proliferation in our AT system, we proceeded to evaluate a number of 
candidate molecules using enriched T cells from gene-targeted mice, including T cells from mice 
deficient in proteins involved in cytotoxicity.  When T cells that lacked either granzyme B or 
perforin were adoptively transferred, we observed a normal frequency of proliferating NK cells 
at 8 days p.i., suggesting that neither protein was required for the suppression of NK cells 
proliferation (Fig. 3.5B).  We subsequently investigated the impact of a number of cytokines 
generated by T cells, including IFN-γ, IL-4, IL-10, IL-17, IL-35, and MIF.  TCRβ/δ mice that 
received T cells that were unable to make one of these cytokines all had a normal frequency of 
proliferating NK cells 8 days p.i. (Fig. 3.5B).  From these results, we conclude that the absence 
of T cell generation of these individual cytokines is not sufficient to inhibit T cell mediated 
resolution of viral-induced NK cell proliferation. 
 
TGFβ has been shown to mediate repression of NK cells by T cells in a variety of contexts (54, 
55, 57).  Because TGFβ-deficient mice have significant embryonic lethality and those that are 
born alive die by 3-4 weeks of age due to multifocal inflammation (58, 59), we could not test the 
requirement of TGFβ for the resolution of NK cell proliferation using our AT system.  Therefore, 
we used TGFβ blocking Abs to determine if TGFβ was involved in the suppression of NK cell 
proliferation during MCMV infection.  There was not an increased frequency of proliferating NK 
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cells from mice that were treated with the anti-TGFβ Ab compared to those that received an 
isotype control Ab, suggesting that TGFβ is not required for the resolution of NK cell 
proliferation (Fig. 3.5C).  It has previously been suggested that IL-21, which limits the duration 
of NK cell activation while promoting CD8+ T cell activity, may be involved in the transition 
between the innate and adaptive immune response (32).  To test whether IL-21 is involved in the 
resolution of NK cell proliferation, we infected IL-21R-/- mice and evaluated NK cell 
proliferation 4, 6, and 8 days p.i. MCMV.  There was not an increase in the frequency of 
proliferating NK cells from IL-21R-/- compared to wt B6 mice (Fig. 3.5D), indicating that IL-21 
is not required for the resolution of NK cell proliferation. 
 
To identify genes required for T cell-mediated resolution NK cell proliferation, we performed an 
unbiased microarray screen to compare gene expression between CD8+ T cells from naïve mice 
to a variety of T cell populations from mice 5 days p.i. MCMV.  The T cell populations from 
infected mice included those that could resolve NK cell proliferation (i.e., MCMV-specific CD8+ 
T cells and γδ T cells) and those that could not (i.e., OTI transgenic CD8+ T cells).  We 
generated lists of genes that were upregulated by T cells from infected mice compared to the 
CD8+ T cells from naïve mice.  We limited our analysis to genes that were upregulated because 
our model suggests that the absence of a gene results in prolonged NK cell proliferation.  As one 
would expect, there were hundred of genes that were upregulated in our infected T cell 
populations (Fig. 3.6A, Supplemental Table 3.I-VII).  The lists of differentially expressed genes 
included some expected results including TCR gamma chain being uniquely expressed by γδ T 
cells and CD44, which was used to sort specifically activated αβ and γδ T cells, being expressed 
by both MCMV-specific CD8+ T cells and γδ T cells (Fig. 3.5B). 
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Because both MCMV-specific CD8+ T cells and γδ T cells can resolve NK cell proliferation, we 
focused on the genes that were uniquely upregulated, at least 3-fold, by these 2 populations (Fig. 
3.6B and C) and not by OTI T cells, which were unable to resolve NK cell proliferation (Fig. 
3.5B).  Furthermore, the lists were limited to proteins that are either expressed on the cell surface 
or secreted by the cell since we know that T cells must be interacting, either directly or 
indirectly, with NK cells.  This approach yielded 35 proteins.  We confirmed the differential 
expression of most of these genes by either qRT-PCR or flow cytometry, which eliminated 6 
genes as false positives (Fig. 3.6D and data not shown). For example, qRT-PCR showed the 
Pglyrp1 was not actually upregulated in MCMV-specific CD8+ T cells.  Additionally, we found 
that Ctla2b was upregulated by all three subsets of T cells. 
 
After confirming the findings from our microarray, we went on to test the requirement of 10 of 
these genes (for which gene-targeted deficient mice were available on a B6 background) in the T 
cell-mediated down-modulation of NK cell proliferation using our AT system (Fig. 3.7).  
However, there was a normal frequency of proliferating NK cells for all 10 of the genes that we 
tested.  Therefore, none of the proteins encoded by these genes are required for the T cell-
mediated suppression of MCMV-induced NK cell proliferation. 
 
Discussion 
Although the differential kinetics of the innate and adaptive immune responses are well 
established, the mechanism of the transition from the early innate immune response to the more 
specific adaptive immune response has been poorly characterized.  Here, we show that there is 
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defective resolution of NK cell proliferation in the absence of adaptive lymphocytes.  This was 
not due to differences in viral titers compared to wt B6 mice nor to the absence of competition 
for IL-15.  Rather, we demonstrate for the first time that αβ and γδ T cells have a redundant 
ability to down-modulate viral-induced NK cell proliferation.  This is particularly interesting 
given the temporal correlation of the resolution of NK cell proliferation and the onset of the T 
cell response to MCMV. 
 
There are several reports in the literature of T cells influencing NK cell responses.  In some 
cases, T cells have been shown to promote NK cell responses.  For example, CD4+ T cells 
promote NK cell responses to Leishmania major (60).  In several different contexts, including 
tumors and autoimmune disease, it has been shown that Tregs can inhibit NK cell responses 
through a couple of different mechanisms.  For example, Tregs can directly limit NK cell activity 
via the production of TGFβ (54, 55) or by limiting the availability of IL-2 (53, 56, 61).  In 
addition, it has been suggested that IL-21 might be important for the transition from the innate to 
the adaptive immune response as it limits the duration of NK cell responses while promoting T 
cell activation (32).  However, to our knowledge, there have been no reports of T cells 
specifically limiting NK cell responses during infection. 
 
We have shown that among αβ T cells both CD8+ and CD4+ T cells are sufficient to down-
modulate NK cell proliferative responses (Fig. 3.5B).  The ability of CD8+ T cells to suppress 
viral-induced NK cell proliferation demonstrates that that this process is not dependent on Treg 
cells.  Treatment of mice with an anti-TGFβ blocking Ab did not result in an increased frequency 
of proliferating NK cells (Fig. 3.5C); therefore, this process is not dependent on the activity of 
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TGFβ.  Similarly, there was no difference in the frequency of proliferating NK cells in IL-21R-/- 
mice compared to wt B6 mice (Fig. 3.5D), which rules out a role for IL-21 in the termination of 
NK cell proliferation.  Moreover, we found that while the high-affinity IL-2 receptor is 
upregulated on MCMV-specific CD8+ T cells, it is not upregulated on γδ T cells (data not 
shown), which eliminates the possibility of activated T cells acting as an IL-2 “sink”. Therefore, 
it appears that a unique mechanism is used by T cells to resolve NK cell proliferation following 
viral infection. 
 
In order to elucidate this novel mechanism, we performed a microarray to compare gene 
expression between T cells that were and were not able to resolve NK cell proliferation.  We 
identified a number of genes that were uniquely upregulated in MCMV-specific CD8+ T cells 
and γδ T cells from MCMV-infected mice compared to CD8+ T cells from naïve mice (Fig. 3.6).  
Based on the literature, these candidates included a number of genes that had the potential to 
inhibit NK cell proliferation.  For example, Fas-mediated apoptosis has been implicated in the 
resolution of T cell activation (reviewed in (62)); therefore, T cell expression of Fas ligand 
(FasL) seemed like a plausible mechanism of limiting NK cell proliferation.  Similarly, it has 
been previously been shown that T cells can inhibit NK cell activity in a tumor challenge model 
through the activity of the gene Entpd1, which encodes the CD39 protein (63).  We tested the 
requirement ten of identified targets (for which gene-targeted deficient mice were available on a 
B6 background), including FasL and Entpd1, using our AT system, but none of these genes were 
required by T cells for the resolution of NK cell proliferation (Fig.  3.7A).   
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There are several possible reasons that we were unable to delineate the mechanism by which T 
cells resolve NK cell proliferation.  First, there are genes identified by the microarray that have 
not yet been tested in the AT system.  Second, while αβ and γδ T cells have a redundant ability to 
resolve NK cell function, they may not use the same mechanism.  Thus, the gene may not be 
upregulated by both αβ and γδ T cells but only one of these subsets.  Finally, it is possible that 
the mechanism is not transcriptionally regulated and therefore cannot be identified based on 
microarray analysis. 
 
Regardless, we provide substantial evidence for the adaptive immune system’s direct role in the 
resolution of viral-induced NK cell proliferation.  While Ly49H+ NK cells are required for early 
protection against MCMV (7-9), this is not sufficient for long-term survival of the host as m157-
escape mutant virus develops in the absence of a T cell response, which can target a broader 
range of viral epitopes than NK cells (17).  Thus, the transition from the innate to the adaptive 
response is vital for the host’s ability to survive infection.  In addition, understanding the 
mechanisms regulating NK cell proliferation are also relevant to human health and disease.  
Dysregulation of NK cell proliferation and/or apoptosis can result in either chronic NK cell 
lymphocytosis (CNKL) or aggressive NK cell large granular cell leukemia (NK-LGL).  While 
CNKL usually follows an indolent course (reviewed in (64)), NK-LGL is a very aggressive 
leukemia.  Even with treatment, patients with NK-LGL generally die within 1-2 months of 
diagnosis (65).  Clearly, a better understanding of the regulation of NK cell proliferation could 
be translated into improved therapy for patients with NK-LGL.   
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Figures 
 
Figure 3.1: There is prolonged proliferation of NK cells in RAG-/- mice. 
A) Proportion of Ly49H+ (solid line, filled circle) and Ly49H- (dotted line, open circle) 
proliferating splenic NK cells (BrdU+) from wt B6 mice at various times following MCMV 
infection (n = 282 mice).  B) Number of splenic NK cells from wt B6 mice at various times 
following MCMV infection (n = 24 mice).  C) Frequency of Ly49H+ NK cells from wt B6 mice 
at various times following MCMV infection (n = 282).  D) Frequency of total proliferating 
splenic NK cells from wt B6 (circles) and RAG-/- (triangles) mice at various times following 
0 2 4 6 8 10
0
10
20
30
40
50
60
days p.i. MCMV
B
rd
U
+  s
pl
en
ic
N
K
 c
el
ls 
(%
) I II III
0 2 4 6 8 10
40
50
60
70
80
90
100
days p.i. MCMV
Ly
49
H
+  N
K
 c
el
ls 
(%
)_
__
0 2 4 6 8 10
0
2
4
6
8
10
days p.i. MCMV
N
um
be
r o
f s
pl
en
ic 
N
K
 c
el
ls 
(x
10
6 )
A
C
B
0 2 4 6 8 10
0
10
20
30
40
50
60
days p.i. MCMV
B
rd
U
+  s
pl
en
ic
N
K
 c
el
ls 
(%
)
D
0 2 4 6 8 10
0
10
20
30
40
50
60
days p.i. MCMV
B
rd
U
+ 
sp
le
ni
c 
N
K
 c
el
ls 
(%
)
E
0 2 4 6 8 10
0
2
4
6
8
10
days p.i. MCMV
N
um
be
r o
f s
pl
en
ic 
N
K
 c
el
ls 
(x
10
6 )
F
  77 
MCMV infection (wt B6: n = 289; RAG-/-: n = 93).  E) Proportion of Ly49H+ (solid line, filled 
triangles) and Ly49H- (dotted line, open triangles) proliferating splenic NK cells (BrdU+) from 
RAG-/- mice at various times following MCMV infection (n = 93 mice).  F) Number of splenic 
NK cells from RAG-/- mice at various times following MCMV infection (n = 24 mice).   
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Figure 3.2: Bim regulates contraction of NK cells but not the resolution of NK cell 
proliferation. 
A) Number of splenic NK cells from wt B6 (black circles) and Bim-/- (open squares) mice at 8 
days p.i. with MCMV.  B) Frequency of total proliferating splenic NK cells from wt B6 (black 
circles) and Bim-/- (open squares) mice at 8 days p.i. with MCMV.  A and B) show cumulative 
results from 3 independent experiments each with 3-4 mice per genotype.  **p<0.01, NS = not 
significant. 
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Figure 3.3: Both αβ and γδ T cells have a redundant ability to resolve NK cell proliferation. 
A and B) Splenic (A) and hepatic (B) viral titers at 8 days p.i. MCMV from wt B6 (black bar), 
RAG-/- (white bar), µMT-/- (grey bar), or TCRβ-/- (grey striped bar) mice.  n = 4 mice per group.  
C) Frequency of proliferating splenic NK cells (BrdU+) from wt B6 (black circles), RAG-/- 
(black triangles), TCRβ-/- (grey squares), TCRδ-/- (grey diamonds), and µMT-/- (grey inverted 
triangles) mice at various times following MCMV infection (wt B6: n = 113 mice; RAG-/-: n = 
80; TCRβ-/-: n = 23; TCRδ-/-: n = 9; µMT-/-: n = 20).  D) Frequency of proliferating splenic NK 
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cells (BrdU+) from wt B6 (black circles), RAG-/- (black triangles), µMT/TCRβ-/- (black squares), 
TCRβ/δ-/- (black diamonds), mice at various times following MCMV infection (wt B6: n = 28 
mice; RAG-/-: n = 16; µMT/TCRβ-/-: n = 25; TCRβ/δ-/-: n = 8).  E) Splenic viral titers at 8 days 
p.i. MCMV from wt B6 (black bar, n = 2) or TCRβ/δ-/- (black striped bar, n = 4) mice.  Spleens 
form both groups had been previously thawed.  F) Hepatic viral titers at various times following 
MCMV infection from wt B6 (circles, n = 2 mice/time point) or TCRβ/δ-/- (diamonds, n = 4 
mice/time point) mice.   
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Figure 3.4: NK/T cell co-culture confirms that activated T cells inhibit NK cell 
proliferation. A) CFSE dilution by NK cells cultured without any T cells in low- (3ng/mL) or 
high-dose (20 ng/mL) IL-15 for 4 days.  B) T cell activation as measured by CD25 and CD44 
expression on T cells cultured for 4 days in low-dose IL-7 with (stimulated) or without 
(unstimulated) plate-bound anti-CD3 and anti-CD28. C) CFSE dilution by NK cells cultured in 
high-dose IL-15 with stimulated (black line) or unstimulated (grey shaded T cells).  Top row 
shows NK cells cultured with T cells that were continuously stimulated with plate bound anti-
CD3 and anti-CD28.  Bottom row shows NK cells that were cultured with T cells that were not 
stimulated after day 2.  The number of T cells per well increases from left to right. 
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Figure 3.5: Adoptive transfer of T cells into TCRβ/δ-/- mice to determine the requirements 
for the resolution of NK cell proliferation. 
A) Schematic depicting AT strategy.  B) Frequency of proliferating NK cells from wt B6 mice 
(open circles, n = 52), TCRβ/δ-/- mice (open diamonds, n = 9) or TCRβ/δ-/- mice injected i.v. with 
PBS (open squares, n = 80) or adoptively transferred with total T cells from wt B6 mice (open 
triangles, n = 80), CD8+ αβ T cells from TCRδ-/- mice (open inverted triangles, n = 11), CD4+ αβ 
T cells from TCRδ-/- mice (black circles, n = 16), T cells from OTI trangenic mice (black 
diamond, n = 10), GzmB-/- mice (black squares, n = 4), Prf1-/- mice (black triangles, n = 7), IFNγ-
/- mice (black inverted triangle, n = 15), IL-4-/- (grey circles, n = 13), IL-10-/- mice (grey 
diamonds, n = 16), IL-17-/- (grey squares, n = 9), IL-35-/- mice (grey triangles, n = 6), or MIF-/- 
mice (grey inverted triangles, n = 11).  Cumulative results shown from 2-25 independent 
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experiments.  C) Frequency of proliferating NK cells 8 days p.i. MCMV form wt B6 mice 
treated with 200 ug of isotype control Ab (black circles) or anti-TGFβ Ab (open diamonds) at 5 
and 7 days p.i. MCMV. Cumulative results from 2 independent experiments, n = 5-6 mice/group.  
D) Frequency of proliferating NK cells 4, 6, and 8 days p.i. MCMV form wt B6 mice (black 
circles) or IL-21R-/- mice (open squares).  Results from a 1-2 experiments each with 3-4 
mice/group/time point.   
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Figure 3.6: Analysis of gene expression in naïve CD8+ T cells compared to CD8+ and γδ T 
cells from mice 5 days p.i. with MCMV. 
A) Hierarchical clustering of gene expression.  B) Venn diagram showing overlap of genes that 
encode secreted or surface expressed proteins that were upregulated at least 3 fold compared to 
expression in naïve CD8+ T cells.  C) Plot showing the fold change of gene expression in 
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MCMV-specific CD8+ T cells (x-axis) and in γδ T cells (y-axis) relative to CD8+ T cells from 
naïve mice.  Genes shown were upregulated greater than 3-fold by both subsets and are either 
expressed on the cell surface or secreted.  Points in grey were not confirmed by subsequent qRT-
PCR or flow cytometry.  Genes labeled in blue were subsequently tested using our AT system.  
D) Representative data showing gene expression as determine by qRT-PCR. 
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Figure 3.7:  Adoptive transfer of T cells into TCRβ/δ-/- mice to test the requirement of genes 
identified in the microarray.  A) Frequency of proliferating NK cells from TCRβ/δ-/- mice 
injected i.v. with PBS (open squares, n = 19) or adoptively transferred with total T cells from wt 
B6 mice (open triangles, n = 25), Casp1-/- mice (open inverted triangles, n = 6), Lgals3-/- mice 
(open circles, n = 5), Lgals1-/- mice (open diamond, n = 5), Fgl2-/- mice (black squares, n = 6), 
Ptprj-/- mice (black triangles, n = 4), FasL-/- mice (black inverted triangle, n = 5), Klrc1-/- (black 
circles, n = 3), TIGIT-/- mice (black diamonds, n = 6), Entpd1-/- (grey squares, n = 5), or IL-10R-/- 
mice (grey triangles, n = 9).  Underlined donor name indicates that T cells were harvested from 
spleens that were shipped overnight from lab of origin.  Cumulative results shown from 1-7 
independent experiments.   
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Supplemental Tables 
Supplemental Table 3.I: List of genes upregulated at least 3 fold in only MCMV-specific CD8+ 
T cells and γδ T cells compared to naïve CD8+ T cells 
MCMV-specific vs. 
naïve γδ T cell vs. naïve 
Ova-specific vs. 
naive Accession 
Number 
Gene 
Symbol Gene Name (Alias) p-value Fold Change p-value 
Fold 
Change p-value 
Fold 
Change 
NM_008630 Mt2 metallothionein 2  9.25E-08 43.4584 1.01E-04 4.43398 5.84E-01 1.10193 
NM_001136068 Klrc1 
killer cell lectin-like receptor subfamily C, 
member 1 (NKG2A)  3.54E-08 43.3192 2.44E-08 85.2363 5.96E-03 1.77338 
NM_175660 Hist1h2ab histone cluster 1, H2ab  2.68E-06 42.939 9.54E-05 11.571 7.96E-02 1.75953 
NM_020034 Hist1h1b histone cluster 1, H1b  2.69E-09 42.6792 1.28E-07 11.0918 1.85E-04 2.0628 
NM_178215 Hist2h3b histone cluster 2, H3b  4.95E-08 42.3249 1.30E-06 13.5234 3.20E-04 2.73257 
NM_029617 Casc5 cancer susceptibility candidate 5  1.58E-07 41.9726 6.89E-06 11.0511 6.13E-04 2.9016 
NM_001081117 Mki67 
antigen identified by monoclonal antibody Ki 
67  4.61E-09 41.4634 1.15E-07 13.7475 3.95E-05 2.68579 
NM_001113179 Bub1 
budding uninhibited by benzimidazoles 1 
homolog (S. cerevisiae) 3.45E-05 39.1308 1.51E-03 9.18563 2.49E-01 1.64121 
NM_016970 Klrg1 
killer cell lectin-like receptor subfamily G, 
member 1  1.00E-08 39.1098 2.23E-07 13.7134 8.91E-03 1.5343 
NM_178215 Hist2h3b histone cluster 2, H3b  1.69E-07 38.5356 4.40E-06 12.5847 1.40E-03 2.48842 
NM_010615 Kif11 kinesin family member 11  1.01E-09 38.4582 4.40E-08 10.7266 3.85E-05 2.18508 
NM_178216 Hist2h3c1 histone cluster 2, H3c1  4.62E-08 38.1888 1.26E-06 12.41 3.13E-04 2.64106 
NM_001172092 Depdc1a DEP domain containing 1a  8.24E-09 37.9935 1.05E-06 7.5128 3.88E-03 1.62783 
NM_175563 Prr11 proline rich 11  2.15E-08 37.0329 1.10E-06 9.78862 6.78E-04 2.13502 
NM_178204 Hist1h3d histone cluster 1, H3d  1.15E-07 36.5061 2.84E-06 12.4201 9.59E-04 2.47816 
NM_009828 Ccna2 cyclin A2  2.92E-09 36.415 1.28E-07 10.2779 1.20E-04 2.11961 
NM_009104 Rrm2 ribonucleotide reductase M2  3.63E-08 36.0027 1.41E-06 10.5261 1.40E-03 2.04621 
NM_008196 Gzmk granzyme K  6.13E-08 34.9689 4.24E-06 8.50915 8.82E-01 -1.0235 
NM_001172092 Depdc1a DEP domain containing 1a  2.00E-08 33.1508 3.07E-06 6.56834 1.27E-02 1.51933 
NM_007630 Ccnb2 cyclin B2  7.20E-09 32.4604 2.57E-07 10.2027 1.03E-03 1.7886 
NM_013552 Hmmr 
hyaluronan mediated motility receptor 
(RHAMM)  1.93E-09 32.3703 2.94E-07 6.57572 2.46E-03 1.50953 
NM_013548 Hist1h3f histone cluster 1, H3f  3.15E-07 32.1184 8.37E-06 10.9556 3.30E-03 2.25112 
NM_145073 Hist1h3g histone cluster 1, H3g  5.25E-07 31.2127 1.37E-05 10.7659 4.58E-03 2.25761 
NM_145073 Hist1h3g histone cluster 1, H3g  3.94E-07 30.2135 9.79E-06 10.7297 2.94E-03 2.31892 
NM_013548 Hist1h3f histone cluster 1, H3f  3.27E-07 30.1586 9.76E-06 10.0653 3.21E-03 2.23621 
NM_007585 Anxa2 annexin A2  1.96E-07 29.774 3.11E-06 12.594 9.79E-04 2.51335 
NM_145073 Hist1h3g histone cluster 1, H3g  4.12E-07 29.1715 1.13E-05 10.1042 4.90E-03 2.13882 
NM_001012273 Birc5 baculoviral IAP repeat-containing 5  8.43E-10 28.9232 3.80E-08 8.8145 7.82E-05 1.8763 
NM_172301 Ccnb1 cyclin B1  3.66E-06 28.3598 5.46E-04 5.58896 1.59E-01 1.49836 
NM_178395 Zdhhc2 zinc finger, DHHC domain containing 2  9.19E-09 27.7803 1.93E-06 5.53779 5.11E-01 -1.07676 
NM_013550 Hist1h3a histone cluster 1, H3a  6.30E-07 27.6513 1.74E-05 9.68832 6.87E-03 2.10487 
NM_008446 Kif4 kinesin family member 4  1.76E-08 26.9716 2.34E-06 6.11422 3.76E-03 1.6411 
NM_172301 Ccnb1 cyclin B1  1.53E-07 26.0814 3.34E-05 5.17163 1.08E-01 1.33563 
NM_010620 Kif15 kinesin family member 15  3.55E-09 25.8394 5.60E-07 5.75579 7.23E-04 1.68446 
NM_001110555 Gm11277 predicted gene 11277 = HistH2Br 8.04E-07 25.6514 8.73E-06 12.8121 2.26E-03 2.54176 
NM_178200 
Hist1h2b
m histone cluster 1, H2bm  4.16E-07 25.3647 8.76E-06 10.0475 8.14E-03 1.9331 
NM_011369 Shcbp1 Shc SH2-domain binding protein 1  1.18E-07 24.9709 1.42E-05 5.92526 3.80E-03 1.88739 
NM_019549 Plek pleckstrin  2.22E-06 24.8887 3.13E-05 11.2271 2.40E-03 2.88977 
NM_026515 
2810417
H13Rik RIKEN cDNA 2810417H13 gene  2.93E-09 24.7882 1.28E-07 8.02343 6.84E-05 2.0816 
NM_011311 S100a4 S100 calcium binding protein A4 (Mts1) 2.16E-06 24.6768 6.08E-05 8.75056 3.45E-01 1.25953 
NM_001110555 Gm11277 predicted gene 11277 = HistH2Br 7.09E-07 24.63 7.14E-06 12.782 1.48E-03 2.65213 
NM_011121 Plk1 polo-like kinase 1 (Drosophila)  6.03E-08 24.0669 5.95E-06 6.15707 2.84E-02 1.44649 
NM_133762 Ncapg2 non-SMC condensin II complex, subunit G2  8.79E-07 23.9932 1.56E-04 5.08111 1.28E-01 1.4064 
NM_001110555 Gm11277 predicted gene 11277 = HistH2Br 5.55E-07 22.8933 5.60E-06 12.0749 1.93E-03 2.40512 
NM_001013368 E2f8 E2F transcription factor 8  4.99E-08 22.8624 1.25E-05 4.74417 1.40E-02 1.51876 
NM_172301 Ccnb1 cyclin B1  2.01E-06 22.8052 3.01E-04 5.07153 2.63E-01 1.30634 
NM_023422 Hist1h2bc histone cluster 1, H2bc  1.10E-06 22.3702 1.09E-05 11.883 2.37E-03 2.5277 
NM_009185 Stil Scl 2.65E-08 22.1737 2.13E-06 6.24289 8.92E-04 1.89699 
NM_023284 Nuf2 
NUF2, NDC80 kinetochore complex 
component, homolog (S. cerevisiae) 2.93E-09 22.1081 1.09E-06 4.35573 2.52E-01 1.11123 
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NM_001141977 Tpx2 
TPX2, microtubule-associated protein 
homolog (Xenopus laevis)  9.22E-09 21.9613 8.80E-07 5.96089 2.65E-03 1.57139 
NM_173762 Cenpe centromere protein E  1.14E-11 21.8661 2.89E-09 4.76581 2.09E-06 1.71315 
NM_001177653 Hist1h2be histone cluster 1, H2be  9.13E-07 21.8488 9.59E-06 11.4214 2.76E-03 2.38927 
NM_007796 Ctla2a 
cytotoxic T lymphocyte-associated protein 2 
alpha  1.11E-07 21.7572 4.08E-07 17.275 2.81E-04 2.58036 
NM_026515 
2810417
H13Rik RIKEN cDNA 2810417H13 gene  1.70E-07 21.7442 5.55E-06 7.88616 9.34E-03 1.70854 
NM_028390 Anln anillin, actin binding protein  2.21E-09 21.2582 2.05E-07 5.92053 3.18E-04 1.69025 
NM_008367 Il2ra interleukin 2 receptor, alpha chain (CD25) 7.99E-08 21.1543 4.91E-07 13.754 1.98E-02 1.49614 
NM_027881 Osbpl3 oxysterol binding protein-like 3  1.81E-09 21.0786 3.28E-08 9.46746 2.29E-03 1.43692 
NM_019438 Ncapg non-SMC condensin I complex, subunit G  2.89E-08 20.8502 3.71E-06 5.33717 3.80E-03 1.63164 
NM_021886 Cenph centromere protein H  7.14E-08 20.0293 3.08E-05 3.93456 6.36E-02 1.32998 
NM_026410 Cdca5 cell division cycle associated 5  1.98E-09 19.1395 2.79E-07 5.03781 4.20E-05 1.98736 
NM_026560 Cdca8 cell division cycle associated 8  5.39E-08 19.0737 1.78E-05 4.08246 4.49E-02 1.34757 
NM_172616 
C330027
C09Rik RIKEN cDNA C330027C09 gene (cip2a) 9.52E-08 18.9887 1.22E-05 5.02297 9.87E-02 1.28719 
NM_009773 Bub1b 
budding uninhibited by benzimidazoles 1 
homolog, beta (S. cerevis 2.43E-09 18.9118 5.83E-07 4.43709 1.47E-03 1.48404 
NM_026785 Ube2c ubiquitin-conjugating enzyme E2C  3.98E-07 18.6923 3.66E-05 5.32614 1.53E-02 1.67836 
NM_007659 Cdk1 cyclin-dependent kinase 1  7.21E-09 18.6491 8.12E-07 5.21458 6.06E-03 1.42265 
NM_016904 Cks1b CDC28 protein kinase 1b  7.43E-09 18.607 4.01E-07 6.28036 4.41E-04 1.76182 
NM_030609 Hist1h1a histone cluster 1, H1a  1.57E-07 18.3116 6.08E-05 3.82627 1.78E-01 1.23471 
NM_175664 Hist1h2bb histone cluster 1, H2bb  6.81E-07 18.1094 3.13E-05 6.24901 9.20E-01 -1.0183 
NM_134471 Kif2c kinesin family member 2C  1.07E-07 17.2946 2.46E-05 4.17363 4.33E-02 1.37927 
NM_144818 Ncaph non-SMC condensin I complex, subunit H  1.04E-09 16.9195 1.57E-07 4.64585 4.10E-05 1.82622 
NM_133851 Nusap1 nucleolar and spindle associated protein 1  5.58E-08 16.8346 5.53E-06 5.01933 4.82E-02 1.32495 
NM_175655 Hist1h4f histone cluster 1, H4f  2.56E-05 16.6013 4.90E-04 7.16995 1.18E-01 1.67205 
NM_198605 
F630043
A04Rik RIKEN cDNA F630043A04 gene  1.23E-07 16.2443 4.90E-05 3.61035 3.53E-01 1.13834 
NM_145150 Prc1 protein regulator of cytokinesis 1  1.26E-07 16.1231 2.17E-05 4.28905 1.31E-01 1.24975 
NM_021790 Cenpk centromere protein K  1.58E-07 16.0905 1.67E-05 4.7762 6.94E-03 1.66263 
NM_001110555 Gm11277 predicted gene 11277 = HistH2Br 3.54E-07 15.7521 3.62E-06 8.95898 1.39E-03 2.15507 
NM_001110555 Gm11277 predicted gene 11277 = HistH2Br 3.54E-07 15.7521 3.62E-06 8.95898 1.39E-03 2.15507 
NM_199007 Sgol2 shugoshin-like 2 (S. pombe)  4.56E-07 15.7175 7.42E-05 4.21613 1.43E-01 1.29283 
NM_001163359 Fignl1 fidgetin-like 1  5.91E-07 15.5967 1.07E-04 4.08442 5.54E-02 1.44818 
NM_001081363 Cenpf centromere protein F  7.63E-08 15.5017 2.27E-05 3.76208 6.39E-03 1.58257 
NM_013538 Cdca3 cell division cycle associated 3  1.73E-10 15.3487 3.11E-08 4.26044 1.98E-03 1.26904 
NM_008234 Hells helicase, lymphoid specific  1.73E-07 14.8503 1.97E-05 4.48003 1.31E-02 1.54872 
NM_009445 Ttk Ttk protein kinase  5.51E-07 14.8295 2.28E-04 3.36251 7.38E-01 1.05605 
NM_197959 Kif18b kinesin family member 18B  1.56E-08 14.7948 5.91E-06 3.55203 3.25E-02 1.28215 
NM_144539 Slamf7 SLAM family member 7 (CRACC) 3.72E-08 14.7814 6.60E-08 15.9911 5.05E-05 2.53213 
NM_010931 Uhrf1 
ubiquitin-like, containing PHD and RING 
finger domains, 1  1.01E-06 14.3565 1.35E-04 4.1487 1.44E-01 1.32103 
NM_007900 Ect2 ect2 oncogene  4.20E-07 14.3286 1.01E-04 3.70283 3.47E-02 1.47557 
NM_011234 Rad51 RAD51 homolog (S. cerevisiae)  2.84E-09 14.2343 6.56E-07 3.86762 2.27E-03 1.40134 
NM_009915 Ccr2 chemokine (C-C motif) receptor 2  4.75E-06 14.2334 3.14E-04 4.73993 3.85E-01 1.21712 
NM_178183 Hist1h2ak histone cluster 1, H2ak  2.26E-07 14.2171 1.28E-05 5.14177 2.82E-02 1.45313 
NM_134250 Havcr2 hepatitis A virus cellular receptor 2 (Tim3) 1.45E-07 14.1033 8.14E-06 5.14347 8.29E-01 1.02878 
NM_001081258 Kif14 kinesin family member 14  2.99E-09 13.9953 1.23E-06 3.43834 2.46E-02 1.2289 
NM_011496 Aurkb aurora kinase B  1.46E-09 13.7912 2.99E-07 3.90363 2.96E-04 1.53636 
NM_028039 Esco2 
establishment of cohesion 1 homolog 2 (S. 
cerevisiae)  4.78E-07 13.4587 1.80E-04 3.28417 4.05E-02 1.4495 
NR_028590 Gm14005 predicted gene 14005  1.01E-05 13.4571 1.27E-03 3.84648 1.18E-01 1.51201 
NM_008495 Lgals1 lectin, galactose binding, soluble 1  1.44E-08 12.898 1.54E-07 7.63304 4.89E-05 2.16716 
NM_029766 Dtl denticleless homolog (Drosophila)  6.36E-09 12.66 3.70E-06 3.0834 1.09E-02 1.30468 
NM_021334 Itgax integrin alpha X (CD11c) 8.05E-07 12.4005 3.70E-04 3.02152 3.50E-01 -1.16743 
NM_175554 Clspn claspin homolog (Xenopus laevis)  2.76E-08 12.3215 1.37E-05 3.10108 1.24E-01 1.17978 
NM_001164362 Cep55 centrosomal protein 55  1.01E-08 12.0428 3.38E-06 3.30477 8.59E-02 1.17596 
NM_001145953 Lgals3 lectin, galactose binding, soluble 3  3.21E-07 11.9774 1.13E-04 3.17214 7.14E-01 -1.05229 
NM_001040435 Tacc3 
transforming, acidic coiled-coil containing 
protein 3  1.50E-08 11.7823 2.85E-06 3.6204 4.85E-03 1.41225 
NM_009712 Arsb arylsulfatase B  1.08E-07 11.3616 3.88E-06 4.99868 3.01E-01 1.13267 
NM_021398 Slc43a3 solute carrier family 43, member 3 (Eeg1) 5.78E-08 11.3227 1.78E-05 3.21863 1.88E-01 1.16004 
NM_009103 Rrm1 ribonucleotide reductase M1  3.89E-08 11.2763 8.45E-06 3.43215 2.67E-01 1.12248 
NM_181416 
Arhgap11
a Rho GTPase activating protein 11A  2.95E-07 11.2721 8.95E-05 3.16805 9.78E-02 1.27823 
NM_021288 Tyms thymidylate synthase  1.33E-06 10.8877 2.87E-04 3.24251 1.72E-01 1.27128 
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NM_139117 Csda cold shock domain protein A  7.20E-07 10.8206 7.94E-05 3.72713 3.65E-03 1.8518 
NM_178184 Hist1h2an histone cluster 1, H2an  1.72E-06 10.3628 5.51E-05 4.72919 5.50E-02 1.44697 
NM_025415 Cks2 CDC28 protein kinase regulatory subunit 2  5.34E-07 10.1674 1.06E-04 3.22715 1.75E-04 2.63345 
NM_008252 Hmgb2 high mobility group box 2  1.31E-06 10.1256 3.08E-05 5.03443 2.25E-02 1.56102 
NM_008252 Hmgb2 high mobility group box 2  8.66E-07 9.99794 1.82E-05 5.14808 2.74E-02 1.48742 
NM_009256 Serpinb9 
serine (or cysteine) peptidase inhibitor, clade 
B, member 9  6.92E-06 9.81145 1.02E-04 5.43953 1.90E-01 1.32287 
NM_016692 Incenp inner centromere protein  3.20E-07 9.79574 6.01E-05 3.22096 1.20E-02 1.51074 
NM_019507 Tbx21 T-box 21  2.66E-08 9.78393 2.09E-07 6.64092 4.13E-06 2.98548 
NM_008252 Hmgb2 high mobility group box 2  9.50E-07 9.75924 2.31E-05 4.8803 1.38E-02 1.59641 
NM_009807 Casp1 caspase 1  5.27E-06 9.73886 8.65E-06 10.631 6.19E-03 2.03885 
NM_001177544 Hist1h2ao histone cluster 1, H2ao  1.84E-06 9.6507 4.88E-05 4.70686 4.42E-02 1.4693 
NM_001177544 Hist1h2ao histone cluster 1, H2ao  1.94E-06 9.64131 5.85E-05 4.56622 6.23E-02 1.4205 
NM_008252 Hmgb2 high mobility group box 2  1.90E-07 9.50189 6.03E-06 4.55133 6.39E-03 1.5375 
NM_001177544 Hist1h2ao histone cluster 1, H2ao  2.11E-06 9.38959 6.22E-05 4.50284 6.52E-02 1.41381 
NM_001177544 Hist1h2ao histone cluster 1, H2ao  2.34E-06 9.37583 7.22E-05 4.44485 7.42E-02 1.40115 
NM_001177544 Hist1h2ao histone cluster 1, H2ao  3.05E-06 9.36245 9.53E-05 4.41188 8.06E-02 1.40644 
NM_001177544 Hist1h2ao histone cluster 1, H2ao  1.86E-06 9.35214 5.48E-05 4.49788 5.77E-02 1.42212 
NM_178208 Hist1h4c histone cluster 1, H4c  3.17E-05 9.2899 1.09E-03 4.09861 2.18E-01 1.37796 
NM_025415 Cks2 CDC28 protein kinase regulatory subunit 2  7.36E-07 9.22989 1.55E-04 3.0294 3.49E-04 2.38698 
NM_019641 Stmn1 stathmin 1  5.13E-07 9.19191 1.86E-05 4.29306 1.88E-02 1.47443 
NM_175661 Hist1h2af histone cluster 1, H2af  3.29E-06 9.00939 9.33E-05 4.39468 1.05E-01 1.36179 
NM_009862 Cdc45 cell division cycle 45 homolog (S. cerevisiae)  2.70E-07 8.9446 4.40E-05 3.15765 4.33E-02 1.32687 
NM_178185 Gm11276 predicted gene 11276 = Hist1H2ap 2.01E-06 8.93155 6.35E-05 4.28784 5.47E-02 1.42517 
NM_019641 Stmn1 stathmin 1  6.76E-07 8.7661 2.10E-05 4.2959 2.16E-02 1.46652 
NM_175654 Hist1h4d histone cluster 1, H4d  1.07E-04 8.60093 2.00E-03 4.37147 2.60E-01 1.40142 
NM_178197 Hist1h2bh histone cluster 1, H2bh  1.38E-06 8.56803 1.47E-04 3.27028 1.93E-01 1.22832 
NM_011454 
Serpinb6
b 
serine (or cysteine) peptidase inhibitor, clade 
B, member 6b  2.50E-06 8.27158 1.30E-05 6.35144 5.66E-01 1.09672 
NM_009712 Arsb arylsulfatase B  1.38E-07 8.2192 1.06E-05 3.47067 4.81E-01 -1.07733 
NM_001167949 Atp2b4 
ATPase, Ca++ transporting, plasma 
membrane 4 (PMCA4) 3.47E-09 8.15954 1.65E-08 6.52847 3.95E-05 1.70658 
NM_178193 Hist1h4b histone cluster 1, H4b  1.41E-04 7.88549 2.19E-03 4.28553 1.97E-01 1.48341 
NM_021542 Kcnk5 
potassium channel, subfamily K, member 5 
(TASK-2) 4.27E-06 7.8195 4.05E-04 3.11959 8.86E-01 1.02423 
NM_013549 
Hist2h2aa
1 histone cluster 2, H2aa1  3.89E-06 7.69867 2.36E-04 3.37368 5.74E-02 1.43201 
XM_001480078 Gm16494 predicted gene 16494  2.44E-06 7.63616 1.62E-04 3.32033 1.11E-01 1.307 
NM_001081102 Whsc1 
Wolf-Hirschhorn syndrome candidate 1 
(human)  2.32E-07 7.37091 2.04E-05 3.16846 1.44E-01 1.18321 
NM_008982 Ptprj 
protein tyrosine phosphatase, receptor type, 
J (CD148) 3.19E-06 7.352 1.39E-04 3.51225 3.58E-01 1.15889 
NM_013549 
Hist2h2aa
1 histone cluster 2, H2aa1  2.79E-06 7.24995 1.65E-04 3.28786 7.56E-02 1.35595 
NM_011498 Bhlhe40 basic helix-loop-helix family, member e40  1.36E-05 7.23607 1.57E-04 4.56021 6.72E-01 1.08499 
NM_009810 Casp3 caspase 3  1.68E-07 6.98232 6.48E-06 3.5651 4.86E-03 1.46966 
NM_010578 Itgb1 
integrin beta 1 (fibronectin receptor beta, 
CD29)  3.18E-06 6.97532 1.20E-04 3.4929 3.01E-01 1.17721 
NM_178196 Hist1h2bg histone cluster 1, H2bg  1.22E-05 6.89059 7.46E-04 3.08906 8.83E-01 1.02736 
NM_007797 Ctla2b 
cytotoxic T lymphocyte-associated protein 2 
beta  1.50E-07 6.71703 1.93E-06 4.33874 1.96E-01 1.14016 
NM_016957 Hmgn2 
high mobility group nucleosomal binding 
domain 2  9.63E-08 6.54038 4.98E-06 3.2513 2.71E-02 1.26609 
NM_022018 Fam129a 
family with sequence similarity 129, member 
A  7.77E-08 6.36362 3.83E-06 3.22457 4.03E-01 1.0747 
NM_010653 Klrc2 
killer cell lectin-like receptor subfamily C, 
member 2 (NKG2C)  3.68E-06 6.03146 2.78E-07 18.7976 1.16E-01 1.28093 
NM_010177 Fasl Fas ligand (TNF superfamily, member 6)  1.95E-05 5.9367 6.17E-06 10.6655 2.93E-01 1.22112 
NM_011660 Txn1 thioredoxin 1  2.14E-07 5.76075 5.05E-06 3.42762 9.67E-05 2.02017 
NM_001146325 Tigit 
T cell immunoreceptor with Ig and ITIM 
domains (Vstm3) 1.75E-05 5.73838 5.71E-05 5.10809 8.55E-03 1.84601 
NM_028341 Ttc39c tetratricopeptide repeat domain 39C  1.14E-05 5.31788 3.03E-04 3.07161 8.78E-01 -1.02446 
NM_031376 Pik3ap1 phosphoinositide-3-kinase adaptor protein 1  6.36E-07 5.31242 2.26E-07 8.76338 7.30E-05 2.27318 
NM_133838 Ehd4 EH-domain containing 4  1.33E-05 5.02872 2.78E-04 3.08241 6.29E-03 1.78399 
NM_016866 Stk39 serine/threonine kinase 39 2.57E-07 4.906 5.14E-07 4.9909 2.09E-02 -1.27823 
NM_010276 Gem 
GTP binding protein (gene overexpressed in 
skeletal muscle)  1.56E-06 4.65651 8.80E-07 6.49521 3.39E-05 2.64088 
NM_053214 Myo1f myosin IF  2.56E-05 4.57156 2.10E-04 3.39749 8.96E-02 1.36 
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NM_028013 Endod1 endonuclease domain containing 1  1.49E-04 4.39652 1.62E-03 3.03734 4.68E-01 1.16578 
NM_001081304 Atf6 activating transcription factor 6  5.34E-07 4.30665 3.61E-06 3.43115 5.31E-05 2.08577 
NM_011660 Txn1 thioredoxin 1  9.55E-07 4.24743 7.95E-06 3.26213 1.71E-04 1.93477 
NM_008368 Il2rb interleukin 2 receptor, beta chain (CD122) 1.97E-07 4.189 8.57E-08 6.08869 1.15E-05 2.19846 
NM_009848 Entpd1 
ectonucleoside triphosphate 
diphosphohydrolase 1(CD39) 7.56E-05 3.94161 3.53E-04 3.3179 4.09E-01 1.1573 
NM_008348 Il10ra interleukin 10 receptor, alpha (CD210) 1.39E-05 3.91592 1.72E-06 8.02924 1.84E-04 2.49912 
NM_001081163 Chsy1 chondroitin sulfate synthase 1  3.62E-07 3.90675 7.32E-07 3.95584 2.06E-05 2.11579 
NM_008013 Fgl2 fibrinogen-like protein 2  1.03E-04 3.86893 1.41E-05 7.80216 4.64E-01 1.14281 
NM_009851 Cd44 CD44 antigen  8.91E-07 3.81073 5.32E-07 5.01758 7.63E-02 1.18932 
NM_146064 Soat2 sterol O-acyltransferase 2  8.64E-06 3.54195 3.93E-05 3.07786 4.32E-01 1.09624 
NM_001004164 Gnptab 
N-acetylglucosamine-1-phosphate 
transferase, alpha and beta s 4.25E-05 3.53554 1.98E-04 3.03092 5.33E-01 1.0962 
NM_010136 Eomes eomesodermin homolog (Xenopus laevis)  9.76E-06 3.49652 1.92E-05 3.53769 2.63E-04 2.12066 
NM_177025 Cobll1 Cobl-like 1  1.04E-05 3.49628 1.73E-05 3.65506 1.77E-03 1.73197 
NM_009402 Pglyrp1 peptidoglycan recognition protein 1  9.22E-06 3.35781 1.34E-05 3.599 1.97E-02 1.3785 
NM_007609 Casp4 
caspase 4, apoptosis-related cysteine 
peptidase  1.90E-03 3.35166 1.29E-04 8.33109 4.08E-03 2.85555 
NM_025385 Prr13 proline rich 13  1.99E-06 3.27731 2.95E-06 3.49735 5.64E-06 2.76612 
NM_007646 Cd38 CD38 antigen  5.39E-05 3.2639 8.15E-06 5.82114 2.98E-03 1.83317 
NM_197990 
1700025
G04Rik RIKEN cDNA 1700025G04 gene  5.74E-05 3.02968 2.03E-05 4.27583 2.66E-01 1.16859 
List of genes that were upregulated greater than 3-fold in only MCMV-specific CD8+ T cells and 
γδ T cells compared to naïve CD8+ T cells.  Genes in red are either secreted proteins or 
proteins that are expressed on the cell surface. 
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Supplemental Table 3.II: List of genes upregulated at least 3 fold in only MCMV-specific CD8+ 
T cells compared to naïve CD8+ T cells 
MCMV-specific vs. 
naïve γδ T cell vs. naïve 
Ova-specific vs. 
naive Accession 
Number 
Gene 
Symbol Gene Name (Alias) p-value Fold Change p-value 
Fold 
Change p-value 
Fold 
Change 
NM_181315 Car5b carbonic anhydrase 5b, mitochondrial 1.39E-06 15.1803 2.71E-03 2.50064 2.10E-01 -1.28355 
NM_013602 Mt1 metallothionein 1 4.07E-08 13.5385 1.53E-04 2.35283 7.36E-01 1.03712 
ENSMUST0000
0028119 Mastl microtubule associated serine 2.51E-07 13.1759 3.06E-04 2.67959 1.85E-01 1.21694 
NM_021397 Zbtb32 zinc finger and BTB domain containing 32 4.93E-08 12.9682 3.93E-05 2.91465 5.71E-01 1.06433 
NM_001081406 Ppil5 peptidylprolyl isomerase (cyclophilin) like 5 2.04E-06 12.342 3.85E-03 2.31236 1.75E-01 1.30627 
NM_001042421 Kntc1 kinetochore associated 1 1.12E-09 12.2756 8.02E-07 2.9627 9.26E-04 1.38664 
NM_027667 Arhgap19 Rho GTPase activating protein 19 9.28E-09 12.0038 1.11E-05 2.68503 1.45E-02 1.29466 
NM_172578 C79407 expressed sequence C79407 8.18E-08 11.9954 6.04E-05 2.84142 2.21E-01 1.15857 
NM_009791 Aspm 
asp (abnormal spindle)-like, microcephaly 
associated (Drosophila) 7.42E-08 11.9336 7.39E-05 2.70698 5.99E-01 -1.06118 
NM_010892 Nek2 
NIMA (never in mitosis gene a)-related 
expressed kinase 2 1.23E-08 11.5923 9.23E-05 2.08202 8.63E-02 1.17807 
NM_009860 Cdc25c cell division cycle 25 homolog C (S. pombe) 9.76E-06 11.576 1.52E-02 2.174 5.13E-01 1.16182 
NM_025565 Spc25 
SPC25, NDC80 kinetochore complex 
component, homolog (S. cerevisia 6.48E-06 11.4458 2.33E-03 2.88775 6.89E-02 1.54872 
NM_013733 Chaf1a 
chromatin assembly factor 1, subunit A 
(p150) 4.14E-07 11.3411 3.83E-04 2.61833 3.67E-03 1.78469 
NM_144553 Dlgap5 
discs, large (Drosophila) homolog-associated 
protein 5 4.90E-07 11.2814 2.04E-04 2.97441 8.27E-01 -1.03195 
NM_028232 Sgol1 shugoshin-like 1 (S. pombe) 1.61E-09 11.2244 1.12E-06 2.85766 4.23E-05 1.72607 
NM_027014 Gins1 GINS complex subunit 1 (Psf1 homolog) 1.75E-08 11.0906 5.80E-05 2.25787 1.72E-02 1.30167 
NM_017407 Spag5 sperm associated antigen 5 1.23E-06 11.0187 5.31E-04 2.87601 5.92E-01 -1.09219 
NM_010721 Lmnb1 lamin B1 2.62E-10 10.9073 1.67E-07 2.87411 1.39E-01 1.07997 
NM_146208 Neil3 nei like 3 (E. coli) 3.34E-07 10.9022 1.91E-04 2.79284 6.98E-02 1.31803 
NM_026282 Spc24 
SPC24, NDC80 kinetochore complex 
component, homolog (S. cerevisia 1.08E-07 10.8523 3.01E-04 2.24583 2.18E-01 1.15977 
NM_008021 Foxm1 forkhead box M1 3.69E-09 10.8068 1.88E-06 2.94138 6.45E-03 1.29332 
NM_029835 
5730590
G19Rik RIKEN cDNA 5730590G19 gene 1.70E-07 10.4601 1.15E-04 2.69888 3.82E-02 1.34073 
NM_028222 Cdkn3 cyclin-dependent kinase inhibitor 3 1.74E-06 10.2921 1.59E-03 2.44703 2.11E-01 1.24712 
NM_029249 
4930547
N16Rik RIKEN cDNA 4930547N16 gene 2.68E-09 10.2587 6.84E-06 2.29868 2.81E-02 1.18902 
NM_007634 Ccnf cyclin F 1.47E-07 10.1946 1.80E-04 2.44673 6.56E-02 1.27505 
NM_009015 Rad54l RAD54 like (S. cerevisiae) 6.42E-08 10.1453 2.51E-05 2.93403 3.68E-02 1.28888 
NM_023223 Cdc20 cell division cycle 20 homolog (S. cerevisiae) 9.92E-09 9.88394 2.76E-05 2.22816 9.98E-02 1.15168 
NM_175384 Cdca2 cell division cycle associated 2 5.97E-08 9.71118 4.75E-05 2.57929 2.49E-02 1.31292 
NM_010049 Dhfr dihydrofolate reductase 9.34E-09 9.67704 4.04E-06 2.8577 5.20E-03 1.33988 
NM_019670 Diap3 diaphanous homolog 3 (Drosophila) 2.77E-06 9.21005 6.21E-04 2.92296 7.58E-01 1.05383 
NM_011497 Aurka aurora kinase A 3.06E-09 9.06518 3.58E-06 2.42183 3.18E-02 1.17582 
NM_010655 Kpna2 karyopherin (importin) alpha 2 1.52E-08 8.98179 3.93E-06 2.98666 1.69E-02 1.26711 
NM_139303 Kif18a kinesin family member 18A 5.41E-07 8.96188 2.70E-04 2.60195 7.49E-01 1.04324 
NM_007525 Bard1 BRCA1 associated RING domain 1 9.67E-11 8.8455 2.72E-07 2.1763 6.35E-05 1.36191 
NM_019499 Mad2l1 MAD2 mitotic arrest deficient-like 1 (yeast) 5.84E-07 8.71881 1.44E-04 2.87587 2.28E-01 -1.18272 
NM_001004140 Ckap2 cytoskeleton associated protein 2 1.56E-06 8.65518 5.90E-04 2.62901 2.24E-01 1.21545 
NM_009404 Tnfsf9 
tumor necrosis factor (ligand) superfamily, 
member 9 3.34E-05 8.60992 1.86E-02 2.19384 2.16E-01 1.36795 
NM_001083188 Lig1 ligase I, DNA, ATP-dependent 8.84E-08 8.5676 2.70E-05 2.80992 9.68E-02 1.20139 
NM_027182 Trip13 thyroid hormone receptor interactor 13 7.26E-07 8.55444 7.21E-04 2.29506 8.47E-01 1.02636 
NM_001109747 
2610036L
11Rik RIKEN cDNA 2610036L11 gene 1.55E-04 8.54005 8.13E-02 1.94181 9.26E-01 -1.02846 
NM_007548 Prdm1 PR domain containing 1, with ZNF domain 1.23E-08 8.53066 2.78E-05 2.16593 1.50E-02 -1.25915 
NM_012012 Exo1 exonuclease 1 2.25E-08 8.45891 3.22E-05 2.27122 1.50E-02 1.28439 
NM_011799 Cdc6 cell division cycle 6 homolog (S. cerevisiae) 1.41E-05 8.45547 7.49E-03 2.29948 4.72E-01 1.16449 
NM_175657 Hist1h4m histone cluster 1, H4m 1.97E-04 8.39808 2.96E-03 4.46919 2.18E-01 1.50254 
NM_175657 Hist1h4m histone cluster 1, H4m 1.97E-04 8.39808 2.96E-03 4.46919 2.18E-01 1.50254 
NM_010683 Lamc1 laminin, gamma 1 8.31E-08 8.28031 2.85E-04 2.00656 8.70E-01 -1.01598 
NM_007708 Cit citron 5.83E-09 8.23829 2.60E-06 2.64671 2.54E-03 1.3378 
NM_001029856 Atad5 ATPase family, AAA domain containing 5 7.45E-08 8.18088 2.17E-05 2.77228 4.43E-01 1.07713 
NM_010655 Kpna2 karyopherin (importin) alpha 2 3.12E-09 8.17625 9.72E-07 2.7851 3.50E-03 1.28361 
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NM_010655 Kpna2 karyopherin (importin) alpha 2 1.89E-09 8.11719 5.55E-07 2.80398 1.92E-03 1.29523 
NM_172723 Adap1 ArfGAP with dual PH domains 1 1.27E-09 8.01842 7.96E-06 1.92275 4.23E-02 1.13308 
NM_178193 Hist1h4b histone cluster 1, H4b 2.66E-04 7.91074 4.01E-03 4.22917 2.78E-01 1.43388 
NM_178309 Brip1 
BRCA1 interacting protein C-terminal 
helicase 1 7.11E-08 7.78781 2.65E-05 2.60986 5.15E-03 1.42643 
NM_008563 Mcm3 
minichromosome maintenance deficient 3 (S. 
cerevisiae) 2.20E-09 7.77792 4.64E-07 2.88379 2.16E-04 1.4547 
NM_023294 Ndc80 
NDC80 homolog, kinetochore complex 
component (S. cerevisiae) 1.66E-06 7.77758 1.12E-03 2.29602 9.74E-01 1.00471 
NM_001033244 Fancd2 Fanconi anemia, complementation group D2 3.46E-08 7.7624 5.85E-05 2.14787 2.76E-03 1.43301 
NM_178193 Hist1h4b histone cluster 1, H4b 2.71E-04 7.65004 3.95E-03 4.16355 2.33E-01 1.48503 
NM_009415 Tpi1 triosephosphate isomerase 1 3.02E-09 7.59712 2.33E-06 2.37568 2.18E-02 1.17742 
NM_026507 Zwilch 
Zwilch, kinetochore associated, homolog 
(Drosophila) 2.65E-08 7.59018 5.15E-05 2.10066 4.36E-02 1.20524 
NM_029971 Pmch pro-melanin-concentrating hormone 2.32E-05 7.56976 1.50E-02 2.08244 2.75E-01 1.2749 
NM_183089 Dscc1 
defective in sister chromatid cohesion 1 
homolog (S. cerevisiae) 8.36E-06 7.54002 5.49E-03 2.17225 5.11E-01 -1.12905 
NM_010790 Melk maternal embryonic leucine zipper kinase 9.77E-09 7.48691 3.76E-05 1.95464 1.73E-01 1.10427 
NM_027290 Mcm10 
minichromosome maintenance deficient 10 
(S. cerevisiae) 7.91E-08 7.46809 8.38E-05 2.22403 2.55E-02 1.28314 
NM_177372 Dna2 DNA replication helicase 2 homolog (yeast) 1.63E-07 7.41008 2.10E-04 2.14685 2.62E-01 1.12623 
NM_023612 Esm1 endothelial cell-specific molecule 1 2.91E-09 7.39691 9.49E-03 1.24083 8.47E-01 1.01096 
NM_181589 Ckap2l cytoskeleton associated protein 2-like 4.42E-08 7.37877 8.15E-05 2.08243 7.08E-01 -1.03193 
BC138225 Fam72a family with sequence similarity 72, member A 1.11E-05 7.32604 5.24E-03 2.23635 2.98E-01 1.2246 
NM_025415 Cks2 CDC28 protein kinase regulatory subunit 2 9.06E-07 7.29365 4.15E-04 2.38941 8.17E-04 2.0046 
NM_133706 Tmem97 transmembrane protein 97 6.62E-05 7.26037 2.20E-01 1.42572 7.67E-01 1.07546 
NM_001014976 Espl1 extra spindle poles-like 1 (S. cerevisiae) 2.41E-08 7.24309 7.11E-05 1.97441 5.00E-02 1.18884 
NM_001163763 Tcf19 transcription factor 19 1.41E-07 7.21204 4.99E-05 2.52257 1.31E-02 1.36456 
NM_008566 Mcm5 
minichromosome maintenance deficient 5, 
cell division cycle 46 (S. 1.24E-09 7.15253 1.13E-06 2.27586 3.75E-03 1.22424 
NM_145588 Kif22 kinesin family member 22 3.41E-06 7.11665 1.13E-03 2.41703 6.88E-01 1.06431 
NM_008892 Pola1 polymerase (DNA directed), alpha 1 1.58E-07 7.11456 5.68E-05 2.49889 6.02E-01 1.05326 
NM_024245 Kif23 kinesin family member 23 2.77E-06 7.09556 8.49E-03 1.79432 2.32E-01 -1.20772 
NM_025495 Cenpp centromere protein P 2.49E-06 7.08212 5.02E-03 1.89462 1.30E-01 1.27593 
NM_023595 Dut deoxyuridine triphosphatase 1.70E-06 7.06727 2.80E-04 2.7256 1.23E-01 1.26476 
NM_027263 Apitd1 apoptosis-inducing, TAF9-like domain 1 2.00E-06 7.06543 8.58E-03 1.74142 5.43E-01 1.0918 
NM_013549 
Hist2h2aa
1 histone cluster 2, H2aa1 6.92E-06 7.05866 6.23E-04 2.94766 1.12E-01 1.34897 
NM_011132 Pole polymerase (DNA directed), epsilon 3.20E-07 7.04315 3.54E-04 2.12704 2.69E-01 1.13404 
NM_016710 Hmgn5 
high-mobility group nucleosome binding 
domain 5 5.62E-05 7.04259 1.16E-02 2.35767 1.48E-01 1.44534 
NM_146171 Ncapd2 non-SMC condensin I complex, subunit D2 1.66E-06 6.99067 9.77E-04 2.24001 2.95E-01 1.16236 
NM_007691 Chek1 checkpoint kinase 1 homolog (S. pombe) 2.87E-07 6.96986 6.83E-05 2.61285 7.48E-01 -1.03494 
NM_010634 Fabp5 fatty acid binding protein 5, epidermal 1.27E-06 6.96874 7.83E-03 1.6911 7.22E-01 -1.0484 
NM_007525 Bard1 BRCA1 associated RING domain 1 2.67E-07 6.94216 2.62E-04 2.15213 7.71E-01 -1.03111 
NM_020567 Gmnn geminin 1.48E-06 6.91868 4.24E-03 1.82992 1.46E-01 1.23682 
NM_010634 Fabp5 fatty acid binding protein 5, epidermal 9.13E-08 6.91683 1.97E-03 1.59139 3.38E-01 -1.09307 
NM_178213 Hist2h2ab histone cluster 2, H2ab 5.26E-06 6.80459 4.71E-04 2.9063 1.52E-01 1.28381 
NM_153173 Hist1h4h histone cluster 1, H4h 1.06E-05 6.78542 1.13E-02 1.92732 2.54E-01 1.23875 
NM_009516 Wee1 WEE 1 homolog 1 (S. pombe) 4.05E-07 6.75538 1.76E-04 2.35375 7.17E-02 1.25252 
NM_001093765 Myadm myeloid-associated differentiation marker 7.03E-06 6.71674 1.70E-03 2.4299 6.44E-01 1.08087 
NM_029023 Scpep1 serine carboxypeptidase 1 5.12E-05 6.67442 2.60E-02 1.9788 2.37E-01 1.32357 
NM_145924 Cenpi centromere protein I 1.90E-08 6.66498 1.27E-04 1.77633 2.79E-01 1.08276 
NM_009387 Tk1 thymidine kinase 1 9.85E-05 6.64682 5.63E-02 1.8439 4.76E-01 1.19787 
NM_025866 Cdca7 cell division cycle associated 7 1.82E-07 6.59496 1.47E-04 2.16799 7.98E-01 1.02506 
NM_023209 Pbk PDZ binding kinase 7.76E-06 6.59036 3.30E-03 2.20222 4.37E-01 1.14274 
NM_025995 Fbxo5 F-box protein 5 8.56E-06 6.56088 2.56E-03 2.31233 1.64E-01 -1.29041 
NM_013929 Siva1 SIVA1, apoptosis-inducing factor 4.67E-05 6.5489 5.75E-02 1.71134 4.09E-01 1.20448 
NM_024184 Asf1b 
ASF1 anti-silencing function 1 homolog B (S. 
cerevisiae) 3.11E-07 6.54135 2.13E-04 2.19392 7.44E-01 1.03479 
NM_008651 Mybl1 myeloblastosis oncogene-like 1 4.47E-06 6.54024 8.35E-03 1.8283 3.22E-01 1.17127 
NM_175666 Hist2h2bb histone cluster 2, H2bb 1.00E-04 6.52929 2.28E-02 2.16613 8.16E-01 -1.05927 
NM_001082960 Itgam integrin alpha M 1.16E-07 6.50392 1.49E-01 1.17012 2.91E-03 -1.47371 
NM_025372 Tipin timeless interacting protein 4.96E-06 6.47877 4.93E-03 1.96951 8.19E-01 -1.03626 
NM_019755 Plp2 proteolipid protein 2 1.72E-08 6.46811 1.89E-06 2.87153 1.59E-02 1.23092 
NM_028083 Chaf1b chromatin assembly factor 1, subunit B (p60) 2.38E-07 6.44018 4.40E-03 1.55695 2.76E-02 1.30424 
NM_177331 Gen1 Gen homolog 1, endonuclease (Drosophila) 2.53E-05 6.38102 1.60E-02 1.95592 4.47E-01 -1.16536 
NM_009361 Tfdp1 transcription factor Dp 1 2.53E-08 6.30532 4.26E-06 2.65289 3.27E-05 1.90094 
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NM_008017 Smc2 structural maintenance of chromosomes 2 9.57E-07 6.25882 3.40E-04 2.31114 6.81E-01 -1.05088 
NM_013549 
Hist2h2aa
1 histone cluster 2, H2aa1 9.89E-06 6.2574 1.13E-03 2.6281 1.60E-01 1.29219 
NM_008197 H1f0 H1 histone family, member 0 5.61E-06 6.22508 7.46E-03 1.86261 7.19E-01 1.0576 
NM_010730 Anxa1 annexin A1 2.12E-05 6.2054 3.19E-03 2.44725 5.43E-01 1.12362 
NM_009846 Cd24a CD24a antigen 2.62E-03 6.19691 6.43E-02 2.67003 2.23E-01 1.70743 
NM_025520 Lsm5 
LSM5 homolog, U6 small nuclear RNA 
associated (S. cerevisiae) 1.78E-05 6.19483 6.60E-03 2.12956 4.42E-01 1.15544 
NM_027009 Rfc3 replication factor C (activator 1) 3 5.30E-07 6.17692 3.20E-04 2.16071 1.99E-02 1.37168 
NM_001039556 Rad54b RAD54 homolog B (S. cerevisiae) 2.66E-06 6.14746 1.01E-03 2.23166 3.29E-01 1.14982 
NM_011495 Plk4 polo-like kinase 4 (Drosophila) 1.49E-07 6.13744 1.85E-04 2.00896 4.56E-01 -1.07125 
NM_146235 Ercc6l 
excision repair cross-complementing rodent 
repair deficiency com 2.18E-05 6.13736 1.10E-01 1.45067 8.20E-01 -1.04399 
NM_022324 Sdf2l1 stromal cell-derived factor 2-like 1 4.63E-08 6.13376 4.33E-06 2.84516 2.10E-04 1.67536 
NM_001080995 
4632434I
11Rik RIKEN cDNA 4632434I11 gene 1.32E-06 6.12804 2.53E-03 1.84673 2.76E-01 1.15176 
NM_012055 Asns asparagine synthetase 1.38E-06 6.11088 2.01E-02 1.49624 5.39E-01 -1.08089 
NM_007525 Bard1 BRCA1 associated RING domain 1 2.23E-08 6.10627 1.20E-04 1.76155 1.28E-02 1.24542 
NM_027930 Fam54a family with sequence similarity 54, member A 4.83E-06 6.09965 4.56E-03 1.94142 1.29E-01 1.28224 
NM_175656 Hist1h4i histone cluster 1, H4i 2.57E-07 6.01909 6.20E-03 1.49653 6.18E-02 1.2304 
NM_009193 Slbp stem-loop binding protein 5.43E-06 6.01213 8.57E-04 2.47595 1.49E-02 1.5971 
NM_028131 Cenpn centromere protein N 1.11E-06 5.98213 5.68E-04 2.1521 6.43E-02 1.28732 
NM_013549 
Hist2h2aa
1 histone cluster 2, H2aa1 9.58E-06 5.94864 1.59E-03 2.41362 1.71E-01 1.27256 
NM_177733 E2f2 E2F transcription factor 2 3.37E-07 5.94092 2.27E-03 1.65578 3.08E-04 1.88696 
NM_025581 Ska1 
spindle and kinetochore associated complex 
subunit 1 8.32E-08 5.86378 1.95E-04 1.85835 7.52E-01 1.026 
NM_009742 Bcl2a1a B-cell leukemia 4.03E-06 5.8513 4.78E-03 1.86898 7.05E-04 -2.20314 
NM_013471 Anxa4 annexin A4 2.55E-06 5.8509 2.84E-03 1.90596 4.28E-01 1.11433 
NM_009128 Scd2 stearoyl-Coenzyme A desaturase 2 1.41E-07 5.8408 9.20E-01 -1.00982 1.09E-02 -1.33515 
NM_027411 Ccdc99 coiled-coil domain containing 99 4.01E-08 5.84054 3.08E-04 1.67656 8.46E-02 1.15133 
BC039993 
2610318
N02Rik RIKEN cDNA 2610318N02 gene 1.51E-05 5.82525 7.59E-03 1.99971 4.03E-01 1.16059 
NM_033596 Hist2h4 histone cluster 2, H4 2.98E-04 5.80459 1.17E-02 2.73162 9.81E-01 1.00671 
NM_001166406 Kif20a kinesin family member 20A 1.53E-06 5.79078 5.67E-03 1.68409 2.26E-01 -1.17046 
BC139425 Gm11275 predicted gene 11275 4.61E-05 5.78677 1.33E-02 2.06717 4.98E-01 1.15165 
NM_016661 Ahcy S-adenosylhomocysteine hydrolase 2.43E-08 5.75867 1.04E-04 1.76374 3.36E-05 1.83041 
NM_001168246 Syce2 
synaptonemal complex central element 
protein 2 9.41E-07 5.73582 2.56E-03 1.75328 2.01E-01 1.16768 
NM_177420 Psat1 phosphoserine aminotransferase 1 6.57E-07 5.71044 2.78E-04 2.17761 4.14E-02 1.29576 
NM_013882 Gtse1 G two S phase expressed protein 1 3.08E-07 5.70822 2.66E-03 1.6044 8.75E-01 1.01528 
NM_007536 Bcl2a1d B-cell leukemia 3.27E-06 5.69759 3.58E-03 1.87972 9.33E-04 -2.05209 
NM_025711 Aspn asporin 8.99E-05 5.68634 4.57E-02 1.80017 7.68E-01 -1.06886 
NM_019755 Plp2 proteolipid protein 2 3.60E-09 5.66321 4.44E-07 2.63118 4.18E-03 1.22552 
ENSMUST0000
0100541 
I830127L
07Rik RIKEN cDNA I830127L07 gene 7.38E-06 5.65465 3.63E-03 2.02831 1.17E-01 1.30207 
NM_007534 Bcl2a1b B-cell leukemia 3.14E-06 5.65393 2.75E-03 1.9274 7.82E-04 -2.08216 
NM_001033331 Gas2l3 growth arrest-specific 2 like 3 2.42E-07 5.6532 2.07E-03 1.60796 1.72E-01 1.14555 
NM_008652 Mybl2 myeloblastosis oncogene-like 2 2.51E-05 5.61609 3.62E-02 1.66704 2.95E-01 1.22155 
NM_001024468 Bcat1 branched chain aminotransferase 1, cytosolic 9.53E-07 5.61154 1.67E-02 1.46211 4.61E-01 1.08845 
NM_027289 Nt5dc2 5'-nucleotidase domain containing 2 1.00E-06 5.61108 7.43E-02 1.29227 6.10E-01 1.06006 
NM_007626 Cbx5 chromobox homolog 5 (Drosophila HP1a) 7.85E-07 5.60849 5.49E-04 2.02711 3.20E-01 1.11963 
NM_007971 Ezh2 enhancer of zeste homolog 2 (Drosophila) 1.75E-07 5.58247 9.25E-05 2.12718 5.76E-01 1.05089 
NM_001081223 Rbbp8 retinoblastoma binding protein 8 1.63E-05 5.57737 3.23E-03 2.24373 3.62E-03 2.02874 
NM_023065 Ifi30 interferon gamma inducible protein 30 6.30E-08 5.57032 4.63E-03 1.39558 7.07E-01 -1.02897 
NM_030159 Troap trophinin associated protein 4.05E-06 5.54318 5.51E-03 1.80358 1.14E-01 1.27239 
NM_010442 Hmox1 heme oxygenase (decycling) 1 1.83E-07 5.5329 1.40E-03 1.62139 2.51E-03 1.47581 
NM_153058 Mapre2 microtubule-associated protein, RP 1.24E-06 5.52715 5.63E-05 2.94049 8.00E-02 -1.25723 
NM_001045513 Raph1 Ras association (RalGDS 9.59E-07 5.52626 1.06E-03 1.90595 1.52E-01 -1.1894 
NM_009764 Brca1 breast cancer 1 2.04E-08 5.52316 8.01E-05 1.75537 9.26E-01 1.00597 
NM_023418 Pgam1 phosphoglycerate mutase 1 3.24E-06 5.52286 9.50E-04 2.19452 1.19E-03 1.96613 
NM_023279 Tubb3 tubulin, beta 3 4.58E-07 5.50785 2.52E-03 1.64096 1.20E-03 1.65879 
NM_026412 
D2Ertd75
0e 
DNA segment, Chr 2, ERATO Doi 750, 
expressed 1.79E-07 5.49656 2.79E-04 1.8767 7.50E-01 -1.02826 
NM_009013 
Rad51ap
1 RAD51 associated protein 1 5.28E-06 5.49349 3.64E-02 1.48955 6.81E-01 1.06096 
NM_009655 Alcam activated leukocyte cell adhesion molecule 2.49E-06 5.47368 5.14E-03 1.73707 9.80E-01 -1.00322 
NM_007681 Cenpa centromere protein A 5.50E-07 5.44158 2.68E-04 2.09932 1.39E-01 -1.17883 
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NM_053108 Glrx glutaredoxin 3.75E-04 5.40399 1.96E-02 2.43772 4.26E-01 -1.25036 
BC039993 
2610318
N02Rik RIKEN cDNA 2610318N02 gene 2.71E-04 5.38558 1.56E-01 1.56116 9.95E-01 1.00154 
NM_009830 Ccne2 cyclin E2 3.13E-05 5.38308 6.11E-03 2.16484 2.85E-01 1.22912 
NM_016661 Ahcy S-adenosylhomocysteine hydrolase 6.18E-09 5.38171 3.75E-05 1.69007 1.63E-05 1.70359 
NM_019755 Plp2 proteolipid protein 2 2.99E-08 5.37151 5.30E-06 2.4183 1.32E-02 1.23521 
AK050877 
D030028
M11Rik RIKEN cDNA D030028M11 gene 1.30E-05 5.36693 1.01E-03 2.56435 1.14E-01 1.32513 
NM_134007 Cisd1 CDGSH iron sulfur domain 1 7.88E-06 5.34767 2.81E-03 2.0651 1.86E-01 1.23532 
NM_175652 Hist4h4 histone cluster 4, H4 7.07E-05 5.32707 9.26E-03 2.22371 5.56E-01 1.13218 
NM_207298 Cercam cerebral endothelial cell adhesion molecule 1.59E-06 5.2906 1.57E-02 1.49325 3.03E-03 1.65129 
NM_178609 E2f7 E2F transcription factor 7 2.58E-08 5.2462 2.74E-05 1.94611 2.05E-01 1.09036 
NM_199467 
F730047
E07Rik RIKEN cDNA F730047E07 gene 1.25E-07 5.24575 5.72E-05 2.11003 1.81E-02 1.26912 
NM_023203 Dctpp1 dCTP pyrophosphatase 1 3.16E-07 5.2394 4.90E-04 1.83253 4.06E-01 1.08174 
NM_016661 Ahcy S-adenosylhomocysteine hydrolase 8.26E-09 5.22988 5.30E-05 1.66503 2.09E-05 1.69187 
NM_007512 Atpif1 ATPase inhibitory factor 1 6.40E-08 5.21223 6.62E-05 1.93519 2.45E-03 1.38257 
NM_007599 Capg capping protein (actin filament), gelsolin-like 6.15E-07 5.14813 2.40E-05 2.89744 6.42E-01 -1.04817 
NM_133888 Smpdl3b 
sphingomyelin phosphodiesterase, acid-like 
3B 7.79E-06 5.13374 8.75E-02 1.36598 6.45E-01 1.07004 
NM_138653 Bspry B-box and SPRY domain containing 3.62E-05 5.1222 3.69E-03 2.32849 6.50E-02 1.47239 
NM_001081317 Anubl1 
AN1, ubiquitin-like, homolog (Xenopus 
laevis) 1.19E-04 5.111 3.60E-02 1.8509 7.58E-01 1.07067 
NM_016764 Prdx4 peroxiredoxin 4 8.42E-05 5.102 5.81E-01 1.13901 2.52E-01 -1.28557 
NM_016957 Hmgn2 
high mobility group nucleosomal binding 
domain 2 5.49E-09 5.09397 4.60E-07 2.61186 3.00E-02 1.14109 
NM_001015046 
Rap1gap
2 RAP1 GTPase activating protein 2 4.61E-08 5.09299 5.29E-05 1.90225 5.15E-03 1.30286 
NM_007671 Cdkn2c 
cyclin-dependent kinase inhibitor 2C (p18, 
inhibits CDK4) 4.15E-04 5.09059 3.60E-02 2.11917 8.05E-01 1.06886 
NM_007669 Cdkn1a cyclin-dependent kinase inhibitor 1A (P21) 5.35E-05 5.08812 3.29E-02 1.74189 3.12E-01 1.22632 
NM_026613 Ccdc34 coiled-coil domain containing 34 4.18E-06 5.08221 7.40E-02 1.3482 8.25E-01 -1.02972 
NM_008565 Mcm4 
minichromosome maintenance deficient 4 
homolog (S. cerevisiae) 4.41E-06 5.0756 4.87E-04 2.40005 1.24E-02 1.53485 
NM_008637 Nudt1 
nudix (nucleoside diphosphate linked moiety 
X)-type motif 1 2.08E-07 5.07105 4.27E-04 1.77156 2.15E-03 1.47239 
NM_183046 Kif20b kinesin family member 20B 6.81E-06 5.04498 2.65E-02 1.53182 3.61E-01 -1.14242 
NM_016957 Hmgn2 
high mobility group nucleosomal binding 
domain 2 4.07E-09 5.04303 4.17E-07 2.52758 3.96E-02 1.1239 
NM_029797 Mnd1 
meiotic nuclear divisions 1 homolog (S. 
cerevisiae) 1.08E-05 5.03235 2.62E-02 1.58069 5.81E-01 -1.08794 
NM_146001 Hip1 huntingtin interacting protein 1 5.30E-07 4.99949 1.41E-04 2.17462 4.01E-01 -1.08681 
NM_133737 Lancl2 
LanC (bacterial lantibiotic synthetase 
component C)-like 2 1.06E-07 4.98044 7.76E-02 1.18498 7.64E-01 -1.02321 
NM_007999 Fen1 flap structure specific endonuclease 1 2.81E-05 4.95825 7.85E-03 1.98741 1.30E-01 1.33152 
ENSMUST0000
0114898 Zc3hav1 zinc finger CCCH type, antiviral 1 5.15E-05 4.94707 2.31E-02 1.80757 9.33E-01 1.01594 
NM_025564 Magohb mago-nashi homolog B (Drosophila) 8.22E-06 4.94286 1.09E-02 1.70163 4.82E-03 1.7534 
NM_197959 Kif18b kinesin family member 18B 4.14E-07 4.9197 5.80E-02 1.25222 4.51E-02 1.24148 
NM_008921 Prim1 DNA primase, p49 subunit 3.78E-05 4.89976 2.04E-02 1.78305 2.21E-01 -1.26239 
NM_008564 Mcm2 
minichromosome maintenance deficient 2 
mitotin (S. cerevisiae) 6.62E-09 4.89493 1.11E-06 2.32959 2.39E-03 1.25314 
NM_008567 Mcm6 
minichromosome maintenance deficient 6 
(MIS5 homolog, S. pombe) (S 3.13E-07 4.88276 3.83E-05 2.38296 2.43E-02 1.27479 
NM_026844 
2310061
C15Rik RIKEN cDNA 2310061C15 gene 1.40E-07 4.87923 8.19E-05 1.98705 6.19E-02 1.18246 
NM_016957 Hmgn2 
high mobility group nucleosomal binding 
domain 2 6.03E-09 4.82317 6.33E-07 2.4541 2.53E-02 1.14444 
NM_010436 H2afx H2A histone family, member X 7.89E-06 4.79927 5.32E-03 1.82333 2.21E-01 1.19886 
NM_133348 Acot7 acyl-CoA thioesterase 7 2.35E-07 4.77537 5.79E-06 2.98075 2.70E-04 1.71626 
NM_001081001 Brca2 breast cancer 2 3.85E-06 4.76364 5.95E-03 1.69162 4.16E-01 -1.10994 
NM_009193 Slbp stem-loop binding protein 4.11E-06 4.74284 1.56E-03 1.97457 1.26E-01 1.23538 
NM_001177653 Hist1h2be histone cluster 1, H2be 1.12E-08 4.73576 1.12E-05 1.8854 4.41E-01 -1.04294 
NM_026695 Etfb 
electron transferring flavoprotein, beta 
polypeptide 8.52E-07 4.72923 4.61E-05 2.60444 3.14E-02 1.29471 
NM_001004174 
AA46719
7 expressed sequence AA467197 1.17E-03 4.70631 3.91E-03 4.01361 5.16E-02 1.99204 
NM_010212 Fhl2 four and a half LIM domains 2 5.14E-07 4.70402 1.12E-03 1.69648 8.74E-03 1.37815 
  96 
NM_025821 Carhsp1 calcium regulated heat stable protein 1 8.48E-08 4.69649 4.31E-05 1.99051 3.10E-02 1.20253 
BC138271 
2610002
D18Rik RIKEN cDNA 2610002D18 gene (aka Clhc1) 1.70E-05 4.681 2.08E-02 1.64074 1.28E-01 1.29353 
NM_027354 Poc1a 
POC1 centriolar protein homolog A 
(Chlamydomonas) 2.66E-09 4.66338 3.30E-05 1.54318 2.32E-02 1.12742 
NM_146061 Prr5 proline rich 5 (renal) 4.38E-08 4.6324 2.49E-02 1.21683 1.39E-02 1.22283 
NM_027429 Cenpl centromere protein L 1.76E-06 4.6115 7.24E-03 1.55358 5.38E-01 1.07063 
NM_007535 Bcl2a1c B-cell leukemia 1.49E-04 4.6012 7.05E-02 1.63489 1.10E-01 -1.45814 
NM_145360 Idi1 isopentenyl-diphosphate delta isomerase 9.97E-05 4.5933 4.55E-01 1.18632 7.67E-01 -1.06139 
NM_023210 Anp32e 
acidic (leucine-rich) nuclear phosphoprotein 
32 family, member E 1.76E-06 4.57625 4.27E-03 1.62695 2.26E-02 1.35671 
NM_001001932 Eea1 early endosome antigen 1 3.89E-05 4.55654 6.37E-04 2.95909 5.90E-01 1.09823 
NM_007999 Fen1 flap structure specific endonuclease 1 4.62E-06 4.54862 1.72E-03 1.93856 8.67E-02 1.27085 
NM_001164734 Mpp6 
membrane protein, palmitoylated 6 (MAGUK 
p55 subfamily member 6 8.97E-05 4.51455 1.00E-01 1.48844 7.20E-01 -1.07274 
BC056351 Rab18 RAB18, member RAS oncogene family 1.37E-04 4.47959 3.03E-02 1.83068 9.67E-01 -1.00849 
NM_133978 Cmtm7 
CKLF-like MARVEL transmembrane domain 
containing 7 7.94E-08 4.46894 8.84E-06 2.31433 2.88E-01 -1.07848 
NM_026845 Ppil1 peptidylprolyl isomerase (cyclophilin)-like 1 8.99E-07 4.42762 2.84E-03 1.59389 3.08E-02 1.28467 
NM_011207 Ptpn3 
protein tyrosine phosphatase, non-receptor 
type 3 1.29E-05 4.42433 1.79E-02 1.6067 4.64E-01 1.11273 
NM_028716 Phf19 PHD finger protein 19 1.95E-05 4.40324 1.45E-02 1.6944 2.14E-01 1.2212 
NM_013754 Insl6 insulin-like 6 8.79E-05 4.39032 3.44E-02 1.71358 5.03E-01 1.13845 
NM_019716 Orc6l 
origin recognition complex, subunit 6-like (S. 
cerevisiae) 5.57E-06 4.38673 1.37E-02 1.55526 5.84E-01 1.07177 
XR_032234 Gm13310 karyopherin (importin) alpha 2 pseudogene 3.17E-07 4.37652 4.24E-04 1.73896 1.05E-01 1.15861 
NM_001033166 
2700094
K13Rik RIKEN cDNA 2700094K13 gene 1.80E-05 4.35994 2.64E-03 2.07417 3.84E-02 1.44082 
NM_011015 Orc1l 
origin recognition complex, subunit 1-like 
(S.cereviaiae) 4.02E-06 4.35447 3.73E-02 1.38873 1.55E-02 -1.4396 
NM_009694 Apobec2 
apolipoprotein B mRNA editing enzyme, 
catalytic polypeptide 2 2.88E-05 4.32289 4.46E-03 2.02515 8.23E-01 1.03625 
NM_009124 Atxn1 ataxin 1 7.65E-07 4.31933 1.07E-04 2.1788 5.84E-03 1.4172 
NM_013929 Siva1 SIVA1, apoptosis-inducing factor 2.32E-05 4.29702 4.51E-02 1.49466 9.72E-01 -1.00544 
BC068129 Fam83d family with sequence similarity 83, member D 2.07E-05 4.28801 2.00E-01 1.25793 2.65E-01 1.19168 
NM_025639 Cenpm centromere protein M 1.66E-05 4.28703 1.17E-02 1.69934 7.23E-01 1.05299 
NM_008655 Gadd45b 
growth arrest and DNA-damage-inducible 45 
beta 7.79E-06 4.27612 1.02E-03 2.12074 1.26E-04 2.58209 
NM_010864 Myo5a myosin VA 7.19E-05 4.25286 2.69E-01 1.26398 7.89E-01 -1.0496 
ENSMUST0000
0099550 Atxn1 ataxin 1 5.29E-05 4.25215 8.29E-02 1.45624 3.64E-01 1.17506 
NM_007590 Calm3 calmodulin 3 1.14E-06 4.24491 8.96E-05 2.31228 3.47E-02 1.27682 
NM_010391 H2-Q10 histocompatibility 2, Q region locus 10 6.34E-06 4.24373 1.55E-02 1.53431 7.30E-01 -1.04412 
NM_008212 Hadh hydroxyacyl-Coenzyme A dehydrogenase 4.43E-06 4.24176 2.03E-02 1.46407 8.10E-01 1.02883 
NM_177752 Eme1 
essential meiotic endonuclease 1 homolog 1 
(S. pombe) 2.27E-06 4.21294 1.54E-02 1.44276 5.20E-01 1.07218 
NM_133777 Ube2s ubiquitin-conjugating enzyme E2S 6.67E-08 4.21084 4.18E-05 1.86091 8.91E-03 1.24684 
NM_001042653 Oip5 Opa interacting protein 5 2.45E-05 4.21052 9.41E-03 1.78907 7.32E-01 1.05377 
NM_008153 Cmklr1 chemokine-like receptor 1 3.64E-05 4.20919 2.19E-02 1.66751 4.49E-01 1.13314 
NM_010220 Fkbp5 FK506 binding protein 5 8.98E-06 4.19817 4.82E-03 1.77014 6.35E-02 1.31941 
NM_009073 Rom1 rod outer segment membrane protein 1 4.99E-06 4.17969 5.16E-04 2.17615 1.80E-03 1.75194 
NM_009388 Tkt transketolase 2.34E-08 4.15373 2.78E-05 1.75541 5.46E-05 1.5745 
NM_009387 Tk1 thymidine kinase 1 3.22E-06 4.13451 7.25E-03 1.56412 2.39E-01 1.14745 
NM_015753 Zeb2 zinc finger E-box binding homeobox 2 1.70E-07 4.12367 7.04E-05 1.90874 6.87E-01 1.02961 
NM_025377 Fam33a family with sequence similarity 33, member A 6.67E-06 4.11713 2.16E-03 1.87155 8.28E-01 -1.02718 
NM_010093 E2f3 E2F transcription factor 3 7.07E-07 4.10846 3.69E-04 1.83884 2.37E-01 1.11652 
NM_133777 Ube2s ubiquitin-conjugating enzyme E2S 3.76E-07 4.10023 2.09E-04 1.83721 2.99E-02 1.23465 
NM_026988 Ptms parathymosin 6.10E-06 4.09653 2.10E-03 1.85782 7.63E-02 1.27469 
NM_009014 Rad51l1 RAD51-like 1 (S. cerevisiae) 2.07E-05 4.07671 1.39E-02 1.66393 5.59E-02 1.37715 
NM_008568 Mcm7 
minichromosome maintenance deficient 7 (S. 
cerevisiae) 1.80E-04 4.0643 2.93E-02 1.81482 4.90E-01 1.15282 
NM_023418 Pgam1 phosphoglycerate mutase 1 3.00E-08 4.06084 2.03E-05 1.8264 2.40E-05 1.69081 
NM_023418 Pgam1 phosphoglycerate mutase 1 3.00E-08 4.06084 2.03E-05 1.8264 2.40E-05 1.69081 
NM_011284 Rpa2 replication protein A2 9.49E-07 4.04464 7.54E-03 1.44046 9.55E-01 1.00519 
NM_021788 Sap30 sin3 associated polypeptide 1.47E-04 4.04282 3.34E-02 1.74322 8.23E-02 1.46431 
NM_153544 
BC03086
7 cDNA sequence BC030867 7.98E-08 4.00306 2.82E-03 1.35804 5.67E-01 1.03723 
NM_019771 Dstn destrin 1.64E-04 3.9994 6.25E-02 1.60044 9.35E-01 1.01622 
  97 
NM_133706 Tmem97 transmembrane protein 97 4.44E-06 3.99739 4.42E-01 1.10493 9.53E-03 -1.47259 
NM_145360 Idi1 isopentenyl-diphosphate delta isomerase 2.56E-05 3.98931 6.98E-01 1.0664 1.63E-01 -1.24778 
NM_025928 Pmf1 polyamine-modulated factor 1 1.86E-05 3.98111 1.92E-02 1.58079 7.29E-01 1.05006 
NM_053272 Dhcr24 24-dehydrocholesterol reductase 4.28E-07 3.97499 4.91E-01 -1.06483 7.64E-02 -1.17423 
NM_026202 Ccdc50 coiled-coil domain containing 50 3.42E-07 3.95796 2.77E-05 2.23073 1.18E-01 1.14219 
NM_080561 Rnf216 ring finger protein 216 4.24E-07 3.93755 1.08E-03 1.58073 8.71E-02 1.16475 
NM_030724 Uck2 uridine-cytidine kinase 2 2.16E-06 3.92614 7.39E-03 1.4987 7.67E-03 1.43209 
NM_178218 Hist3h2a histone cluster 3, H2a 6.65E-05 3.92239 1.40E-02 1.80706 9.46E-01 1.01155 
NM_025994 Efhd2 EF hand domain containing 2 1.94E-09 3.92214 4.07E-08 2.68141 2.42E-04 1.27232 
ENSMUST0000
0022897 
4930447
A16Rik RIKEN cDNA 4930447A16 gene 1.33E-05 3.92168 7.77E-04 2.23316 9.55E-02 1.27771 
NM_026632 Rpa3 replication protein A3 1.00E-06 3.89442 2.93E-03 1.53781 2.91E-01 -1.10344 
NM_028481 Ccdc18 coiled-coil domain containing 18 1.28E-06 3.88636 2.87E-02 1.31528 1.66E-01 1.14808 
NM_011204 Ptpn13 
protein tyrosine phosphatase, non-receptor 
type 13 9.22E-07 3.85971 8.81E-04 1.68715 3.61E-02 1.24486 
NM_001025615 Ccdc50 coiled-coil domain containing 50 4.35E-05 3.85586 7.04E-03 1.88337 1.81E-02 1.58696 
NM_009987 Cx3cr1 chemokine (C-X3-C) receptor 1 6.52E-06 3.85543 2.46E-04 2.368 9.12E-01 1.01302 
NM_001165989 Ckap5 cytoskeleton associated protein 5 2.09E-06 3.85056 2.63E-03 1.62368 8.43E-01 -1.01971 
NM_030715 Polh 
polymerase (DNA directed), eta (RAD 30 
related) 3.13E-05 3.84244 2.39E-02 1.58095 5.10E-01 1.10416 
NM_146218 Rfwd3 ring finger and WD repeat domain 3 2.97E-08 3.83715 5.33E-05 1.64522 2.54E-02 1.15597 
NM_028448 Cenpv centromere protein V 1.25E-05 3.83554 5.67E-03 1.72405 8.70E-01 1.02118 
NM_008922 Prim2 DNA primase, p58 subunit 8.16E-06 3.83377 1.19E-02 1.54954 1.43E-01 1.21154 
NM_008928 Map2k3 mitogen-activated protein kinase kinase 3 1.70E-05 3.83143 1.21E-02 1.62799 5.08E-01 1.09458 
NM_007523 Bak1 BCL2-antagonist 5.48E-07 3.8076 6.47E-05 2.08077 1.89E-03 1.45566 
NM_028108 Naa50 
N(alpha)-acetyltransferase 50, NatE catalytic 
subunit 2.26E-06 3.79769 7.90E-04 1.82289 2.27E-03 1.56231 
BC006736 
3200002
M19Rik RIKEN cDNA 3200002M19 gene 2.32E-06 3.79326 8.26E-03 1.47639 5.86E-01 1.05612 
NM_025676 Mcm8 
minichromosome maintenance deficient 8 (S. 
cerevisiae) 5.16E-07 3.78581 5.46E-03 1.40413 2.96E-02 1.23211 
NM_001009818 sept11 septin 11 2.68E-08 3.77845 3.94E-06 2.05143 4.74E-05 1.55522 
NM_011239 Ranbp1 RAN binding protein 1 1.69E-08 3.77136 2.12E-05 1.68498 3.28E-04 1.35505 
NM_025900 Dek DEK oncogene (DNA binding) 9.84E-08 3.77003 5.94E-05 1.77596 1.18E-02 1.22506 
NM_026001 
Rnaseh2
b ribonuclease H2, subunit B 4.51E-06 3.76991 9.65E-03 1.51321 2.38E-01 -1.14521 
NM_026115 Hat1 histone aminotransferase 1 5.80E-06 3.76821 2.13E-02 1.43335 5.81E-01 -1.06521 
NM_001081115 Nccrp1 
non-specific cytotoxic cell receptor protein 1 
homolog (zebra 6.96E-07 3.75449 1.65E-01 1.1481 2.57E-03 1.4387 
XR_032130 Gm8681 predicted gene 8681 3.74E-05 3.74885 5.78E-04 2.59882 2.32E-01 1.20701 
NM_025281 Lyar Ly1 antibody reactive clone 1.86E-05 3.7478 2.74E-02 1.49411 1.20E-01 1.25691 
NM_146218 Rfwd3 ring finger and WD repeat domain 3 4.99E-08 3.73343 9.52E-05 1.61646 4.19E-02 1.14379 
NM_145480 Rfc4 replication factor C (activator 1) 4 4.71E-06 3.72814 3.16E-02 1.36891 1.52E-02 -1.39761 
NM_175294 Nucks1 
nuclear casein kinase and cyclin-dependent 
kinase substrate 1 5.81E-08 3.72542 7.01E-05 1.67208 1.27E-03 1.33131 
NM_206882 Hist3h2bb histone cluster 3, H2bb 2.27E-04 3.71771 1.01E-01 1.49261 2.82E-01 1.24752 
NM_146116 Tubb2c tubulin, beta 2C 1.92E-07 3.71401 1.98E-03 1.42009 6.08E-02 1.15731 
NM_018797 Plxnc1 plexin C1 1.13E-04 3.71349 1.84E-01 1.32258 8.25E-01 -1.03962 
NM_176982 Fbxo48 F-box protein 48 4.19E-06 3.71325 2.61E-02 1.38125 1.85E-01 -1.16303 
NM_008020 Fkbp2 FK506 binding protein 2 1.93E-08 3.69815 3.83E-06 1.96743 1.95E-03 1.25229 
NM_011712 Wbp5 WW domain binding protein 5 6.40E-06 3.69532 7.94E-03 1.5646 2.24E-01 1.15633 
NM_008479 Lag3 lymphocyte-activation gene 3 2.85E-05 3.68492 6.47E-03 1.79177 8.13E-02 1.31959 
NM_009643 Ahnak AHNAK nucleoprotein (desmoyokin) 1.64E-06 3.68128 1.18E-03 1.68549 8.71E-03 -1.3776 
NM_174848 Crybg3 beta-gamma crystallin domain containing 3 8.50E-06 3.67336 5.01E-01 -1.09403 6.32E-01 -1.05835 
NM_028006 Tube1 epsilon-tubulin 1 1.60E-06 3.66613 9.49E-02 1.20978 3.97E-01 -1.08277 
NM_025520 Lsm5 
LSM5 homolog, U6 small nuclear RNA 
associated (S. cerevisiae) 1.05E-05 3.66323 3.40E-02 1.40834 1.18E-01 1.23117 
NM_172598 Wdhd1 
WD repeat and HMG-box DNA binding 
protein 1 3.24E-06 3.65615 2.33E-02 1.3714 8.19E-01 -1.02349 
NM_019803 Ube2g2 ubiquitin-conjugating enzyme E2G 2 5.06E-07 3.64234 8.32E-05 1.96099 6.86E-04 1.53425 
NM_001164117 
Serpinb6
a 
serine (or cysteine) peptidase inhibitor, clade 
B, member 1.79E-05 3.63991 4.48E-03 1.78383 8.42E-01 1.02634 
NM_134092 Mtbp 
Mdm2, transformed 3T3 cell double minute 
p53 binding protein 3.70E-06 3.62166 4.49E-02 1.30946 5.48E-02 -1.25577 
NM_013812 Cdk2ap1 
CDK2 (cyclin-dependent kinase 2)-
associated protein 1 4.61E-05 3.61972 1.88E-02 1.63591 8.54E-01 1.02803 
NM_013635 Sypl synaptophysin-like protein 6.65E-06 3.61061 4.74E-04 2.09384 6.13E-01 1.0587 
NM_197997 4930422 RIKEN cDNA 4930422G04 gene 1.03E-06 3.60656 9.54E-04 1.64533 1.30E-01 1.15023 
  98 
G04Rik 
NM_009545 Pcgf2 polycomb group ring finger 2 2.57E-06 3.604 2.95E-03 1.59289 7.83E-02 1.21226 
NM_146116 Tubb2c tubulin, beta 2C 5.06E-07 3.60381 2.26E-03 1.46966 1.28E-01 1.13539 
NM_001134829 Lpgat1 lysophosphatidylglycerol acyltransferase 1 3.51E-06 3.59846 1.10E-02 1.45434 1.27E-01 1.18445 
NM_008737 Nrp1 neuropilin 1 1.28E-05 3.59699 4.77E-01 1.10473 7.99E-01 1.03184 
NM_008613 Mns1 meiosis-specific nuclear structural protein 1 2.94E-06 3.59022 1.30E-02 1.42122 2.35E-01 1.13125 
NM_029977 Polq polymerase (DNA directed), theta 1.21E-07 3.58364 3.20E-03 1.33932 5.45E-01 -1.0386 
NM_029573 Idh3a isocitrate dehydrogenase 3 (NAD+) alpha 1.47E-05 3.56864 5.03E-03 1.71724 6.27E-03 1.58895 
NM_008982 Ptprj 
protein tyrosine phosphatase, receptor type, 
J 1.42E-05 3.55987 2.93E-04 2.42488 8.66E-01 -1.02112 
NM_009940 Coq7 demethyl-Q 7 3.96E-06 3.5443 7.36E-01 1.03934 3.17E-01 -1.11162 
NM_178856 Gins2 GINS complex subunit 2 (Psf2 homolog) 3.75E-07 3.53144 2.04E-03 1.44701 8.94E-01 1.00965 
NM_175265 
6720463
M24Rik RIKEN cDNA 6720463M24 gene (aka Bora) 2.77E-05 3.52991 7.06E-02 1.36679 7.26E-01 1.04905 
NM_013614 Odc1 ornithine decarboxylase, structural 1 7.26E-05 3.52884 3.22E-03 2.10798 2.24E-02 1.55871 
NM_011568 Thoc4 THO complex 4 2.99E-06 3.52624 1.99E-03 1.65366 7.01E-02 1.22209 
BC042740 
2700029
M09Rik RIKEN cDNA 2700029M09 gene 7.44E-06 3.5163 2.12E-03 1.7643 2.94E-02 1.34007 
NM_027959 Pdia6 protein disulfide isomerase associated 6 4.28E-08 3.51271 5.07E-06 2.01348 8.54E-04 1.32346 
NM_009361 Tfdp1 transcription factor Dp 1 9.20E-05 3.50416 7.87E-03 1.90741 1.50E-01 1.28923 
NM_008894 Pold2 
polymerase (DNA directed), delta 2, 
regulatory subunit 2.62E-06 3.48488 2.85E-03 1.57972 5.23E-01 1.06328 
NM_007951 Erh 
enhancer of rudimentary homolog 
(Drosophila) 6.45E-06 3.4792 3.17E-03 1.66827 1.03E-02 1.43629 
NM_010137 Epas1 endothelial PAS domain protein 1 9.53E-06 3.47811 1.22E-01 1.24233 8.69E-02 -1.24553 
NM_198652 Hjurp Holliday junction recognition protein 3.44E-06 3.47634 3.20E-02 1.32713 7.41E-02 -1.22005 
NM_010827 Msc musculin 4.36E-06 3.47044 1.64E-01 1.1856 8.58E-02 1.21647 
NM_026556 Dynll2 dynein light chain LC8-type 2 1.90E-06 3.4681 1.52E-04 2.0435 5.33E-04 1.68439 
NM_198654 Nsl1 
NSL1, MIND kinetochore complex 
component, homolog (S. cerevisiae) 4.67E-05 3.46712 4.56E-02 1.46272 4.40E-01 1.12152 
NM_016777 Nasp 
nuclear autoantigenic sperm protein (histone-
binding) 1.83E-05 3.46543 6.88E-02 1.33827 4.29E-01 1.10729 
NM_010807 Marcksl1 MARCKS-like 1 1.03E-05 3.46079 4.05E-01 1.11657 6.72E-01 -1.05041 
NM_015789 Dkkl1 dickkopf-like 1 7.72E-07 3.45255 1.81E-01 1.13393 8.03E-01 1.01982 
XR_033304 Gm7172 predicted gene 7172 6.08E-07 3.45011 3.45E-04 1.69563 1.40E-03 1.45112 
NM_011352 Sema7a 
sema domain, immunoglobulin domain (Ig), 
and GPI membrane anchor 6.27E-06 3.44703 7.33E-04 1.92769 2.52E-02 1.33899 
NM_153785 Cdkl3 cyclin-dependent kinase-like 3 3.71E-05 3.44526 5.47E-02 1.41405 5.23E-01 1.09464 
NM_007457 Ap1s1 adaptor protein complex AP-1, sigma 1 9.04E-06 3.44444 3.14E-03 1.70745 5.44E-02 1.28484 
NM_013812 Cdk2ap1 
CDK2 (cyclin-dependent kinase 2)-
associated protein 1 3.08E-05 3.44369 1.71E-02 1.57469 8.54E-01 1.02519 
NM_007875 Dpagt1 
dolichyl-phosphate (UDP-N-
acetylglucosamine) acetylglucosamineph 1.38E-05 3.44075 6.59E-02 1.32528 2.15E-01 1.17064 
NM_019770 Tmed2 
transmembrane emp24 domain trafficking 
protein 2 1.51E-06 3.4249 2.16E-04 1.91002 2.74E-04 1.7452 
NM_026310 Mrpl18 mitochondrial ribosomal protein L18 9.84E-04 3.4043 8.89E-02 1.64647 1.52E-01 1.43844 
NM_009302 Swap70 SWA-70 protein 5.16E-06 3.40408 4.98E-04 1.96064 1.57E-01 1.16989 
NM_001037999 Dbi diazepam binding inhibitor 1.36E-05 3.40332 1.59E-02 1.49842 9.24E-01 1.01144 
NM_011738 Ywhah tyrosine 3-monooxygenase 1.43E-08 3.3989 2.56E-06 1.90429 2.35E-06 1.79205 
NM_008828 Pgk1 phosphoglycerate kinase 1 3.60E-07 3.39755 1.53E-03 1.45501 4.54E-02 1.17638 
NM_008828 Pgk1 phosphoglycerate kinase 1 3.60E-07 3.39755 1.53E-03 1.45501 4.54E-02 1.17638 
NM_011701 Vim vimentin 4.17E-07 3.39621 2.79E-04 1.66637 1.06E-03 -1.44127 
NM_021498 Pole3 
polymerase (DNA directed), epsilon 3 (p17 
subunit) 1.37E-05 3.39385 3.07E-03 1.75902 6.70E-03 1.54384 
NM_007747 Cox5a cytochrome c oxidase, subunit Va 3.04E-06 3.39186 6.98E-04 1.79793 3.30E-03 1.48908 
NM_013726 Dbf4 DBF4 homolog (S. cerevisiae) 1.20E-05 3.38911 7.33E-02 1.30124 9.01E-01 -1.01458 
NM_023258 Pycard PYD and CARD domain containing 5.22E-07 3.38208 1.85E-02 1.27113 9.23E-04 -1.47004 
NM_025531 Slmo2 slowmo homolog 2 (Drosophila) 9.70E-05 3.37503 6.07E-02 1.46725 1.16E-01 1.3174 
XR_033533 Gm6560 predicted gene 6560 9.03E-07 3.35528 2.90E-04 1.75495 2.53E-03 1.41452 
NM_016925 Fanca Fanconi anemia, complementation group A 1.71E-07 3.35526 1.02E-02 1.2605 4.92E-01 1.04403 
NM_030234 Wdr76 WD repeat domain 76 4.00E-05 3.35198 5.26E-02 1.41434 4.44E-01 1.11399 
NM_182995 
6330503
K22Rik RIKEN cDNA 6330503K22 gene 3.04E-05 3.35162 4.96E-03 1.77834 7.41E-02 1.30702 
NM_008828 Pgk1 phosphoglycerate kinase 1 2.63E-07 3.34542 1.21E-03 1.44557 3.63E-02 1.17685 
NM_011404 Slc7a5 
solute carrier family 7 (cationic amino acid 
transporter, y+ sys 4.62E-05 3.34512 2.71E-01 1.19904 2.38E-01 1.1915 
NM_145946 Fanci Fanconi anemia, complementation group I 8.27E-06 3.33603 2.70E-02 1.38457 1.56E-01 -1.1804 
NM_133753 Errfi1 ERBB receptor feedback inhibitor 1 3.69E-06 3.326 3.73E-04 1.93344 8.05E-01 1.0239 
  99 
NM_011045 Pcna proliferating cell nuclear antigen 6.48E-07 3.31991 5.70E-05 1.98822 2.33E-02 1.22923 
NM_016662 Mxd3 Max dimerization protein 3 7.62E-07 3.31553 1.73E-02 1.2881 1.41E-01 1.12878 
NM_025853 Dsn1 
DSN1, MIND kinetochore complex 
component, homolog (S. cerevisiae) 1.88E-04 3.30827 5.65E-02 1.53392 5.31E-01 -1.11684 
NM_025520 Lsm5 
LSM5 homolog, U6 small nuclear RNA 
associated (S. cerevisiae) 4.25E-06 3.30808 1.48E-02 1.4016 1.66E-01 1.1561 
NM_011014 Sigmar1 sigma non-opioid intracellular receptor 1 6.81E-07 3.30804 6.77E-02 1.18905 3.13E-03 1.37169 
NM_009270 Sqle squalene epoxidase 2.93E-06 3.30689 5.16E-01 1.07034 8.99E-02 1.19096 
NM_177780 Dock5 dedicator of cytokinesis 5 2.07E-07 3.30643 8.31E-05 1.72824 6.48E-03 1.25951 
NM_010325 Got2 
glutamate oxaloacetate transaminase 2, 
mitochondrial 4.87E-04 3.29546 3.83E-02 1.74326 2.08E-01 1.31134 
NM_001128096 Atp13a3 ATPase type 13A3 1.26E-04 3.28463 4.67E-01 1.14389 3.17E-02 1.51971 
NM_133933 Rpn1 ribophorin I 1.10E-06 3.28385 2.13E-04 1.8189 5.34E-04 1.58445 
NM_053074 Nup62 nucleoporin 62 1.00E-05 3.28043 8.37E-03 1.53799 4.99E-01 1.07847 
NM_013863 Bag3 BCL2-associated athanogene 3 6.93E-06 3.27983 6.04E-04 1.93577 7.20E-03 1.45584 
NM_011045 Pcna proliferating cell nuclear antigen 7.22E-07 3.27879 5.85E-05 1.9901 2.58E-02 1.22438 
NM_016660 Hmga1 high mobility group AT-hook 1 1.95E-08 3.27203 3.81E-05 1.545 1.46E-05 1.56873 
NM_027722 Nudt4 
nudix (nucleoside diphosphate linked moiety 
X)-type motif 4 4.57E-05 3.27202 9.22E-03 1.69871 6.23E-01 -1.07087 
NM_013692 Klf10 Kruppel-like factor 10 9.46E-06 3.26076 1.01E-02 1.50455 7.14E-02 1.24841 
NM_001166589 Eif5a eukaryotic translation initiation factor 5A 2.79E-07 3.2474 8.89E-05 1.74502 1.22E-04 1.60616 
NM_009226 Snrpd1 small nuclear ribonucleoprotein D1 2.65E-05 3.24715 2.23E-02 1.4878 1.14E-01 1.24527 
NM_025548 Tbcb tubulin folding cofactor B 1.52E-06 3.23336 8.39E-05 2.0486 2.84E-03 1.42661 
NM_175329 Chchd10 
coiled-coil-helix-coiled-coil-helix domain 
containing 10 2.34E-05 3.23248 1.01E-02 1.59147 4.23E-01 1.10641 
NM_010019 Dapk2 death-associated protein kinase 2 4.19E-07 3.22178 3.06E-04 1.61909 1.91E-01 1.09929 
NM_028677 Ppih peptidyl prolyl isomerase H 3.84E-04 3.21733 5.99E-02 1.58579 8.67E-01 1.03238 
NM_199035 Alg8 
asparagine-linked glycosylation 8 homolog 
(yeast, alpha-1,3-glucos 1.81E-06 3.20862 5.11E-03 1.4357 3.05E-01 1.09336 
NM_010281 Ggh gamma-glutamyl hydrolase 4.06E-03 3.19602 3.45E-01 1.36868 9.84E-01 -1.00574 
NM_010281 Ggh gamma-glutamyl hydrolase 4.06E-03 3.19602 3.45E-01 1.36868 9.84E-01 -1.00574 
NM_025570 Mrpl20 mitochondrial ribosomal protein L20 4.11E-05 3.19551 1.43E-02 1.59101 3.78E-02 1.38814 
NM_026065 Mrpl42 mitochondrial ribosomal protein L42 1.25E-03 3.19191 8.38E-02 1.65223 4.22E-01 1.20938 
NM_008525 Alad aminolevulinate, delta-, dehydratase 9.63E-05 3.19116 1.29E-02 1.7195 1.18E-01 1.29824 
NM_023579 Ipo5 importin 5 2.47E-06 3.18427 1.38E-02 1.35779 5.70E-02 1.21036 
NM_011654 Tuba1b tubulin, alpha 1B 3.35E-07 3.18369 1.65E-04 1.66566 1.90E-02 1.20937 
NM_182990 Ssrp1 structure specific recognition protein 1 2.60E-07 3.18247 9.53E-05 1.70882 8.35E-03 1.24512 
NM_025935 Tbc1d7 TBC1 domain family, member 7 6.89E-06 3.18096 4.99E-01 1.08084 8.12E-01 1.02438 
NM_011032 P4hb prolyl 4-hydroxylase, beta polypeptide 3.01E-08 3.17583 2.50E-06 1.97243 1.55E-05 1.58832 
NM_010858 Myl4 myosin, light polypeptide 4 6.34E-06 3.17161 2.14E-03 1.66233 5.58E-02 1.2464 
NM_133878 Rcc1 regulator of chromosome condensation 1 1.59E-07 3.17088 8.03E-03 1.25775 7.03E-02 1.12689 
NM_019830 Prmt1 protein arginine N-methyltransferase 1 2.38E-06 3.16949 1.12E-02 1.37336 4.34E-01 1.07137 
NM_025595 Mrpl51 mitochondrial ribosomal protein L51 1.63E-04 3.16752 1.39E-02 1.77783 7.50E-02 1.39129 
BC083356 Ran RAN, member RAS oncogene family 2.11E-06 3.16696 2.28E-03 1.53139 5.73E-03 1.37725 
NM_009127 Scd1 stearoyl-Coenzyme A desaturase 1 5.19E-05 3.16656 9.52E-02 -1.32918 8.52E-01 -1.02586 
NM_010066 Dnmt1 DNA methyltransferase (cytosine-5) 1 8.58E-10 3.16491 1.15E-06 1.57651 3.93E-02 -1.06895 
NM_025595 Mrpl51 mitochondrial ribosomal protein L51 4.57E-04 3.16412 8.48E-02 1.51998 2.33E-01 1.2756 
XR_030853 Gm8956 predicted gene 8956 6.13E-06 3.16316 3.53E-04 1.98843 1.48E-02 1.35871 
NM_001159284 Smtn smoothelin 2.94E-06 3.16205 6.77E-02 1.22941 8.49E-01 1.01703 
NM_009863 Cdc7 cell division cycle 7 (S. cerevisiae) 1.61E-05 3.15291 1.16E-01 1.24697 7.94E-01 1.03022 
NM_009112 S100a10 S100 calcium binding protein A10 (calpactin) 2.17E-06 3.15014 1.45E-04 1.97001 9.47E-04 1.56048 
NM_197997 
4930422
G04Rik RIKEN cDNA 4930422G04 gene 5.95E-05 3.14834 6.16E-02 1.39563 6.97E-01 -1.05596 
NM_023117 Cdc25b cell division cycle 25 homolog B (S. pombe) 1.10E-07 3.14635 1.74E-04 1.53062 1.09E-02 1.19856 
NM_009471 Umps uridine monophosphate synthetase 2.09E-06 3.14574 3.09E-03 1.49205 5.50E-02 1.2048 
BC059209 Vcpip1 valosin containing protein (p97) 4.76E-06 3.14386 4.99E-03 1.50984 1.73E-01 1.14862 
NM_172288 Nup133 nucleoporin 133 1.20E-05 3.13689 2.07E-01 1.17682 6.06E-01 1.05813 
NM_198664 Tbc1d2 TBC1 domain family, member 2 8.96E-05 3.13435 1.22E-01 1.32298 1.89E-01 1.23046 
NM_007451 Slc25a5 
solute carrier family 25 (mitochondrial carrier, 
adenine nucleo 1.27E-08 3.13182 1.10E-05 1.60905 5.12E-06 1.61091 
NM_019562 Uchl5 ubiquitin carboxyl-terminal esterase L5 1.65E-06 3.12537 1.02E-03 1.59841 9.73E-03 1.31484 
NM_007550 Blm Bloom syndrome homolog (human) 1.49E-04 3.11939 2.01E-01 1.27434 3.76E-01 -1.1562 
NM_028128 Rfc5 replication factor C (activator 1) 5 5.15E-06 3.11517 1.42E-02 1.39453 2.95E-01 1.10936 
BC103775 Fam136a 
family with sequence similarity 136, member 
A 2.06E-04 3.11248 5.21E-02 1.5246 3.21E-01 1.18834 
BC080730 
3200002
M19Rik RIKEN cDNA 3200002M19 gene 4.36E-07 3.11127 1.97E-03 1.40785 2.56E-01 1.08213 
NM_001146038 Runx2 runt related transcription factor 2 1.13E-06 3.11029 7.14E-06 2.62708 1.06E-03 1.48041 
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NM_018831 Dclre1a 
DNA cross-link repair 1A, PSO2 homolog (S. 
cerevisiae) 1.01E-05 3.10809 4.72E-03 1.58665 5.52E-02 1.26207 
NM_019746 Pdcd5 programmed cell death 5 7.28E-06 3.10697 4.78E-04 1.93567 1.09E-03 1.67094 
NM_010325 Got2 
glutamate oxaloacetate transaminase 2, 
mitochondrial 2.55E-04 3.10435 2.96E-02 1.66183 1.93E-01 1.27154 
NM_013820 Hk2 hexokinase 2 6.14E-08 3.09269 4.14E-04 1.39784 1.81E-03 1.26178 
NM_008084 Gapdh glyceraldehyde-3-phosphate dehydrogenase 5.40E-08 3.08956 3.41E-06 1.99169 4.09E-04 1.34235 
NM_010480 
Hsp90aa
1 
heat shock protein 90, alpha (cytosolic), 
class A member 1 1.29E-08 3.08274 3.85E-06 1.73282 2.44E-06 1.69232 
NM_026310 Mrpl18 mitochondrial ribosomal protein L18 1.12E-04 3.07921 2.63E-02 1.5768 2.79E-01 1.18577 
NM_012025 Racgap1 Rac GTPase-activating protein 1 1.53E-04 3.0749 8.90E-02 1.3998 7.53E-02 1.37451 
NM_030198 Gins3 GINS complex subunit 3 (Psf3 homolog) 7.02E-07 3.07376 5.61E-03 1.34692 5.86E-02 1.16491 
NM_011482 Nhp2l1 
NHP2 non-histone chromosome protein 2-
like 1 (S. cerevisiae) 1.01E-07 3.06529 6.90E-05 1.60896 2.38E-03 1.26628 
NM_012050 Omd osteomodulin 4.81E-04 3.06479 2.33E-01 1.30629 4.80E-01 -1.14631 
NM_020616 
D930014
E17Rik RIKEN cDNA D930014E17 gene 5.30E-04 3.06394 3.99E-02 1.68801 3.86E-01 -1.18746 
NM_001080969 Thg1l 
tRNA-histidine guanylyltransferase 1-like (S. 
cerevisiae) 2.51E-05 3.05783 5.00E-01 1.09522 1.40E-02 1.45097 
NM_007891 E2f1 E2F transcription factor 1 2.19E-06 3.05443 1.99E-03 1.53038 1.05E-02 1.31693 
NM_144802 Hnrpll 
heterogeneous nuclear ribonucleoprotein L-
like 6.24E-05 3.05047 9.31E-02 1.33045 6.51E-01 -1.06403 
NM_172453 Pif1 
PIF1 5'-to-3' DNA helicase homolog (S. 
cerevisiae) 1.21E-05 3.0428 1.30E-02 1.45913 5.41E-01 -1.0678 
NM_145417 Rnpep arginyl aminopeptidase (aminopeptidase B) 2.11E-06 3.0427 6.77E-03 1.39638 3.88E-01 -1.07524 
NM_007951 Erh 
enhancer of rudimentary homolog 
(Drosophila) 2.73E-06 3.04137 1.80E-03 1.562 5.27E-03 1.38551 
NM_026467 Rps27l ribosomal protein S27-like 5.58E-05 3.04114 4.41E-02 1.42298 6.38E-01 1.0654 
XR_033865 Gm5263 predicted gene 5263 1.03E-05 3.03961 8.73E-04 1.85214 6.43E-03 1.46476 
NM_001127346 Ndufaf2 
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, assembly 2.49E-05 3.03561 2.64E-02 1.42756 5.72E-01 -1.06969 
NM_028334 Nup37 nucleoporin 37 2.56E-05 3.02999 1.46E-01 1.23166 5.52E-01 -1.07375 
NM_148928 Gtf3c5 
general transcription factor IIIC, polypeptide 
5 4.60E-05 3.02883 4.03E-03 1.79521 2.28E-02 1.43594 
NM_173752 
1110067
D22Rik RIKEN cDNA 1110067D22 gene 5.11E-07 3.02088 4.45E-04 1.55383 1.49E-03 1.37799 
NM_001110130 Ppih peptidyl prolyl isomerase H 2.55E-04 3.01596 7.09E-02 1.47192 9.49E-01 1.01079 
NM_175400 Sephs1 selenophosphate synthetase 1 1.03E-04 3.01344 9.53E-02 1.35381 1.17E-01 1.2856 
NM_008084 Gapdh glyceraldehyde-3-phosphate dehydrogenase 4.00E-08 3.01276 2.04E-06 2.00608 1.46E-04 1.38499 
NM_010948 Nudc 
nuclear distribution gene C homolog 
(Aspergillus) 5.27E-08 3.00962 4.36E-04 1.3729 5.95E-04 1.30888 
NM_010477 Hspd1 heat shock protein 1 (chaperonin) 5.62E-08 3.00719 1.18E-04 1.48423 2.11E-04 1.3798 
NM_009681 Ap3s1 
adaptor-related protein complex 3, sigma 1 
subunit 5.71E-05 3.00323 2.03E-02 1.53219 2.31E-01 1.1826 
NM_009652 Akt1 thymoma viral proto-oncogene 1 1.13E-05 3.00191 1.67E-02 1.41716 1.93E-01 1.15465 
NM_007951 Erh 
enhancer of rudimentary homolog 
(Drosophila) 3.17E-06 3.00118 2.02E-03 1.55413 6.50E-03 1.37152 
NM_172574 Pqlc3 PQ loop repeat containing 2.91E-05 3.00018 1.41E-03 1.92658 1.86E-01 1.18384 
NM_008828 Pgk1 phosphoglycerate kinase 1 3.60E-07 3.39755 1.53E-03 1.45501 4.54E-02 1.17638 
NM_008828 Pgk1 phosphoglycerate kinase 1 3.60E-07 3.39755 1.53E-03 1.45501 4.54E-02 1.17638 
NM_011701 Vim vimentin 4.17E-07 3.39621 2.79E-04 1.66637 1.06E-03 -1.44127 
NM_021498 Pole3 
polymerase (DNA directed), epsilon 3 (p17 
subunit) 1.37E-05 3.39385 3.07E-03 1.75902 6.70E-03 1.54384 
NM_007747 Cox5a cytochrome c oxidase, subunit Va 3.04E-06 3.39186 6.98E-04 1.79793 3.30E-03 1.48908 
NM_013726 Dbf4 DBF4 homolog (S. cerevisiae) 1.20E-05 3.38911 7.33E-02 1.30124 9.01E-01 -1.01458 
NM_023258 Pycard PYD and CARD domain containing 5.22E-07 3.38208 1.85E-02 1.27113 9.23E-04 -1.47004 
NM_025531 Slmo2 slowmo homolog 2 (Drosophila) 9.70E-05 3.37503 6.07E-02 1.46725 1.16E-01 1.3174 
XR_033533 Gm6560 predicted gene 6560 9.03E-07 3.35528 2.90E-04 1.75495 2.53E-03 1.41452 
NM_016925 Fanca Fanconi anemia, complementation group A 1.71E-07 3.35526 1.02E-02 1.2605 4.92E-01 1.04403 
NM_030234 Wdr76 WD repeat domain 76 4.00E-05 3.35198 5.26E-02 1.41434 4.44E-01 1.11399 
NM_182995 
6330503
K22Rik RIKEN cDNA 6330503K22 gene 3.04E-05 3.35162 4.96E-03 1.77834 7.41E-02 1.30702 
NM_008828 Pgk1 phosphoglycerate kinase 1 2.63E-07 3.34542 1.21E-03 1.44557 3.63E-02 1.17685 
NM_011404 Slc7a5 
solute carrier family 7 (cationic amino acid 
transporter, y+ sys 4.62E-05 3.34512 2.71E-01 1.19904 2.38E-01 1.1915 
NM_145946 Fanci Fanconi anemia, complementation group I 8.27E-06 3.33603 2.70E-02 1.38457 1.56E-01 -1.1804 
NM_133753 Errfi1 ERBB receptor feedback inhibitor 1 3.69E-06 3.326 3.73E-04 1.93344 8.05E-01 1.0239 
NM_011045 Pcna proliferating cell nuclear antigen 6.48E-07 3.31991 5.70E-05 1.98822 2.33E-02 1.22923 
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NM_016662 Mxd3 Max dimerization protein 3 7.62E-07 3.31553 1.73E-02 1.2881 1.41E-01 1.12878 
NM_025853 Dsn1 
DSN1, MIND kinetochore complex 
component, homolog (S. cerevisiae) 1.88E-04 3.30827 5.65E-02 1.53392 5.31E-01 -1.11684 
NM_025520 Lsm5 
LSM5 homolog, U6 small nuclear RNA 
associated (S. cerevisiae) 4.25E-06 3.30808 1.48E-02 1.4016 1.66E-01 1.1561 
NM_011014 Sigmar1 sigma non-opioid intracellular receptor 1 6.81E-07 3.30804 6.77E-02 1.18905 3.13E-03 1.37169 
NM_009270 Sqle squalene epoxidase 2.93E-06 3.30689 5.16E-01 1.07034 8.99E-02 1.19096 
NM_177780 Dock5 dedicator of cytokinesis 5 2.07E-07 3.30643 8.31E-05 1.72824 6.48E-03 1.25951 
NM_010325 Got2 
glutamate oxaloacetate transaminase 2, 
mitochondrial 4.87E-04 3.29546 3.83E-02 1.74326 2.08E-01 1.31134 
NM_001128096 Atp13a3 ATPase type 13A3 1.26E-04 3.28463 4.67E-01 1.14389 3.17E-02 1.51971 
NM_133933 Rpn1 ribophorin I 1.10E-06 3.28385 2.13E-04 1.8189 5.34E-04 1.58445 
NM_053074 Nup62 nucleoporin 62 1.00E-05 3.28043 8.37E-03 1.53799 4.99E-01 1.07847 
NM_013863 Bag3 BCL2-associated athanogene 3 6.93E-06 3.27983 6.04E-04 1.93577 7.20E-03 1.45584 
NM_011045 Pcna proliferating cell nuclear antigen 7.22E-07 3.27879 5.85E-05 1.9901 2.58E-02 1.22438 
NM_016660 Hmga1 high mobility group AT-hook 1 1.95E-08 3.27203 3.81E-05 1.545 1.46E-05 1.56873 
NM_027722 Nudt4 
nudix (nucleoside diphosphate linked moiety 
X)-type motif 4 4.57E-05 3.27202 9.22E-03 1.69871 6.23E-01 -1.07087 
NM_013692 Klf10 Kruppel-like factor 10 9.46E-06 3.26076 1.01E-02 1.50455 7.14E-02 1.24841 
NM_001166589 Eif5a eukaryotic translation initiation factor 5A 2.79E-07 3.2474 8.89E-05 1.74502 1.22E-04 1.60616 
NM_009226 Snrpd1 small nuclear ribonucleoprotein D1 2.65E-05 3.24715 2.23E-02 1.4878 1.14E-01 1.24527 
NM_025548 Tbcb tubulin folding cofactor B 1.52E-06 3.23336 8.39E-05 2.0486 2.84E-03 1.42661 
NM_175329 Chchd10 
coiled-coil-helix-coiled-coil-helix domain 
containing 10 2.34E-05 3.23248 1.01E-02 1.59147 4.23E-01 1.10641 
NM_010019 Dapk2 death-associated protein kinase 2 4.19E-07 3.22178 3.06E-04 1.61909 1.91E-01 1.09929 
NM_028677 Ppih peptidyl prolyl isomerase H 3.84E-04 3.21733 5.99E-02 1.58579 8.67E-01 1.03238 
NM_199035 Alg8 
asparagine-linked glycosylation 8 homolog 
(yeast, alpha-1,3-glucos 1.81E-06 3.20862 5.11E-03 1.4357 3.05E-01 1.09336 
NM_010281 Ggh gamma-glutamyl hydrolase 4.06E-03 3.19602 3.45E-01 1.36868 9.84E-01 -1.00574 
NM_010281 Ggh gamma-glutamyl hydrolase 4.06E-03 3.19602 3.45E-01 1.36868 9.84E-01 -1.00574 
NM_025570 Mrpl20 mitochondrial ribosomal protein L20 4.11E-05 3.19551 1.43E-02 1.59101 3.78E-02 1.38814 
NM_026065 Mrpl42 mitochondrial ribosomal protein L42 1.25E-03 3.19191 8.38E-02 1.65223 4.22E-01 1.20938 
NM_008525 Alad aminolevulinate, delta-, dehydratase 9.63E-05 3.19116 1.29E-02 1.7195 1.18E-01 1.29824 
NM_023579 Ipo5 importin 5 2.47E-06 3.18427 1.38E-02 1.35779 5.70E-02 1.21036 
NM_011654 Tuba1b tubulin, alpha 1B 3.35E-07 3.18369 1.65E-04 1.66566 1.90E-02 1.20937 
NM_182990 Ssrp1 structure specific recognition protein 1 2.60E-07 3.18247 9.53E-05 1.70882 8.35E-03 1.24512 
NM_025935 Tbc1d7 TBC1 domain family, member 7 6.89E-06 3.18096 4.99E-01 1.08084 8.12E-01 1.02438 
NM_011032 P4hb prolyl 4-hydroxylase, beta polypeptide 3.01E-08 3.17583 2.50E-06 1.97243 1.55E-05 1.58832 
NM_010858 Myl4 myosin, light polypeptide 4 6.34E-06 3.17161 2.14E-03 1.66233 5.58E-02 1.2464 
NM_133878 Rcc1 regulator of chromosome condensation 1 1.59E-07 3.17088 8.03E-03 1.25775 7.03E-02 1.12689 
NM_019830 Prmt1 protein arginine N-methyltransferase 1 2.38E-06 3.16949 1.12E-02 1.37336 4.34E-01 1.07137 
NM_025595 Mrpl51 mitochondrial ribosomal protein L51 1.63E-04 3.16752 1.39E-02 1.77783 7.50E-02 1.39129 
BC083356 Ran RAN, member RAS oncogene family 2.11E-06 3.16696 2.28E-03 1.53139 5.73E-03 1.37725 
NM_009127 Scd1 stearoyl-Coenzyme A desaturase 1 5.19E-05 3.16656 9.52E-02 -1.32918 8.52E-01 -1.02586 
NM_010066 Dnmt1 DNA methyltransferase (cytosine-5) 1 8.58E-10 3.16491 1.15E-06 1.57651 3.93E-02 -1.06895 
NM_025595 Mrpl51 mitochondrial ribosomal protein L51 4.57E-04 3.16412 8.48E-02 1.51998 2.33E-01 1.2756 
XR_030853 Gm8956 predicted gene 8956 6.13E-06 3.16316 3.53E-04 1.98843 1.48E-02 1.35871 
NM_001159284 Smtn smoothelin 2.94E-06 3.16205 6.77E-02 1.22941 8.49E-01 1.01703 
NM_009863 Cdc7 cell division cycle 7 (S. cerevisiae) 1.61E-05 3.15291 1.16E-01 1.24697 7.94E-01 1.03022 
NM_009112 S100a10 S100 calcium binding protein A10 (calpactin) 2.17E-06 3.15014 1.45E-04 1.97001 9.47E-04 1.56048 
NM_197997 
4930422
G04Rik RIKEN cDNA 4930422G04 gene 5.95E-05 3.14834 6.16E-02 1.39563 6.97E-01 -1.05596 
NM_023117 Cdc25b cell division cycle 25 homolog B (S. pombe) 1.10E-07 3.14635 1.74E-04 1.53062 1.09E-02 1.19856 
NM_009471 Umps uridine monophosphate synthetase 2.09E-06 3.14574 3.09E-03 1.49205 5.50E-02 1.2048 
BC059209 Vcpip1 valosin containing protein (p97) 4.76E-06 3.14386 4.99E-03 1.50984 1.73E-01 1.14862 
NM_172288 Nup133 nucleoporin 133 1.20E-05 3.13689 2.07E-01 1.17682 6.06E-01 1.05813 
NM_198664 Tbc1d2 TBC1 domain family, member 2 8.96E-05 3.13435 1.22E-01 1.32298 1.89E-01 1.23046 
NM_007451 Slc25a5 
solute carrier family 25 (mitochondrial carrier, 
adenine nucleo 1.27E-08 3.13182 1.10E-05 1.60905 5.12E-06 1.61091 
NM_019562 Uchl5 ubiquitin carboxyl-terminal esterase L5 1.65E-06 3.12537 1.02E-03 1.59841 9.73E-03 1.31484 
NM_007550 Blm Bloom syndrome homolog (human) 1.49E-04 3.11939 2.01E-01 1.27434 3.76E-01 -1.1562 
NM_028128 Rfc5 replication factor C (activator 1) 5 5.15E-06 3.11517 1.42E-02 1.39453 2.95E-01 1.10936 
List of genes that were upregulated greater than 3-fold in only MCMV-specific CD8+ T cells 
compared to naïve CD8+ T cells.  Genes in red are either secreted proteins or proteins that are 
expressed on the cell surface. 
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Supplemental Table 3.III: List of genes upregulated at least 3 fold in only γδ T cells compared 
to naïve CD8+ T cells 
MCMV-specific vs. 
naïve γδ T cell vs. naïve 
Ova-specific vs. 
naive Accession 
Number 
Gene 
Symbol Gene Name (Alias) p-value Fold Change p-value 
Fold 
Change p-value 
Fold 
Change 
ENSMUST0000
0103558 Tcrg-V3 T-cell receptor gamma, variable 3  5.89E-02 -1.93495 4.29E-06 64.5721 4.34E-01 -1.27512 
ENSMUST0000
0103563 Naip3 NLR family, apoptosis inhibitory protein 3  8.47E-03 -2.13162 5.58E-07 55.1406 1.57E-01 -1.39231 
ENSMUST0000
0103685 Tcrd-V5 predicted gene 6683  7.66E-01 -1.08887 9.65E-06 32.0613 6.54E-03 2.86001 
NM_009430 Prss2 protease, serine, 2  4.55E-01 -1.07383 5.96E-09 27.9146 9.43E-01 1.00671 
NM_001168294 Serpina3f 
serine (or cysteine) peptidase inhibitor, clade 
A, member  2.48E-03 1.68593 5.72E-08 20.7282 6.67E-02 1.27918 
NM_001033767 Gm4951 predicted gene 4951  9.80E-01 -1.00553 6.06E-06 16.9157 2.19E-03 2.67964 
NM_133871 Ifi44 interferon-induced protein 44  1.51E-01 -1.6391 8.76E-05 15.8284 8.67E-03 3.02374 
NM_025378 Ifitm3 interferon induced transmembrane protein 3  3.13E-02 2.74002 3.30E-04 15.3661 3.42E-03 5.08537 
NM_001115154 Samd3 sterile alpha motif domain containing 3  9.63E-05 1.78618 6.92E-09 14.1324 3.50E-05 1.97125 
ENSMUST0000
0103676 TCRvd1 predicted gene 13895  2.19E-02 -2.03156 2.81E-05 13.352 5.01E-03 -2.64581 
NM_008510 Xcl1 chemokine (C motif) ligand 1  2.76E-01 -1.23128 7.31E-06 10.1036 7.33E-01 1.06438 
XR_033405 Gm5970 predicted gene 5970  6.87E-01 1.05568 1.78E-06 8.05914 6.41E-03 1.63881 
NM_153590 Klre1 
killer cell lectin-like receptor family E member 
1  9.55E-02 1.4437 3.70E-05 7.10538 5.20E-01 1.13785 
ENSMUST0000
0103660 
Trav15-2-
dv6-2 predicted gene 13926  9.56E-03 -1.49297 1.43E-06 6.6769 1.59E-02 -1.43115 
NM_021378 Klrc3 
killer cell lectin-like receptor subfamily C, 
member 3  3.09E-04 2.33 3.86E-06 6.4012 1.60E-01 -1.22355 
NM_001045542 Gm12253 predicted gene 12253  2.78E-02 1.31496 8.07E-07 6.04868 2.80E-02 1.31428 
NM_011337 Ccl3 chemokine (C-C motif) ligand 3  3.97E-03 2.51327 1.58E-04 6.01502 9.99E-02 1.5138 
NM_029005 Mlkl mixed lineage kinase domain-like  4.82E-06 2.51566 1.11E-07 5.99781 1.19E-05 2.23838 
NM_001163496 Cd160 CD160 antigen  7.43E-03 2.13368 1.04E-04 5.95022 8.09E-01 1.05246 
NM_001146287 Cables1 CDK5 and Abl enzyme substrate 1  1.02E-02 1.15827 2.56E-09 5.81385 1.95E-02 1.13545 
NM_001163539 
5430427
O19Rik RIKEN cDNA 5430427O19 gene  5.91E-06 2.58251 1.87E-07 5.81222 4.32E-05 2.01873 
NM_172909 Cd163l1 CD163 molecule-like 1  2.75E-01 1.18586 1.30E-05 5.6831 6.14E-04 2.33191 
NM_015811 Rgs1 regulator of G-protein signaling 1  2.72E-03 2.1993 4.87E-05 5.57206 2.39E-01 -1.2514 
NM_001045543 Gm11435 predicted gene 11435  1.50E-03 2.22773 3.46E-05 5.22334 7.73E-01 1.04891 
NM_011027 P2rx7 
purinergic receptor P2X, ligand-gated ion 
channel, 7  3.32E-05 -1.59351 1.55E-08 4.98552 2.23E-01 1.06886 
NM_011723 Xdh xanthine dehydrogenase  1.94E-03 1.49498 5.99E-07 4.89317 5.76E-02 1.20868 
NM_011770 Ikzf2 IKAROS family zinc finger 2  3.57E-03 -1.88174 3.72E-05 4.5333 2.41E-01 1.20759 
NM_007551 Cxcr5 chemochine (C-X-C motif) receptor 5  1.38E-01 -1.40615 3.05E-04 4.49241 7.92E-02 1.51902 
NM_001163640 Chn2 chimerin (chimaerin) 2  2.14E-04 1.98556 2.74E-06 4.44502 4.27E-01 -1.08626 
NM_001005421 Amica1 
adhesion molecule, interacts with CXADR 
antigen 1  2.12E-01 -1.16699 7.93E-06 4.30337 4.57E-05 2.72125 
NM_001034859 Gm4841 predicted gene 4841  9.26E-02 -1.24728 8.49E-06 4.29884 4.70E-01 -1.09047 
NM_017466 Ccrl2 chemokine (C-C motif) receptor-like 2  3.14E-01 1.08569 5.68E-07 4.26523 1.00E-05 2.3373 
NM_207244 Cd200r4 CD200 receptor 4  2.28E-02 1.81643 4.02E-04 4.25339 1.23E-01 1.43254 
NR_002858 Gm4956 predicted gene 4956  3.86E-01 -1.2102 4.23E-04 4.23844 7.06E-01 -1.08465 
NM_172685 Slc25a24 
solute carrier family 25 (mitochondrial carrier, 
phosphate car 6.37E-04 2.66251 1.36E-04 4.08878 7.93E-01 -1.0467 
NM_026004 Nt5c3 5'-nucleotidase, cytosolic III  5.89E-01 1.1364 8.57E-04 4.07129 5.91E-03 2.41447 
NM_008337 Ifng interferon gamma  1.16E-05 2.94262 4.31E-06 4.05385 1.43E-02 1.37515 
NM_017379 Tuba8 tubulin, alpha 8  6.89E-01 -1.06078 5.37E-05 3.95791 4.89E-02 1.40088 
NM_001162917 Dennd4a DENN 1.50E-01 1.30638 1.57E-04 3.87983 1.29E-02 1.72844 
NM_011076 Abcb1a ATP-binding cassette, sub-family B (MDR 3.45E-01 1.08241 1.13E-06 3.87826 8.96E-01 1.01062 
ENSMUST0000
0103590 
Trav15d-
1-dv6d-1 predicted gene, OTTMUSG00000015223  1.18E-03 -1.63286 3.84E-06 3.85344 1.94E-02 -1.32526 
ENSMUST0000
0103590 
Trav15d-
1-dv6d-1 predicted gene, OTTMUSG00000015223  1.18E-03 -1.63286 3.84E-06 3.85344 1.94E-02 -1.32526 
NM_009630 Adora2a adenosine A2a receptor  3.00E-05 2.99175 1.59E-05 3.85203 3.57E-03 1.64223 
NM_053099 Setbp1 SET binding protein 1  5.16E-01 -1.07467 8.88E-06 3.82919 9.83E-01 -1.00231 
NM_001162917 Dennd4a DENN 5.15E-02 1.31686 1.90E-05 3.80792 2.84E-03 1.69405 
BC005685 BC00568 cDNA sequence BC005685  6.33E-05 -2.36208 7.52E-06 3.77345 1.29E-04 -2.15777 
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NM_010870 Naip5 NLR family, apoptosis inhibitory protein 5  1.75E-02 1.27382 1.39E-06 3.72116 8.70E-01 -1.01335 
ENSMUST0000
0070887 Gm10002 predicted gene 10002  5.69E-01 -1.09221 9.71E-05 3.69182 7.84E-02 1.35491 
NM_009373 Tgm2 transglutaminase 2, C polypeptide  2.84E-01 -1.07703 3.93E-07 3.64063 4.99E-03 1.29409 
NM_001162917 Dennd4a DENN 1.20E-01 1.35365 2.68E-04 3.63081 1.96E-02 1.67524 
BC005685 
BC00568
5 cDNA sequence BC005685  5.49E-04 -2.68168 2.25E-04 3.58514 2.45E-03 -2.13819 
NM_001162917 Dennd4a DENN 2.20E-02 1.29079 3.96E-06 3.50041 6.43E-04 1.66119 
NM_008501 Lif leukemia inhibitory factor  8.04E-02 1.17172 1.90E-06 3.47399 9.32E-06 2.40958 
NM_001145859 Sh3bp2 SH3-domain binding protein 2  1.55E-03 2.20925 2.32E-04 3.39077 3.53E-04 2.77359 
NM_027258 Rnf157 ring finger protein 157  1.04E-01 1.4345 7.84E-04 3.38325 5.83E-02 1.54817 
NM_026835 Ms4a6d 
membrane-spanning 4-domains, subfamily A, 
member 6D  1.12E-02 1.71533 2.32E-04 3.37819 2.82E-03 2.0328 
NM_011372 
St6galnac
3 
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-
galactosyl-1,3)-N-ac 1.85E-02 -1.49179 7.41E-05 3.35378 7.90E-01 1.03694 
L78788 
D17H6S5
6E-5 DNA segment, Chr 17, human D6S56E 5  1.45E-05 2.91849 1.38E-05 3.3442 3.81E-05 2.52269 
BC005685 
BC00568
5 cDNA sequence BC005685  3.26E-04 -2.73005 2.19E-04 3.31139 1.97E-03 -2.09184 
NM_009895 Cish cytokine inducible SH2-containing protein  1.11E-03 1.37963 4.89E-07 3.27547 1.04E-02 1.23423 
NM_146142 Tdrd7 tudor domain containing 7  3.21E-01 -1.15293 9.46E-05 3.2676 5.91E-02 1.34957 
NM_008365 Il18r1 interleukin 18 receptor 1  8.33E-02 1.38832 3.58E-04 3.2145 7.65E-03 1.82463 
NM_028139 Atxn7l1 ataxin 7-like 1  1.06E-04 2.64117 7.05E-05 3.17958 4.64E-03 1.6619 
NM_001162917 Dennd4a DENN 4.42E-01 1.16523 9.23E-04 3.16191 4.04E-02 1.60222 
NM_010848 Myb myeloblastosis oncogene  5.60E-05 2.65418 3.96E-05 3.16114 1.81E-02 -1.41511 
NM_008175 Grn granulin  3.74E-04 1.79042 1.13E-05 3.07492 2.14E-04 1.892 
NM_001162917 Dennd4a DENN 6.99E-01 1.0655 3.82E-04 3.06227 4.46E-02 1.4687 
NM_146191 Lrrk1 leucine-rich repeat kinase 1  1.02E-04 2.38023 4.28E-05 3.03118 3.42E-01 1.11908 
List of genes that were upregulated greater than 3-fold in only γδ T cells compared to naïve 
CD8+ T cells.  Genes in red are either secreted proteins or proteins that are expressed on the 
cell surface. 
 
  104 
 
Supplemental Table 3.IV: List of genes upregulated at least 3 fold in only ova-specific CD8+ T 
cells compared to naïve CD8+ T cells 
MCMV-specific vs. 
naïve γδ T cell vs. naïve 
Ova-specific vs. 
naive Accession 
Number 
Gene 
Symbol Gene Name (Alias) p-value Fold Change p-value 
Fold 
Change p-value 
Fold 
Change 
NM_010260 Gbp2 guanylate binding protein 2  3.41E-02 -1.45605 1.44E-03 2.2518 5.16E-06 5.87253 
NM_033601 Bcl3 B-cell leukemia 5.98E-04 2.10655 3.56E-03 1.8349 3.15E-06 5.37225 
NM_011817 Gadd45g 
growth arrest and DNA-damage-inducible 45 
gamma  1.15E-01 1.30957 2.81E-03 2.12408 1.43E-05 4.92016 
NM_019963 Stat2 
signal transducer and activator of 
transcription 2  2.47E-02 -1.42859 3.17E-04 2.50425 8.61E-06 4.20392 
NM_138606 Pim2 proviral integration site 2  1.66E-03 -1.78711 1.37E-02 1.53585 8.64E-06 3.83963 
NM_001164289 Gm6907 predicted gene 6907  5.85E-01 -1.08136 2.68E-04 2.80353 2.52E-05 3.7982 
NM_001039647 
EG63465
0 predicted gene, EG634650  1.64E-02 -1.81833 2.87E-03 2.59718 2.68E-04 3.61118 
NM_145545 Gbp6 guanylate binding protein 6  3.38E-02 1.2982 3.83E-05 2.75796 4.70E-06 3.4711 
ENSMUST0000
0093297 Gm10773 predicted gene 10773  3.02E-04 2.64874 4.60E-04 2.76352 7.04E-05 3.41425 
NM_010591 Jun Jun oncogene  6.85E-01 1.06839 2.73E-03 2.20403 1.22E-04 3.30364 
NM_008326 Irgm1 immunity-related GTPase family M member 1  2.38E-02 -1.39708 2.39E-04 2.44018 1.83E-05 3.28771 
NM_019440 Irgm2 immunity-related GTPase family M member 2  1.57E-04 -1.81647 5.20E-05 2.21131 1.67E-06 3.28514 
NM_021524 Nampt nicotinamide phosphoribosyltransferase  2.16E-03 1.87904 3.13E-04 2.66937 5.29E-05 3.20204 
NM_001045540 Gm12185 predicted gene 12185  1.66E-03 -2.6943 6.41E-03 2.36078 7.02E-04 3.16072 
NM_007829 Daxx Fas death domain-associated protein  5.76E-01 -1.05933 2.53E-04 2.11083 8.72E-06 3.07984 
NM_194336 Mpa2l macrophage activation 2 like  2.44E-08 -2.57348 6.18E-08 2.51956 7.33E-09 3.07647 
NM_008332 Ifit2 
interferon-induced protein with 
tetratricopeptide repeats 2  9.33E-01 -1.00791 1.53E-05 2.87426 5.05E-06 3.05021 
NM_001013371 Dtx3l deltex 3-like (Drosophila)  1.33E-02 -1.33881 1.01E-04 2.18305 4.78E-06 3.0367 
NM_178087 Pml promyelocytic leukemia  2.41E-02 1.34454 1.21E-04 2.41875 1.32E-05 3.03501 
NM_001164314 Wars tryptophanyl-tRNA synthetase  2.19E-03 1.90342 2.64E-02 1.53522 8.69E-05 3.01083 
NM_010260 Gbp2 guanylate binding protein 2  3.41E-02 -1.45605 1.44E-03 2.2518 5.16E-06 5.87253 
NM_033601 Bcl3 B-cell leukemia 5.98E-04 2.10655 3.56E-03 1.8349 3.15E-06 5.37225 
NM_011817 Gadd45g 
growth arrest and DNA-damage-inducible 45 
gamma  1.15E-01 1.30957 2.81E-03 2.12408 1.43E-05 4.92016 
NM_019963 Stat2 
signal transducer and activator of 
transcription 2  2.47E-02 -1.42859 3.17E-04 2.50425 8.61E-06 4.20392 
NM_138606 Pim2 proviral integration site 2  1.66E-03 -1.78711 1.37E-02 1.53585 8.64E-06 3.83963 
NM_001164289 Gm6907 predicted gene 6907  5.85E-01 -1.08136 2.68E-04 2.80353 2.52E-05 3.7982 
NM_001039647 
EG63465
0 predicted gene, EG634650  1.64E-02 -1.81833 2.87E-03 2.59718 2.68E-04 3.61118 
NM_145545 Gbp6 guanylate binding protein 6  3.38E-02 1.2982 3.83E-05 2.75796 4.70E-06 3.4711 
ENSMUST0000
0093297 Gm10773 predicted gene 10773  3.02E-04 2.64874 4.60E-04 2.76352 7.04E-05 3.41425 
NM_010591 Jun Jun oncogene  6.85E-01 1.06839 2.73E-03 2.20403 1.22E-04 3.30364 
NM_008326 Irgm1 immunity-related GTPase family M member 1  2.38E-02 -1.39708 2.39E-04 2.44018 1.83E-05 3.28771 
NM_019440 Irgm2 immunity-related GTPase family M member 2  1.57E-04 -1.81647 5.20E-05 2.21131 1.67E-06 3.28514 
NM_021524 Nampt nicotinamide phosphoribosyltransferase  2.16E-03 1.87904 3.13E-04 2.66937 5.29E-05 3.20204 
NM_001045540 Gm12185 predicted gene 12185  1.66E-03 -2.6943 6.41E-03 2.36078 7.02E-04 3.16072 
NM_007829 Daxx Fas death domain-associated protein  5.76E-01 -1.05933 2.53E-04 2.11083 8.72E-06 3.07984 
NM_194336 Mpa2l macrophage activation 2 like  2.44E-08 -2.57348 6.18E-08 2.51956 7.33E-09 3.07647 
NM_008332 Ifit2 
interferon-induced protein with 
tetratricopeptide repeats 2  9.33E-01 -1.00791 1.53E-05 2.87426 5.05E-06 3.05021 
NM_001013371 Dtx3l deltex 3-like (Drosophila)  1.33E-02 -1.33881 1.01E-04 2.18305 4.78E-06 3.0367 
NM_178087 Pml promyelocytic leukemia  2.41E-02 1.34454 1.21E-04 2.41875 1.32E-05 3.03501 
NM_001164314 Wars tryptophanyl-tRNA synthetase  2.19E-03 1.90342 2.64E-02 1.53522 8.69E-05 3.01083 
List of genes that were upregulated greater than 3-fold in only ova-specific T cells compared to 
naïve CD8+ T cells.  Genes in red are either secreted proteins or proteins that are expressed on 
the cell surface. 
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Supplemental Table 3.V: List of genes upregulated at least 3 fold in only γδ T cells and ova-
specific CD8+ T cells compared to naïve CD8+ T cells 
MCMV-specific vs. 
naïve γδ T cell vs. naïve 
Ova-specific vs. 
naive Accession 
Number 
Gene 
Symbol Gene Name (Alias) p-value Fold Change p-value 
Fold 
Change p-value 
Fold 
Change 
NM_008147 Gp49a glycoprotein 49 A  2.41E-02 1.9948 1.82E-04 5.62369 2.36E-06 42.2084 
NM_013532 Lilrb4 
leukocyte immunoglobulin-like receptor, 
subfamily B, member 4  1.22E-02 1.56744 1.39E-05 4.17995 1.52E-07 22.3882 
NM_021274 Cxcl10 chemokine (C-X-C motif) ligand 10  3.32E-01 1.1961 1.51E-06 12.8248 1.56E-06 17.0844 
BC038285 
A630038
E17Rik RIKEN cDNA A630038E17 gene  7.95E-04 -1.79302 3.82E-07 6.57722 5.57E-08 16.1852 
NM_010846 Mx1 myxovirus (influenza virus) resistance 1  4.01E-02 1.95659 3.11E-05 12.4523 5.94E-05 12.8357 
XM_889589 Gm6545 predicted gene 6545  2.82E-05 -1.96919 9.43E-09 8.92686 1.00E-08 11.3264 
NM_133720 Cysltr2 cysteinyl leukotriene receptor 2  2.86E-05 2.88839 2.88E-07 8.13324 2.62E-07 10.7615 
NM_001146275 Iigp1 interferon inducible GTPase 1  1.05E-01 -1.51659 6.18E-05 6.69956 3.26E-05 10.4476 
NM_001005858 
I830012O
16Rik RIKEN cDNA I830012O16 gene  2.43E-02 -2.31579 3.98E-05 14.446 2.16E-04 9.87804 
NM_011854 Oasl2 2'-5' oligoadenylate synthetase-like 2  7.07E-04 -2.82305 2.52E-06 12.0515 1.07E-05 9.43925 
NM_021384 Rsad2 
radical S-adenosyl methionine domain 
containing 2  3.22E-01 -1.10544 2.05E-08 13.5558 1.50E-07 8.91125 
NR_003508 Mx2 myxovirus (influenza virus) resistance 2  3.82E-02 -1.66993 4.53E-06 12.6825 2.65E-05 8.82845 
NM_011852 Oas1g 2'-5' oligoadenylate synthetase 1G  4.50E-01 1.11862 3.53E-06 6.27603 2.57E-06 8.60917 
NM_145211 Oas1a 2'-5' oligoadenylate synthetase 1A  5.10E-01 1.07725 3.96E-07 6.93378 4.89E-07 8.16102 
NM_011909 Usp18 ubiquitin specific peptidase 18  1.09E-02 -1.71859 9.49E-06 5.94468 1.88E-05 6.03947 
NM_016850 Irf7 interferon regulatory factor 7  1.54E-02 -1.48607 1.01E-06 7.09199 4.89E-06 5.66957 
NM_145226 Oas3 2'-5' oligoadenylate synthetase 3  1.76E-03 1.75162 6.54E-07 6.82898 3.18E-06 5.48707 
NM_133211 Tlr7 toll-like receptor 7  8.26E-04 -2.41474 7.85E-06 6.26192 2.92E-05 5.37756 
NM_198095 Bst2 bone marrow stromal cell antigen 2  7.93E-02 1.32628 5.81E-06 5.33045 1.72E-05 4.90206 
NM_027835 Ifih1 interferon induced with helicase C domain 1  3.62E-01 1.18924 3.48E-05 5.21807 1.16E-04 4.62455 
NM_001163470 Trafd1 TRAF type zinc finger domain containing 1  6.27E-02 1.4078 2.34E-05 4.59789 4.75E-05 4.62195 
NM_011163 Eif2ak2 
eukaryotic translation initiation factor 2-alpha 
kinase 2  6.77E-03 1.65712 5.47E-06 5.12439 1.81E-05 4.60199 
NM_015783 Isg15 ISG15 ubiquitin-like modifier  3.08E-02 -1.43347 2.90E-06 6.05293 1.88E-05 4.58612 
NM_030150 Dhx58 DEXH (Asp-Glu-X-His) box polypeptide 58  5.82E-01 1.10451 1.08E-05 6.74902 1.07E-04 4.49147 
NM_199146 AI451617 expressed sequence AI451617  2.95E-04 -2.46841 3.92E-05 3.46232 2.96E-05 4.26021 
NM_019949 Ube2l6 ubiquitin-conjugating enzyme E2L 6  6.71E-03 1.39324 4.54E-06 3.00776 1.83E-06 4.08528 
NM_029000 Gvin1 GTPase, very large interferon inducible 1  1.32E-02 1.61327 6.59E-05 3.39172 7.06E-05 3.86157 
NM_001135115 Gm12250 predicted gene 12250  8.95E-01 1.0175 1.76E-06 6.25733 3.03E-05 3.81625 
NM_029803 Ifi27l2a interferon, alpha-inducible protein 27 like 2A  6.97E-01 -1.06271 1.05E-04 3.23824 9.27E-05 3.81593 
NM_020557 Cmpk2 
cytidine monophosphate (UMP-CMP) kinase 
2, mitochondrial  8.09E-03 1.55932 2.91E-06 5.13786 2.94E-05 3.64736 
NM_011150 Lgals3bp 
lectin, galactoside-binding, soluble, 3 binding 
protein  6.06E-04 1.46712 2.17E-07 3.60408 4.64E-07 3.60938 
NM_020583 Isg20 interferon-stimulated protein  3.13E-02 -1.44175 1.14E-05 4.47623 7.02E-05 3.55971 
NM_029499 Ms4a4c 
membrane-spanning 4-domains, subfamily A, 
member 4C  9.68E-06 -2.53894 1.49E-06 3.41786 2.63E-06 3.54103 
NM_021394 Zbp1 Z-DNA binding protein 1  3.73E-03 -1.56437 2.51E-06 4.24692 1.37E-05 3.50706 
NM_175533 
5830411
N06Rik RIKEN cDNA 5830411N06 gene  5.76E-01 1.11169 8.75E-05 4.28374 5.00E-04 3.41667 
NM_001037713 Xaf1 XIAP associated factor 1  6.45E-02 -1.25992 5.77E-06 3.60975 1.95E-05 3.30641 
NM_172893 Parp12 
poly (ADP-ribose) polymerase family, 
member 12  6.21E-04 -1.65694 7.64E-07 4.10449 5.06E-06 3.30404 
NM_025992 Herc5 hect domain and RLD 5  2.11E-03 -1.8462 1.95E-05 3.71432 7.75E-05 3.278 
NM_145209 Oasl1 2'-5' oligoadenylate synthetase-like 1  2.97E-04 -1.84102 2.58E-06 3.53704 9.41E-06 3.20668 
List of genes that were upregulated greater than 3-fold in only ova-specific CD8+ T cells and γδ 
T cells compared to naïve CD8+ T cells.  Genes in red are either secreted proteins or proteins 
that are expressed on the cell surface. 
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Supplemental Table 3.VI: List of genes upregulated at least 3 fold in only MCMV-specific CD8+ 
T cells and ova-specific CD8+ T cells compared to naïve CD8+ T cells 
MCMV-specific vs. 
naïve γδ T cell vs. naïve 
Ova-specific vs. 
naive Accession 
Number 
Gene 
Symbol Gene Name (Alias) p-value Fold Change p-value 
Fold 
Change p-value 
Fold 
Change 
NM_013674 Irf4 interferon regulatory factor 4  6.36E-08 8.20211 
0.000132
567 2.12583 2.06E-06 3.55405 
NM_026438 Ppa1 pyrophosphatase (inorganic) 1  3.07E-06 4.08654 
0.000113
669 2.48327 1.06E-05 3.22183 
NM_007381 Acadl 
acyl-Coenzyme A dehydrogenase, long-
chain  1.89E-05 3.23584 9.61E-05 2.77993 2.34E-05 3.1173 
List of genes that were upregulated greater than 3-fold in only MCMV-specific CD8+ T cells and 
ova-specific CD8+ T cells compared to naïve CD8+ T cells.   
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Supplemental Table 3.VII: List of genes upregulated at least 3 fold in MCMV-specific CD8+ T 
cells, γδ T cells, and ova-specific CD8+ T cells compared to naïve CD8+ T cells 
MCMV-specific vs. 
naïve γδ T cell vs. naïve 
Ova-specific vs. 
naive Accession 
Number 
Gene 
Symbol Gene Name (Alias) p-value Fold Change p-value 
Fold 
Change p-value 
Fold 
Change 
NM_011313 S100a6 S100 calcium binding protein A6 (calcyclin)  1.09E-08 146.807 8.72E-08 62.5104 3.58E-05 4.57709 
NM_013542 Gzmb granzyme B  1.23E-08 131.043 3.28E-08 113.368 2.46E-06 9.56646 
NM_010370 Gzma granzyme A  2.71E-11 72.5991 1.15E-10 49.2947 1.17E-07 3.62978 
NM_011623 Top2a topoisomerase (DNA) II alpha  1.04E-09 33.3755 2.37E-08 12.2102 2.53E-06 3.11076 
NM_009917 Ccr5 chemokine (C-C motif) receptor 5  5.63E-10 29.9278 1.34E-09 28.6938 8.20E-07 3.28158 
NM_009917 Ccr5 chemokine (C-C motif) receptor 5  5.63E-10 29.9278 1.34E-09 28.6938 8.20E-07 3.28158 
NM_013653 Ccl5 chemokine (C-C motif) ligand 5  2.76E-07 17.1514 1.80E-07 29.3815 1.74E-05 4.67097 
NM_009910 Cxcr3 chemokine (C-X-C motif) receptor 3  1.07E-08 15.9293 3.29E-08 13.8951 3.23E-06 3.34303 
NM_010738 Ly6a lymphocyte antigen 6 complex, locus A  3.87E-11 12.3891 2.21E-11 21.0928 8.32E-12 22.9857 
NM_008354 Il12rb2 interleukin 12 receptor, beta 2  8.05E-08 11.3094 1.72E-07 11.3522 1.88E-07 8.55091 
NM_010553 Il18rap interleukin 18 receptor accessory protein  3.60E-09 9.52089 2.80E-09 13.6367 8.92E-08 4.13503 
NM_010741 Ly6c1 lymphocyte antigen 6 complex, locus C1  5.63E-07 6.89924 1.81E-07 12.7556 1.43E-07 10.5553 
NM_021439 Chst11 carbohydrate sulfotransferase 11  3.01E-07 5.85153 7.04E-07 5.7286 4.33E-07 5.34261 
NM_019835 B4galt5 
UDP-Gal:betaGlcNAc beta 1,4-
galactosyltransferase, polypeptide  2.39E-07 5.17909 2.28E-06 3.75481 3.11E-06 3.09636 
NM_013885 Clic4 
chloride intracellular channel 4 
(mitochondrial)  1.77E-06 4.78431 2.98E-05 3.14979 1.69E-05 3.06113 
NM_172603 Phf11 PHD finger protein 11  2.63E-06 4.76986 2.83E-06 5.62972 6.25E-06 3.95162 
NM_139198 Plac8 placenta-specific 8  1.26E-07 4.66853 2.65E-08 8.64756 7.12E-09 10.293 
NM_001099217 Ly6c2 lymphocyte antigen 6 complex, locus C2  4.98E-05 4.60535 9.90E-06 8.86603 1.21E-05 6.64614 
NM_018734 Gbp3 guanylate binding protein 3  4.67E-05 3.37258 3.57E-05 4.12103 3.81E-05 3.5055 
NM_011313 S100a6 S100 calcium binding protein A6 (calcyclin)  1.09E-08 146.807 8.72E-08 62.5104 3.58E-05 4.57709 
NM_013542 Gzmb granzyme B  1.23E-08 131.043 3.28E-08 113.368 2.46E-06 9.56646 
NM_010370 Gzma granzyme A  2.71E-11 72.5991 1.15E-10 49.2947 1.17E-07 3.62978 
NM_011623 Top2a topoisomerase (DNA) II alpha  1.04E-09 33.3755 2.37E-08 12.2102 2.53E-06 3.11076 
NM_009917 Ccr5 chemokine (C-C motif) receptor 5  5.63E-10 29.9278 1.34E-09 28.6938 8.20E-07 3.28158 
NM_009917 Ccr5 chemokine (C-C motif) receptor 5  5.63E-10 29.9278 1.34E-09 28.6938 8.20E-07 3.28158 
NM_013653 Ccl5 chemokine (C-C motif) ligand 5  2.76E-07 17.1514 1.80E-07 29.3815 1.74E-05 4.67097 
NM_009910 Cxcr3 chemokine (C-X-C motif) receptor 3  1.07E-08 15.9293 3.29E-08 13.8951 3.23E-06 3.34303 
NM_010738 Ly6a lymphocyte antigen 6 complex, locus A  3.87E-11 12.3891 2.21E-11 21.0928 8.32E-12 22.9857 
NM_008354 Il12rb2 interleukin 12 receptor, beta 2  8.05E-08 11.3094 1.72E-07 11.3522 1.88E-07 8.55091 
NM_010553 Il18rap interleukin 18 receptor accessory protein  3.60E-09 9.52089 2.80E-09 13.6367 8.92E-08 4.13503 
NM_010741 Ly6c1 lymphocyte antigen 6 complex, locus C1  5.63E-07 6.89924 1.81E-07 12.7556 1.43E-07 10.5553 
NM_021439 Chst11 carbohydrate sulfotransferase 11  3.01E-07 5.85153 7.04E-07 5.7286 4.33E-07 5.34261 
NM_019835 B4galt5 
UDP-Gal:betaGlcNAc beta 1,4-
galactosyltransferase, polypeptide  2.39E-07 5.17909 2.28E-06 3.75481 3.11E-06 3.09636 
NM_013885 Clic4 
chloride intracellular channel 4 
(mitochondrial)  1.77E-06 4.78431 2.98E-05 3.14979 1.69E-05 3.06113 
NM_172603 Phf11 PHD finger protein 11  2.63E-06 4.76986 2.83E-06 5.62972 6.25E-06 3.95162 
NM_139198 Plac8 placenta-specific 8  1.26E-07 4.66853 2.65E-08 8.64756 7.12E-09 10.293 
NM_001099217 Ly6c2 lymphocyte antigen 6 complex, locus C2  4.98E-05 4.60535 9.90E-06 8.86603 1.21E-05 6.64614 
NM_018734 Gbp3 guanylate binding protein 3  4.67E-05 3.37258 3.57E-05 4.12103 3.81E-05 3.5055 
List of genes that were upregulated greater than 3-fold in only MCMV-specific CD8+ T cells, γδ 
T cells, and ova-specific CD8+ T cells compared to naïve CD8+ T cells.  Genes in red are either 
secreted proteins or proteins that are expressed on the cell surface. 
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Abstract 
Activation of NK cells results in cytotoxicity, cytokine production, and proliferation.  NK cell 
activation is controlled by cytokines as well as signals from activation and inhibitory receptors.  
While the signals and stimuli responsible for NK cell activation have been well characterized, it 
remains unclear how NK cell activation is limited or resolved.  Following infection with murine 
cytomegalovirus (MCMV), NK cells robustly produce IFNγ.  The kinetics of MCMV-induced 
IFNγ production have been well defined, with NK cell production of IFNγ peaking at 1.5 days 
post infection and rapidly returning to baseline.  We sought to delineate the mechanism that 
resolves NK cell production of IFNγ following MCMV infection.  Here we show that the down-
modulation of NK cell production of IFNγ occurs concurrently with a 5-fold decrease in NK cell 
number and a concomitant increase in the frequency of apoptosis, specifically through the 
extrinsic apoptotic pathway.  Furthermore, this process appears to be dependent on signaling 
through TRAIL-R but independent of Fas. 
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Introduction 
NK cells are innate immune lymphocytes whose activation is regulated by signals through 
cytokine receptors and germ-line encoded activation and inhibitory receptors.  NK cell activation 
results in cytokine/chemokine production, cytotoxicity, and proliferation.   
 
Apoptosis has been implicated in limiting the activity of a variety of immune cells.  It depends 
on the activity of caspases, a family of cysteine-proteases that exist as inactive, pro-enzymes in 
non-apoptotic cells.  Upon initiation of the apoptosis cascade, caspases are cleaved into their 
active form.  Apoptosis can occur either through the extrinsic (i.e. death receptor) or the intrinsic 
(i.e. mitochondrial) pathway.  The extrinsic pathway is initiated by the ligation of a death 
receptor (e.g. TRAIL receptor (TRAIL-R)) to its ligand (e.g. TRAIL).  This results in the 
activation of caspase-8. Caspase-8 can subsequently cleave pro-caspase-3 and -7 into their active 
forms.  Once active, caspases-3 and -7 can mediate the morphological changes classically 
associated with apoptosis: cell shrinkage, membrane blebbing, DNA fragmentation, and 
chromatin condensation.  
 
Death receptors are members of the tumor necrosis factor (TNF) receptor superfamily, and they 
contain a death domain in their cytoplasmic tail (reviewed in (1, 2)).  The death domain is 
required for the recruitment of FADD, an adaptor protein that links the death receptor to pro-
caspase 8, and the induction of apoptosis.  In mice, there are three death receptors: TRAIL-R, 
Fas, and TNF receptor 1 (TNF-R1).  It has been shown that activated T cells are susceptible to 
Fas-mediated apoptosis and that this is an important mechanism that regulates the immune 
response (3).  TRAIL has also been shown to have a role in regulating the immune response.  For 
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example, TRAIL can inhibit cell cycle progression in peripheral T cells (4).  Additionally, it has 
been shown that apoptosis of human NK cells stimulated to produce interferon gamma (IFNγ) in 
culture is dependent on NK cell production of TNFα, the ligand for TNF-R1 (5). 
 
Apoptosis has previously been implicated in the control of NK cell activation.  For example, 
withdrawal of IL-15, a key survival cytokine for NK cells, has been shown to result in loss of 
bcl-2 expression (6).  Moreover, there is loss of bcl-2 protein expression in NK cells at late times 
following MCMV infection (greater than 1 week) (7, 8).  Additionally, we and others have 
shown that there is prolonged expansion of NK cells following MCMV infection in Bim-
deficient mice (Fig. 3.2) (9, 10). 
 
NK cells produce significant amounts of IFNγ 1.5 days post infection with MCMV (11, 12).  
This production of IFNγ is dependent on IL-12 and IL-18 signaling (13-16).  It has previously 
been shown that at 3 days post infection (p.i.) control of MCMV replication in the liver, but not 
the spleen, is dependent on IFNγ (17).  Moreover, prophylactic treatment of mice with IFNγ 
resulted in reduced mortality following MCMV infection (18).  Together, these results 
demonstrate the importance of NK cell production of IFNγ in host defense against MCMV 
infection. 
 
Despite its protective effects, IFNγ can also cause immunopathology.  For example, TH1 cell 
production of IFN-γ during toxoplasmosis infection of mice results in dysbiosis of gut bacteria 
and Paneth cell elimination (19).  Moreover, IFNγ has also been shown to exacerbate a variety of 
autoimmune diseases including systemic lupus erythematosis and type I diabetes mellitus 
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(reviewed in (20)).  Furthermore, CD56bright NK cells in the synovium of patients with 
rheumatoid arthritis have been shown to make more IFNγ than CD56bright NK cells from the 
peripheral blood of the same patients (21).    
 
Here we show that the resolution of IFNγ production occurs coincidentally with a 5-fold 
decrease in NK cell number and a significant increase in the frequency of apoptotic NK cells.  
Moreover, it is associated with the formation of active caspase-8, which is uniquely formed 
through the extrinsic pathway of apoptosis.  While both TRAIL-R and Fas are upregulated on 
NK cells early following MCMV infection, Fas is not required for the resolution of IFN-γ 
production.  Preliminary data using TRAIL-deficient mice, suggests that TRAIL/TRAIL-R 
interactions are required for the termination of IFNγ production by NK cells. 
 
Materials and Methods 
Mice 
C57BL/6 mice were obtained from National Cancer Institute (Charles River, MA).  IFNγ-Thy1.1 
reporter mice (22) were a kind gift from Megan Cooper (Washington University).  TRAIL-
deficient mice (TRAIL-/-, (23)) were generously provided by Thomas Griffith (University of 
Minnesota).  Mice carrying the Fas-lpr mutation (Fas-/-, (24)) were purchased from The Jackson 
Laboratory (Bar Harbor, ME).  All mice were on a C57BL/6 background.  Mice were maintained 
under specific pathogen-free conditions and used between 8 and 14 weeks of age.  All 
experiments were conducted in accordance with institutional guidelines for animal care and use. 
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Antibodies 
Biotinylated anti-Ly49H Ab (3D10) was kindly provided by Wayne Yokoyama (Washington 
University).  Unless stated otherwise, the following antibodies and PE-streptavidin were 
purchased from eBioscience (San Diego, CA): unconjugated anti-active caspase 8 (D5B2, Cell 
Signaling Technology, Danvers, MA); biotinylated anti-TRAILR (MD5-1); FITC-conjugated 
anti-Ly49H (3D10); PE-conjugated anti-IFNγ (XMG1.2); PerCP/Cy5.5-conjugated anti-CD3 
(145-2C11) and -NK1.1 (PK136); PE/Cy7-conjugated anti-Fas (Jo2, BD Pharmingen, San 
Diego, CA); eFluor® 450-conjugated anti-CD69 (H1.2F3); Alexa Fluor® 647-conjugated anti-
rabbit IgG F(ab’)2 fragments (Cell Signaling Technology); allophycocyanin-conjugated anti-
Ly49H (3D10), -TNF-R1 (55R-286, Biolegend, San Diego, CA); allophycocyanin/eFluor® 780-
conjugated anti-CD3 (17A2); allophycocyanin/Cy7-conjugated anti-CD3e (145-2C11, BD 
Pharmingen, San Diego, CA); Brilliant Violet 421-conjugated anti-NK1.1 (PK136, BD 
Biosciences, San Jose, CA).  FITC-conjugated AnnexinV was purchased from BD Pharmingen, 
and staining was performed according to the manufacturer’s protocol. 
 
Viruses and injection of mice 
Salivary gland stock of Smith strain MCMV (American Type Culture Collection [ATCC]; 
Manassas, VA) was prepared as previously described (12).  The titer of the stock was determined 
using a standard plaque assay (25) in permissive NIH3T3 fibroblasts (ATCC).  Mice were 
infected i.p. with 5 x 104 PFU/mouse of salivary gland stock MCMV.  
 
Splenocyte preparation and determination of NK cell numbers                                             
Standard techniques were used to prepare single-cell suspensions of splenocytes (11).  
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Splenocytes were incubated in 2.4G2 (anti-Fcγ II/III receptor) supernatants (hybridoma from 
ATCC) prior to staining with labeled Abs in order to block non-specific binding of antibodies to 
Fc receptors.  NK cell numbers were determined using calibration beads (Spherotech, Lake 
Forest, IL). 
 
Intracellular staining 
Intracellular IFNγ staining was performed as previously described (11).  For active caspase-8 
staining, splenocytes were prepared as previously described and were stained with cell surface 
Abs.  Cells were fixed and permeabilized using the Cytofix/Cytoperm kit (BD Pharmingen) 
according to the manufacturer’s instructions.  Cells were then stained with anti-active caspase-8 
followed by staining with an Alexa Fluor® 647-conjugated anti-rabbit F(ab’)2 fragments.   
 
Flow Cytometry 
Data was acquired using either a FACSCalibur flow cytometer (BD Pharmingen) using 
CellQuest software (BD Biosciences) or with a FACScan (BD Pharmingen) with DxP multi-
color upgrade (Cytek Development, Fremont, CA) and FlowJo CE software (TreeStar, Ashland, 
OR).  FlowJo (TreeStar) was used to analyze data.  NK cells were identified as CD3-, NK1.1+.   
 
Statistical analysis 
Data analysis was done with Microsoft Excel and GraphPad Prism (GraphPad Software, La 
Jolla, CA).  Unless otherwise noted, unpaired, two-tailed t tests were used to determine 
statistically significant differences.  Error bars in figures represent standard deviations from 
mean value. 
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Results 
As has been previously shown (12), IFNγ production by splenic NK cells peaks at 1.5 days p.i. 
with MCMV (Fig. 1A).  We found that there is a 5-fold decrease in NK cell numbers and a 
significant increase in the frequency of apoptotic NK cells (at 2 days p.i., 47.09 ± 13.76%) 
coincident with the resolution of NK cell production of IFNγ (Fig. 4.1B and C).  This suggested 
that the resolution of NK cell production of IFNγ following MCMV infection is dependent on 
apoptosis.  To determine whether this was the result of extrinsically or intrinsically triggered 
apoptosis, we assessed the formation of active caspase-8, which is specifically formed following 
death receptor activation.  Indeed, there is a substantial increase in the frequency of active 
caspase-8+ NK cells early following MCMV infection (at 2 days p.i., 52.14 ± 17.87%; Fig. 
4.1D).  
 
Next we sought to ascertain whether there was a correlation between NK cell IFNγ production 
and apoptosis.  Indeed, at both 1.5 and 2 days p.i. MCMV, there is an increased proportion of 
IFNγ+ NK cells that contain active caspase-8 (Fig. 4.2A).  In order to analyze NK cells that have 
previously made IFNγ, and not just those that are currently making it, we utilized IFNγ-Thy1.1 
reporter mice (22), which express Thy1.1 under the control of the IFNγ promoter.  While these 
mice accurately report IFNγ production by NK cells 1.5 days p.i. MCMV, there is prolonged 
expression of Thy1.1 past that of IFNγ, which makes this model useful in analyzing NK cells 
that previously made IFNγ (Fig. 4.2B).  Using this model we found that there is an increased 
proportion of NK cells that have made IFNγ (Thy1.1+) that are apoptotic compared to those that 
have not (Fig. 4.2C).  Together, these results demonstrate a correlation between NK cell 
production of IFNγ and apoptosis. 
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To determine what death receptors might be responsible for initiating extrinsic apoptosis in NK 
cells, we analyzed the expression of TRAIL-R, Fas, and TNF-R1 on NK cells following MCMV 
infection.  There is minimal expression of all of three of these receptors on naïve NK cells, but 
rapidly following MCMV infection there is increased expression of both TRAIL-R (at 2 days 
p.i., 50.91 ± 15.17%) and Fas (at 2 days p.i., 42.42 ± 14.83%) on NK cells (Fig. 4.3A).  To 
determine the requirement of Fas and/or TRAIL-R in this process, we infected Fas-/- and  
TRAIL-/- mice.  There was no difference in the frequency of IFNγ+ or active caspase-8 formation 
in Fas-/- mice 2 days p.i. with MCMV (Fig. 4.3B and C).  Therefore, Fas is not required for the 
resolution of IFNγ production by NK cells.  In contrast, preliminary results with TRAIL-/- mice 
showed prolonged IFNγ production and decreased formation of active caspase-8 (Fig. 4.3D and 
E), which suggests that TRAIL/TRAIL-R interactions are required for the termination of IFNγ 
production by NK cells following MCMV infection.  Similar to the increased proportion of 
IFNγ+ NK cells that contain active caspase-8 (Fig 4.2A), there is an increased proportion of 
IFNγ+ NK cells that express TRAIL-R (Fig. 4.3F).  Thus, there is a correlation between NK cell 
production of IFNγ and TRAIL-R expression. 
 
Discussion 
While the kinetics of IFNγ production by NK cells following MCMV infection has been known 
for some time (11, 12), the mechanism that limits NK cell production of IFNγ has not been 
elucidated.  Here we show that the resolution of IFNγ production by NK cells following MCMV 
infection is the result of death receptor-mediated apoptosis.  Our preliminary data suggests that 
this process is dependent on signaling through TRAIL-R, but it is independent of Fas. 
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It has been previously shown that apoptosis is important for the contraction of the NK cell 
population following MCMV infection (Fig. 3.2, (8-10)).  This process seems to be largely 
dependent on Bim, a component of the intrinsic pathway of apoptosis (Fig. 3.2 (9, 10)).  
Similarly, we show that the resolution of IFNγ production following MCMV infection is also 
associated with the apoptosis of NK cells (Figs. 4.1 and 4.2).  In contrast to the contraction of 
NK cell numbers following MCMV infection, the down-modulation of IFNγ production appears 
to be dependent on the extrinsic pathway of apoptosis, as we see an increase in the frequency of 
active caspase-8+ NK cells (Fig. 1D). 
 
It has previously been reported that in vitro stimulation of human NK cells to produce IFNγ is 
limited by apoptosis induced by TNFα (5); however, we did not detect significant expression of 
TNF-R1 on NK cells following MCMV infection (Fig. 4.3A).  Moreover, we did not detect 
expression of TNFα by NK cells (data not shown).  In addition to its role in limiting IFNγ 
production by human NK cells, death receptor-mediated apoptosis also has a role in the 
resolution of T cell responses following infection (reviewed in (26)).  While the contraction of T 
cell numbers appears to be dependent on the activity of Fas, our results suggest that the down-
modulation of IFNγ production by NK cells is dependent on signaling through TRAIL-R (Fig. 
4.3C and D).  Like Fas ligand, TRAIL is a member of the TNF superfamily, which has been 
shown to be a potent inducer of apoptosis in transformed cell lines (27, 28).  Indeed, 
TRAIL/TRAIL-R induced apoptosis appears to have a role in defense against tumors and in 
preventing automimmunity as TRAIL-deficient mice experience increased tumor metastases (29) 
and more severe progression of autoimmune disease (30). 
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Previously it was reported that macrophages from mice that lacked TRAIL-R produced 
significantly more cytokines following a variety of TLR stimuli (31), suggesting a role for 
TRAIL-R-mediated apoptosis in limiting cytokine production.  Similarly, we have preliminary 
data that shows prolonged production of IFNγ in TRAIL-deficient mice (Fig. 4.3C and D).  
Interestingly, it has previously been reported that MCMV infection of TRAIL-R-deficient mice 
results in decreased splenic viral titers 3 and 5 days p.i. with MCMV (31).  Diehl et al. did not 
see a difference in NK cell production of IFNγ at 1 day p.i., but this is not surprising as IFNγ 
production by NK cells does not peak until 1.5 days p.i.  While this might result in better control 
of the virus at these early time points, it is possible that it could adversely affect the development 
of the adaptive immune response and subsequent immunological memory. 
 
In the future, we would like to repeat our experiments in TRAIL-deficient mice to confirm our 
preliminary findings that TRAIL/TRAIL-R interactions are required for the resolution of IFNγ 
production by NK cells.  Moreover, we will evaluate viral titers and the development of the 
adaptive immune response in these mice to determine the effect of prolonged IFNγ production on 
MCMV infection.  In addition, it would be interesting to define the mechanism responsible for 
the upregulation of TRAIL-R on NK cells and the identity of the cell type that expresses TRAIL.   
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Figures 
 
 
 
Figure 4.1: Time course of NK cell responses to MCMV.  A) Frequency of IFNγ+ NK cells 
following MCMV infection.  (n=115 mice).  B) Number of splenic NK cells following MCMV 
infection (n=16 mice).  C) Frequency of AnnexinV+ NK cells following MCMV infection (n=86 
mice). D) Frequency of active caspase-8+ NK cells following MCMV infection. Cumulative 
results from 2-4 independent experiments each with 3-5 mice/time point.  
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Figure 4.2: IFNγ production by NK cells is associated with apoptosis. A) Proportion of IFNγ- 
(open diamond) or IFNγ+ (solid diamond) NK cells that express active caspase-8.  Cumulative 
results from 2-3 independent experiments each with 3-4 mice/time point.  B) Frequency of 
Thy1.1+ (grey circles) or IFNγ+ (black diamonds) NK cells from IFNγ-Thy1.1 reporter mice at 
1.5 or 2 days p.i. with MCMV.  Cumulative results from 2 independent experiments each with 3-
4 mice/time point.  C) Proportion of Thy1.1- (open circle) or Thy1.1+ (solid circle) NK cells that 
are AnnexinV+.  Cumulative results from 2 independent experiments with 3-4 mice/time point.  
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Statistical significance for all panels was determined using paired, two-tailed t-tests.  ***p < 
0.001, **p < 0.01 
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Figure 4.3: TRAIL-R, but not Fas, is required for the resolution of IFNγ production by NK 
cells. A) Frequency of death receptor expression (TRAIL-R+: squares, solid line; Fas+: triangles, 
dashed line; TNF-R1+: diamonds, dotted line) on splenic NK cells following MCMV infection.  
Cumulative results from 2-4 independent experiments with 3-4 mice/time point.  B and C) 
Frequency of IFNγ+ (B) and active caspase-8+ (C) NK cells from wt B6 (black diamond) and 
Fas-/- (open circle) mice 2 days p.i. MCMV.  Cumulative results from 2 independent experiments 
each with 3-4 mice/group.  D and E) Frequency of IFNγ+ (D) and active caspase-8+ (E) NK cells 
from wt B6 (black diamond) and TRAIL-/- (open square or triangle) mice 2 days p.i. MCMV.  
Results from a single experiment with 4 mice/group.  Triangles represent mice that were 
pregnant at the time of infection.  F) Proportion of IFNγ- (open diamond) or IFNγ+ (solid 
diamond) NK cells that express TRAIL-R.  Cumulative results from 2-3 independent 
experiments each with 3-4 mice/time point.  Statistical significance was determined using paired, 
two-tailed t-tests.  ***p < 0.001 
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Chapter 5: Future Experiments 
Markers of NK cell activation 
We have conclusively identified markers of nonselective activation and markers of specific 
activation.  This work has been finalized and published (1).  In the future, these markers could be 
used to determine previously unidentified activation receptors involved in the specific response 
to infection.  For example, during vaccinia virus infection, there is the preferential proliferation 
of Ly49H- NK cells (2).  Presumably, these cells express an activation receptor that is 
specifically being activated during vaccinia virus infection, but the identity of this receptor is 
unknown.  
 
Resolution of NK cell proliferation 
We have collected a significant amount of data to substantiate the role of αβ and γδ T cells in 
resolving NK cell proliferation following MCMV infection.  However, the mechanism by which 
this happens remains unclear.  Using our AT system, we have shown that this process can be 
mediated by both CD4+ and CD8+ αβ T cells and that this process is dependent on TCR 
specificity as T cells from RAG/OTI mice were unable to resolve NK cell proliferation.  We 
have attempted with both a candidate-based approach as well as a non-biased microarray screen 
to try and elucidate how αβ and γδ T cells mediate this process, but we have not been able to 
identify any factors that are required. 
 
Future experiments will try to delineate the mechanism of resolution of NK cell proliferation.  
First, we can use our in vitro system to further elucidate various characteristics of this process.  
For example, the use of a transwell system, will allow us to determine whether the interaction 
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between T cells and NK cells is contact-dependent.  Second, we can continue to test the 
requirement for the genes that we identified in our microarray screen using our AT system.   
 
In addition to testing whether these genes are necessary for the resolution of NK cell 
proliferation, we could also test whether these genes are sufficient for this process.  To do this 
we could transduce T cells with lentiviruses that overexpress our genes of interest.  Then, we 
would screen them for the ability to resolve NK cell proliferation using our in vitro system.  By 
using an overexpression system, we would also be able to avoid any complications caused by 
redundancy of multiple genes.   
 
Apoptosis and the resolution of IFNγ production 
As outlined in the proceeding chapter, we need to repeat our evaluation of IFNγ production in 
TRAIL-/- mice to confirm our preliminary data.  Moreover, we would like to evaluate viral titers 
and the development of the adaptive immune response in these mice to determine the effect of 
prolonged IFNγ production on the immune response to MCMV.  Additionally we would like to 
determine the mechanism responsible for the upregulation of TRAIL-R on NK cells following 
infection.  To do this we will infect mice that are unable to produce/respond to a variety of 
cytokines and evaluate TRAIL-R expression.  Finally, we would like to determine what cells 
express TRAIL early following MCMV infection. 
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